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Abstract 
3-iodothyronamine (3-T1AM) and thyronamine (T0AM) are novel endogenous signaling molecules 
that exhibit great structural similarity to thyroid hormones but apparently antagonize classical thy-
roid hormone (T3) actions. The present study investigated whether thyronamines (TAMs) are sub-
strates of the three Dio isozymes (Dio1, Dio2 and Dio3).  
TAMs were incubated with isozyme specific Dio preparations. Deiodination products were ana-
lyzed using a newly established method applying liquid chromatography and tandem mass spec-
trometry (LC-MS/MS). Phenolic ring deiodinations of 3,3’,5’-triiodothyronamine, 3’,5’- and 3,3’-
diiodothyronamine as well as tyrosyl ring deiodinations of 3,5,3’-triiodothyronamine and 3,5-
diiodothyronamine were observed with preparations containing Dio1. Preparations of Dio2 also 
deiodinated 3,3’,5’-triiodothyronamine and 3’,5’-diiodothyronamine at the phenolic rings. All TAMs 
with tyrosyl ring iodine atoms were deiodinated by Dio3 containing preparations. In functional 
competition assays, the newly identified TAM substrates inhibited an established iodothyronine 
deiodination reaction. By contrast, TAMs which had been excluded as Dio substrates in LC-
MS/MS experiments, failed to show any effect in the competition assays, thus verifying the former 
results.  
In summary, all three Dio isozymes catalyzed TAM deiodination reactions with each isozyme ex-
hibiting a unique substrate specificity. These data support a role for Dio isozymes in TAM biosyn-
thesis and contribute to confining the biosynthetic pathways of 3-T1AM and T0AM. Furthermore, 
they provide new insights into the structural requirements for Dio substrates in general since 
TAMs represent the only endogenous Dio substrates described, so far, which possess a positively 
charged tyrosyl ring side chain. 
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Deutscher Abstract 
3-Jodthyronamin (3-T1AM) und Thyronamin (T0AM) sind endogene Signalmoleküle, die eine gro-
ße strukturelle Ähnlichkeit zu Schilddrüsenhormonen aufweisen, allerdings die klassischen Wir-
kungen des aktiven Schilddrüsenhormons 3,5,3’-Trijodthyronin (T3) antagonisieren. In der vorlie-
genden Arbeit wurde untersucht, ob Thyronamine (TAMs) Substrate von Dejodasen (Dio1, Dio2, 
Dio3) sind.  
Die TAMs wurden mit isozymspezifischen Dio-Präparationen inkubiert. Die Dejodierungsprodukte 
wurden mittels Hochleistungsflüssigkeitschromatographie und Tandemmassenspektrometrie (LC-
MS/MS) analysiert. Mit Präparationen der Dio1 wurden Dejodierungen von 3,3’,5’-
Trijodthyronamin, 3’,5’- und 3,3’-Dijodthyronamin am phenolischen Ring sowie Dejodierungen von 
3,5,3’-Trijodthyronamin und 3,5-Dijodthyronamin am Tyrosylring beobachtet. Dio2 haltige Präpara-
tionen katalysierten ebenfalls Dejodierungen von 3,3’,5’-Trijodthyronamin und 3’,5’-
Dijodthyronamin am phenolischen Ring. Mit Dio3 haltigen Präparationen wurden alle TAMs mit 
jodiertem Tyrosylring dejodiert. In Kompetitionsversuchen inhibierten ausschließlich die TAMs, die 
als Substrate von Dio Isozymen identifizierten wurden, eine etablierte Dejodierungsreaktion eines 
bekannten Substrats. Im Gegensatz dazu interferierten TAMs, die in den LC-MS/MS Experimen-
ten als Substrate der Dio Isozyme ausgeschlossen wurden, nicht mit der genannten etablierten 
Dejodierungsreaktion.  
Zusammenfassend wurde in der vorliegenden Arbeit gezeigt, dass TAMs Substrate aller drei Dio 
Isozyme sind und jedes Isozym eine eigene Substratspezifität aufweist. Diese Befunde weisen 
darauf hin, dass Dio Isozyme an der Biosynthese von TAMs beteiligt sein könnten. Ferner wurden 
die Biosynthesewege für 3-T1AM und T0AM eingegrenzt. Desweiteren gestatten die Ergebnisse 
neue Einblicke in die generellen strukturellen Voraussetzungen für Dio Substrate, da TAMs die 
bisher einzigen endogenen Dio Substrate darstellen, deren Seitenkette am Tyrosylring eine posi-
tive Ladung aufweist.  
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Summary 
Thyronamines (TAMs) are a novel class of endogenous signaling compounds. In 
terms of structure, they differ from thyronines (THs), such as the thyroid hormone 
L-thyroxine (T4) and deiodinated thyroid hormone derivatives, merely concerning 
the absence of the carboxylate group of the β-alanine side chain. So far, only two 
representatives of TAMs, namely 3-iodothyronamine (3-T1AM) and thyronamine 
(T0AM), have been detected in-vivo in various species. Although their physiologi-
cal roles still remain elusive, 3-T1AM and T0AM have exhibited short-term hypo-
thermic, negative chronotropic and negative inotropic effects that are opposite in 
direction to the actions of the classical biologically active thyroid hormone 3,5,3’-
triiodothyronine (T3). Thus, TAMs were suggested to be derivatives of thyroid 
hormones that might serve to fine-tune or even antagonize thyroid hormone ef-
fects.  
Yet, the pathways of TAM biosynthesis are still unknown. If TAMs were deriva-
tives of THs (e.g. T4 or T3), a decarboxylation of the β-alanine side chain would 
be required for their biosynthesis. However, so far, no TH decarboxylating en-
zyme has been identified. If the putative decarboxylating enzyme was converting 
only THs with higher iodine content, deiodinases (Dio) would be directly required 
to complete 3-T1AM and T0AM biosynthesis by removing one to four iodine at-
oms. A role of Dio isozymes in TAM biosynthesis presupposes their ability to ac-
cept TAMs as substrates. 
So far, the deiodinase isozymes (Dio1, Dio2 and Dio3) have been described to 
catalyze the sequential reductive removal of iodine from THs and various TH me-
tabolites thus controling the bioavailability of thyroid hormones. While Dio1 exhib-
its both phenolic and tyrosyl ring deiodination activity, Dio2 and Dio3 are more 
specific with respect to the position of the iodine atom removed. Dio2 catalyzes 
only deiodination reactions of the phenolic ring, e.g. the conversion of the pro-
hormone T4 to active T3, whereas Dio3 catalyzes only deiodination reactions of 
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the tyrosyl ring, e.g. the conversion of T4 to inactive 3,3’,5’-triiodothyronine (re-
verse T3, rT3).  
In the present study the complete panel of TAM deiodination reactions was inves-
tigated systematically. Since the various TAMs differ only regarding the number or 
the position of the iodine atoms, their distinction by immunological methods has 
been hampered, so far. Therefore, a novel liquid chromatography tandem mass 
spectrometry (LC-MS/MS) method was developed, which allowed for the simulta-
neous detection of all TAMs in the same sample. TAMs were incubated with 
isozyme specific Dio preparations. The deiodination products were analyzed us-
ing LC-MS/MS. Phenolic ring deiodinations of 3,3’,5’-triiodothyronamine (rT3AM), 
3’,5’-diiodothyronamine (3’,5’-T2AM), 3,3’-diiodothyronamine (3,3’-T2AM) as well 
as tyrosyl ring deiodinations of 3,5,3’-triiodothyronamine (T3AM) and 3,5-
diiodothyronamine (3,5-T2AM) were observed with Dio1. Dio2 containing prepara-
tions also deiodinated rT3AM and 3’,5’-T2AM at the phenolic rings. All TAMs with 
tyrosyl ring iodine atoms were deiodinated by Dio3 containing preparations. In 
functional competition assays, the newly identified TAM substrates inhibited an 
established iodothyronine deiodination reaction. By contrast, TAMs which had 
been excluded as Dio substrates in LC-MS/MS experiments, failed to show any 
effect in the competition assays, thus verifying the former results. Finally, the ap-
parent Km and vmax of selected TAM deiodination reactions were studied and 
compared to that of the corresponding TH. Some TAMs displayed a higher 
vmax/Km ratios and thus represented better substrates of the respective Dio 
isozyme than their corresponding TH. 
In summary, all three Dio isozymes catalyzed TAM deiodination reactions with 
each isozyme exhibiting a unique substrate specificity. These data support a role 
for Dio isozymes in TAM biosynthesis and contribute to confining the biosynthetic 
pathways for 3-T1AM and T0AM. Moreover, they provide new insights into the 
structural requirements of Dio substrates in general since TAMs represent the 
only endogenous Dio substrates described, so far, which possess a positively 
charged tyrosyl ring side chain.  
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Zusammenfassung 
Thyronamine (TAMs) sind eine neue Gruppe endogener Signalmoleküle. Sie un-
terscheiden sich strukturell von Thyroninen (THs), wie zum Beispiel dem 
Schilddrüsenprohormon Thyroxin (T4) und dessen Dejodierungsprodukten, nur 
durch das Fehlen der Carboxylgruppe in der β-Alanin-Seitenkette. Bisher wurden 
zwei Vertreter der TAMs, genauer 3-Jodthyronamin (3-T1AM) und Thyronamin 
(T0AM), in-vivo in verschiedenen Spezies nachgewiesen. Die physiologische 
Funktion der TAMs ist nicht bekannt. 3-T1AM und T0AM führten in Tierversuchen 
in pharmakologischen Dosen zu einem schnellen Abfall der Körpertemperatur um 
fast 8 °C sowie zu negativer Chronotropie und Inotropie. Damit lösen TAMs Effek-
te aus, die den klassischen Wirkungen des biologisch aktiven Schilddüsenhor-
mons 3,5,3’-Trijodthyronin (T3) direkt entgegenstehen.  
Aufgrund der gegensätzlichen Wirkungen von TAMs und Schilddrüsenhormonen 
wurde mehrfach die Hypothese formuliert, TAMs wären Metabolite von Schilddrü-
senhormonen und könnten deren Wirkung antagonisieren. Die Biosynthesereak-
tionen für TAMs sind allerdings nicht bekannt. Falls TAMs als Metabolite von THs, 
zum Beispiel T4 und T3, biosynthetisiert werden, müsste deren β-Alanin-
Seitenkette decarboxyliert werden. Bisher wurde allerdings noch keine TH spezi-
fische Decarboxlaseaktivität beschrieben. Falls diese putative Decarboxylase nur 
THs mit höherem Jodgehalt umsetzt, wären Dejodasen (Dio) notwendig, um die 
Biosynthese von 3-T1AM und T0AM durch die Abspaltung von einem bis vier 
Jodatomen abzuschließen. Eine Funktion der Dio Isozyme bei der Biosynthese 
der TAMs setzt voraus, dass TAMs dejodiert werden. 
Bisher wurde beschrieben, dass drei Dio Isozyme (Dio1, Dio2 und Dio3) die re-
duktive Abspaltung von Jodatomen aus THs und verschiedenen TH-Metaboliten 
katalysieren und damit die Bioverfügbarkeit der Schilddrüsenhormone regulieren. 
Während Dio1 sowohl Dejodierungen am phenolischen und am Tyrosylring kata-
lysiert, haben Dio2 und Dio3 begrenztere katalytische Aktivitäten. Dio2 katalysiert 
ausschließlich Dejodierungen am phenolischen Ring, zum Beispiel die Synthese 
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des aktiven T3 aus dem Prohormon T4. Dio3 hingegen katalysiert ausschließlich 
Dejodierungen am Tyrosylring, zum Beispiel den Abbau von T4 zum inaktiven 
3,3’,5’-Trijodthyronin (reverses T3, rT3). 
In der vorliegenden Arbeit wurden alle TAM Dejodierungsreaktionen systematisch 
anaylsiert. Da sich die TAMs untereinander nur hinsichtlich der Anzahl oder Posi-
tion der Jodatome unterscheiden, wurde in dieser Arbeit eine auf Hoch-
leistungsflüssigkeitschromatographie und Tandemmassenspektrometrie (LC-
MS/MS) basierende Methode entwickelt, die es ermöglichte, alle TAMs in einer 
Probe in einem Analysenlauf zu detektieren. Die TAMs wurden mit isozymspezifi-
schen Dio-Präparationen inkubiert und die Dejodierungsprodukte mittels LC-
MS/MS analysiert. Mit Präparationen der Dio1 wurden Dejodierungen von 3,3’,5’-
Trijodthyronamin (rT3AM), 3’,5’-Dijodthyronamin (3’,5’-T2AM) und 3,3’-
Dijodthyronamin (3,3’-T2AM) am phenolischen Ring sowie Dejodierungen von 
3,5,3’-Trijodthyronamin (T3AM) und 3,5-Dijodthyronamin (3,5-T2AM) am Tyrosyl-
ring beobachtet. Dio2 haltige Präparationen katalysierten ebenfalls Dejodierun-
gen von rT3AM und 3’,5’-T2AM am phenolischen Ring. Mit Dio3 haltigen Präpara-
tionen wurden alle TAMs mit jodiertem Tyrosylring auch entsprechend am 
Tyrosylring dejodiert. In Kompetitionsversuchen inhibierten ausschließlich die 
TAMs, die als Substrate von Dio Isozymen identifizierten wurden, eine etablierte 
Dejodierungsreaktion eines bekannten Substrats. Im Gegensatz dazu interferier-
ten TAMs, die in den LC-MS/MS Experimenten als Substrate der Dio Isozyme 
ausgeschlossen wurden, nicht mit der genannten etablierten Dejodierungsreakti-
on. Mit diesen Befunden wurden die Ergebnisse LC-MS/MS-Experimente bestä-
tigt. Schließlich wurden die apparenten Km- und vmax-Werte repräsentativer TAM-
Dejodierungsreaktionen gemessen und mit denen des korrespondieren THs ver-
glichen. Dabei wurde in einigen Fällen das TAM mit einem höheren apparenten 
vmax/Km Verhältnis umgesetzt und stellte somit ein besseres Dio-Substrat dar, als 
das entsprechende TH.  
Zusammenfassend wurde in der vorliegenden Arbeit gezeigt, dass TAMs Sub-
strate aller drei Dio Isozyme sind. Jedes Isozym wies eine eigene Substratspezifi-
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tät auf. Die Befunde dieser Arbeit weisen darauf hin, dass Dio Isozyme an der 
Biosynthese von TAMs beteiligt sein könnten. Ferner wurden auf dieser Grundla-
ge die Biosynthesewege für 3-T1AM und T0AM eingegrenzt. Desweiteren gestat-
ten die Ergebnisse neue Einblicke in die generellen strukturellen Voraussetzun-
gen für Dio Substrate, da TAMs die bisher einzigen endogenen Dio Substrate 
darstellen, deren Seitenkette am Tyrosylring eine positive Ladung aufweist. .
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1 Introduction 
1.1 Thyronines 
1.1.1 Thyroidal biosynthesis of T4 and T3 
The major secretion product of the thyroid gland is L-3,5,3’,5’-tetraiodothyronine, 
which is also referred to as thyroxine or T4 [Engler, 84]. T4 is biosynthesized in a 
multistep process as an iodinated derivative of the amino acid tyrosine (Fig-
ure 1A). To concentrate iodine within the thyroid gland, the Na+/I - symporter (NIS) 
localized to the basolateral plasma membrane of the thyrocytes actively trans-
ports iodide from the blood stream into the thyrocyte [Dai, 96; Smanik, 96; Ri-
esco-Eizaguirre, 06]. The trapped iodide is further transported across the apical 
plasma membrane into the follicular lumen by the pendrin transporter [Royaux, 
00]. The follicular lumen contains colloid, which mainly consists of thyroglobulin 
(Tg), a 660 kD glycoprotein rich in tyrosine and secreted from thyrocytes [Taurog, 
00]. Several steps of T4 biosynthesis are catalyzed by the thyroid peroxidase 
(TPO), which is a hemoprotein anchored within the apical plasma membrane with 
the active site of the enzyme facing the colloid [Taurog, 00]. Firstly, the TPO cata-
lyzes the oxidation of iodide. This reaction requires H2O2, which is produced by 
dual oxidases (DUOX1 and 2) that co-localize with TPO [De Deken, 00; Ris-
Stalpers, 06]. Secondly, the TPO catalyzes the iodination of tyrosyl residues 
within the Tg molecule yielding mono- and diiodo-tyrosyl residues (MIT) and 
(DIT). Finally, the TPO catalyzes the coupling of MIT and DIT, which remain cova-
lently bound to Tg [Taurog, 00]. Coupling of two DIT residues gives rise to T4 
(Figure 1B). Coupling of MIT to the phenolic group of DIT represents the thyroidal 
biosynthetic pathway of another representative of thyronines which is referred to 
as L-3,5,3’-triiodothyronine (T3) (Figure 1C).  
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Figure 1: Biosynthesis of T4 and T3 in the thyroid gland. Subcellular localization and simplified 
activities of NIS, pendrin, DUOX and TPO allowing for MIT and DIT biosynthesis within the Tg 
molecule (A). TPO-catalyzed coupling of MIT and DIT residues allowing for biosynthesis of T4 (B) 
and T3 (C). Partly adopted from [Löffler, 03]. Red spheres: iodide. 
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The secretion of THs requires the endocytosis of iodinated Tg from the apical thy-
rocyte plasma membrane [Taurog, 00]. Within the endocytotic vesicles, Tg is pro-
teolytically cleaved, which leads to the release of THs from Tg. THs are secreted 
into the blood via the basolateral thyrocyte plasma membrane.  
The TH biosynthesis within the thyroid gland is exquisitely regulated by the syn-
ergistic action of two further hormones, namely TRH (TSH releasing hormone) 
and TSH (thyroid stimulating hormone, thyrotropin) [Yen, 01]. The fraction of TRH 
regulating the thyroidal TH biosynthesis is produced in the paraventricular nu-
cleus of the hypothalamus. Composed of the three amino acids pyro-Glu-His-Pro-
NH2, TRH represents the smallest known releasing hormone [Yen, 01]. To acti-
vate TSH secretion, TRH is transported from the hypothalamic neurons to the 
anterior pituitary via the blood of the portal capillary plexus. By binding to its cog-
nate receptor, which is a Gq11-protein coupled receptor (Gq11PCR) expressed in 
the plasma membrane of the thyrotropes of the anterior pituitary, TRH activates 
TSH secretion and de-novo synthesis [Yen, 01].  
TSH is a heterodimeric glycoprotein composed of an α-subunit, which is identical 
to the α-subunit of FSH (follicle stimulating hormone), LH (luteinizing hormone) 
and hCG (human chorionic gonadotropin), as well as a non-covalently linked β-
subunit, which is unique to TSH. Upon secretion into the blood, TSH acts as the 
primary activator of the thyroidal TH biosynthesis by binding to its cognate 
GsPCR, which is located to the plasma membrane of thyrocytes [Parmentier, 89]. 
Activation of the TSH receptor stimulates the expression of genes involved in TH 
biosynthesis (e.g. Tg, NIS, TPO) and TH secretion. The net activity of this so-
called hypothalamus-pituitary-thyroid-axis is regulated by negative feedback 
loops. TRH biosynthesis and secretion are inhibited by T3 and TSH [Fekete, 07; 
Prummel, 04], while TSH biosynthesis and secretion are inhibited by T3 and TSH 
itself [Schneider, 01; Prummel, 04].  
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1.1.2 Biological actions of T4 and T3 
Secreted THs are transported to their target tissues via the blood stream. In hu-
mans, the total T4 and T3 blood concentrations are 90 nM and 2 nM, respectively 
[Schussler, 00]. However, since 99.9 % of T4 and 99.0 % of T3 are bound to spe-
cific plasma proteins, such as TBG (thyroxine binding globulin), TTR 
(transthyretin, thyroxin binding prealbumin, TBPA) and albumin (also thyroxine 
binding albumin, TBA), the free T4 and T3 concentrations, which are available to 
uptake into target cells, are considerably lower [Richardson, 07].  
In target cells, THs modulate classical genomic and rapid plasma membrane-
initiated signaling pathways to exert their biological effects. To exert genomic ac-
tions, THs are transported across the plasma membrane of the target cell by 
transport proteins, such as MCT8 [Friesema, 06], MCT10 [Visser, 07] or 
OATP1C1 [Friesema, 05], and further transported into the nucleus where they 
modulate the activity of nuclear thyroid hormone receptors (TRs) [Oetting, 07]. 
Since T3 binds to TRs with much greater affinity than other THs, T3 is considered 
as the biologically active thyroid hormone [Hiroi, 06]. TRs belong to the second 
class of the superfamily of nuclear receptors, which implies that they are mostly 
constitutively localized to the nucleus and heterodimerize with 9-cis-retinoic-X-
receptors (RXRs) to bind to the cognate thyroid hormone response elements 
(TRE) in their target genes promoters [Mangelsdorf, 95]. So far, three TRs have 
been described, which are encoded by two distinct genes designated as Thra and 
Thrb [Oetting, 07]. TRα1 is expressed from the Thra gene [Mitsuhashi, 88] while 
TRβ1 and TRβ2 are expressed from the Thrb gene by alternative splicing [Hodin, 
89]. TRα1 and TRβ1 are expressed widely expressed among TH target tissues 
[Ribeiro, 08], but the expression of TRβ2 is restricted to specific tissues, such as 
the anterior pituitary, some areas of hypothalamus, developing hippocampus, 
striatum, chochlea and cone photoreceptors [Hodin, 90; Cook, 92; Bradley, 92; 
Yanagi, 02; Jones, 07]. Upon activation by T3 binding, the nuclear TRs modulate 
the expression of T3 target genes [Oetting, 07]. Some target genes are positively 
regulated, such as the cardiac β1 adrenergic receptor gene [Williams, 77; Ba-
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houth, 91], while others are negatively regulated, such as the pituitary TSHβ gene 
[Bodenner, 91] and the hypothalamic TRH gene [Hollenberg, 95]. So far, no over-
arching model has become available to explain how T3 can trigger the activation 
of one target gene and the repression of a second target gene [Oetting, 07]. Fur-
thermore, in the absence of ligand, TRs do not only bind to TREs but also repress 
the basal transcription of positively regulated target genes [Chen, 95; Baniahmad, 
92]. 
As mentioned above, THs also exert rapid plasma membrane-initiated effects 
which are insensitive to transcriptional blockade [Oetting, 07]. Some of these ef-
fects are mediated independently from TRs, such as the activation of MAPK upon 
binding of T4 or T3 to plasma membrane bound αVβ3 integrin [Bergh, 05]. Interest-
ingly, T4 was more potent than T3 at eliciting this effect. Other rapid effects of THs 
involve the roughly 10 % of TRs which are located outside the nucleus, such as 
the T3 dependent interaction between cytosolic TRβ2 and phosphoinositide 3-
kinase (PI3K) described for a rat pituitary cell line [Baumann, 01; Storey, 06]. 
The biological effects attributed to thyroid hormones appear very complex and 
cannot be addressed completely herein. Throughout the vertebrate kingdom, thy-
roid hormones are critically involved in the regulation of ontogenic development 
and growth of various organs, such as brain [Silva, 03]. In homeothermic species, 
they additionally acquired a role in metabolic regulation including thermogenesis 
[Kim, 08]. Thyroid hormones increase adenosine triphosphate (ATP) consumption 
by activating the expression of Na+/K+ ATPases and sarcoplasmatic Ca2+ AT-
Pases as well as by accelerating practically all anabolic and catabolic pathways 
[Ribeiro, 08; Silva, 03]. The latter effect does not only account for their metabolic 
actions whose net effects are lipogenesis and increased food intake but also for 
their obligatory hyperthermic function [Silva, 03]. Thyroid hormones increase the 
proton leak of the inner mitochondrial membrane thus reducing the efficiency of 
ATP synthesis and allowing energy dissipation as heat [Harper, 93]. Locally pro-
duced T3 is also essential to mediate facultative thermogenesis in brown adipose 
tissue upon cold exposure [Bianco, 87]. Finally, T3 has positive inotropic and 
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chronotropic effects on the heart and lowers peripheral vascular resistance, which 
altogether leads to an increased cardiac output [Klein, 01].  
 
1.2 Deiodinases 
As outlined above (section 1.1.1), T4 is exclusively biosynthesized de-novo in the 
thyroid gland [Engler, 84]. By contrast, T3 is either produced de-novo within the 
Tg molecule or by enzymatic deiodination of T4 at the phenolic ring [Köhrle, 02].  
Deiodination reactions imply the sequential reductive removal of iodine from the 
precursor molecule. They are catalyzed by a group of three isozymes designated 
as iodothyronine deiodinases (Dio1, 2 and 3). Dio1 exhibits both phenolic and 
tyrosyl ring deiodination activity [Köhrle, 02] Figure 2). Phenolic ring deiodinations 
are also referred to as 5’- and 3’-deiodinations, depending on whether the sub-
strate possesses two or one iodine atoms in the phenolic ring, respectively. Ac-
cordingly, tyrosyl ring deiodinations are also referred to as 5- and 3-deiodinations 
(Figure 2). Both the 5’- and 3’-position as well as the 5- and 3-position are chemi-
cally equal [Köhrle, 84]. In contrast to Dio1, Dio2 and Dio3 are more specific with 
respect to the position of the iodine removed. Dio2 catalyzes only deiodinations of 
the phenolic ring, e.g. the conversion of T4 to T3 [Köhrle, 02] Figure 2). Due to this 
biosynthetic pathway of T3 as a T4 metabolite and due to the finding that T3 binds 
to thyroid hormone receptors with greater affinity than T4 [Hiroi, 06], T3 is consid-
ered as the biologically active thyroid hormone whereas T4 is considered as a 
prohormone [Moreno, 08]. Dio3 catalyzes only deiodinations of the tyrosyl ring, 
e.g. the conversion of T4 to another representative of thyronines which is referred 
to as L-3,3’,5’-T3 (reverse T3, rT3) [Köhrle, 02] Figure 2). Since no definite biologi-
cal function has been elucidated for rT3, so far, it is considered as an inactive T4 
metabolite rather than a thyroid hormone [Moreno, 08].  
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Figure 2: Catalytic properties of Dio isozymes. Dio1 catalyzes both phenolic and tyrosyl ring deio-
dinations whereas Dio2 and Dio3 catalyze only one type of deiodination as indicated. 
 
However, not only T4 but also T3 and rT3 are substrates of deiodination reactions 
yielding further representatives of the group of thyronines, namely L-
diiodothyronines (3,5-T2, 3,3’-T2, 3’,5’-T2), L-monoiodothyronines (3-T1, 3’-T1) and 
L-thyronine (T0) [Chopra, 78b] Figure 3). Though T2s, T1s and T0 have been de-
tected in-vivo [Chopra, 78a; Wu, 76; Meinhold, 78; Maciel, 79; Smallridge, 79; 
Corcoran, 83; Willetts, 79; Ramsden, 84], their biological functions remain elu-
sive. Thus, so far, deiodinations of T3 have been interpreted as a reactions de-
grading biologically active thyroid hormone rather than as reactions biosynthesiz-
ing another TH. Accordingly, controlling the local and systemic bioavailability and 
thus the action of T3 has been considered as the main function of Dio isozymes 
[Köhrle, 02].  
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TH R3 R5 R3’ R5’ 
T4 I I I I 
rT3 I H I I 
T3 I I I H 
3’,5’-T2 H H I I 
3,3’-T2 I H I H 
3,5-T2 I I H H 
3’-T1 H I H H 
3-T1 I H H H 
T0 H H H H 
Figure 3: Structure and nomenclature of the group of thyronines (THs). R: variable residue, I: io-
dine, H: hydrogen.  
 
In all species cloned to date, the Dio isozymes contain the amino acid selenocys-
teine (Sec) as part of a highly similar active center and a Sec insertion sequence 
(SECIS) in their genes [Köhrle, 02]. Thus, Dio isozymes are representatives of 
selenoproteins, which require a more complex translation machinery compared to 
typical non-selenoproteins [Köhrle, 05].  
Despite this structural similarity and their concerted function in regulating thyroid 
hormone bioavailability, the Dio isozymes differ considerably in terms of catalytic 
properties, substrate specificities, kinetic properties, mechanisms of reaction, ex-
pression patterns, physiological functions and pathophysiological implications 
[Bianco, 02]. 
Since this study was focused on the identification of new Dio substrates and the 
determination of their kinetic parameters, the published substrate specificities of 
the Dio isozymes towards THs are summarized in Figure 4. 
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Figure 4: Substrate specificities of Dio1 (A), Dio2 (B) and Dio3 (C) towards THs. Arrows: pointing 
to lower left: phenolic ring deiodinations, pointing to lower right: tyrosyl ring deiodinations, light 
green: phenolic ring deiodinations catalyzed by the respective Dio isozyme, dark green: tyrosyl 
ring deiodinations catalyzed by the respective Dio isozyme, black: deiodination reactions which 
were either yet or found not to be catalyzed by the respective Dio isozyme.  
a [Köhrle, 02] 
b [Kuiper, 05; Wu, 05] 
c Several studies have excluded T3 as a substrate of phenolic ring deiodination catalyzed by Dio1 
[Sorimachi, 77; Höffken, 78a; Visser, 78; Kaplan, 78; Moreno, 08]. However, two studies have 
reported that homogenates of the NCLP-6E monkey hepatocarcinoma cell line, which expresses 
Dio1 enzymatic activity [Sorimachi, 79b], catalyze the phenolic ring deiodination of T3 [Sorimachi, 
79a; Sorimachi, 79b]. Nevertheless, these findings were referred to as unpublished data and have 
never been officially published, so far. 
d 3’,5’-T2 was detected in serum of euthyroid human subjects upon a bolus injection of [5’-125I]rT3 
[Rudolph, 78; Sakurada, 78; Lumholtz, 78]. However, since euthyroid humans express both Dio1 
and Dio3 enzymatic activity, the observed tyrosyl ring deiodination of rT3 cannot be assigned un-
ambiguously to either Dio isozyme as no isozyme specific inhibitors, such as 6-n-propyl-2-
thiouracil (PTU) (see section 1.2.1), were included in the study. 
e [Chopra, 82] 
f excluded [Sorimachi, 80a; Otten, 84] 
g excluded [Chopra, 81] 
h In some studies 3’-T1 was not deiodinated to T0 by Dio1 preparations [Sorimachi, 80a; Otten, 84; 
Chopra, 81] while in other studies weak 3’-T1 degradations were observed by Dio1 preparations 
[Smallridge, 81; Smallridge, 82; Smallridge, 84]. However, T0 formation was measured in any of 
these studies. 
i not reported, so far 
j In the only study reporting on the phenolic ring deiodination of 3,3’-T2 by Dio2 containing prepa-
rations [Chopra, 81], 3,3’-T2 was not 3’-deiodinated by rat brain homogenates. However, this 
study appears inappropriate to exclude 3,3’-T2 as a Dio2 substrate since rat brain expresses both 
Dio1 and Dio2 enzymatic activity [Bates, 99] and should thus have 3’-deiodinated 3,3’-T2 anyway. 
k Although serum 3’-T1 concentrations increased in human subjects receiving an intravenous infu-
sion of 3’,5’-T2, the observed tyrosyl ring deiodination of 3’,5’-T2 cannot be assigned unambigu-
ously to Dio2 since no isozyme specific inhibitors, such as PTU (see section 1.2.1), were included 
in the study to discriminate between the two phenolic ring deiodination activities expressed in 
humans, namely Dio1 and Dio2. In the same study cited under j [Chopra, 81], rat brain homoge-
nates, which contain both Dio1 and Dio2 [Bates, 99], did not 5’-deiodinate 3’,5’-T2. As delineated 
above, this study was not appropriate to unequivocally exclude 3’,5’-T2 as a substrate of Dio2. 
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l excluded [Smallridge, 84] 
m [Sorimachi, 79a; Sorimachi, 79b] 
n [Sorimachi, 77; Kaplan, 80] 
o So far, the tyrosyl ring deiodination of 3-T1 to T0 by Dio3 has not been demonstrated unequivo-
cally, i.e. by experiments demonstrating both the disappearance of 3-T1 and the formation of T0. 
One study, which demonstrated the monodeiodination and sulfation of [3,5-125I]T2 by Dio3 ex-
pressing intact cultured monkey hepatocarcinoma NCLP-6E cells, provided indirect evidence for a 
tyrosyl ring deiodination of 3,3’-T2 by Dio3 since the production rate of 125I - was slightly greater 
than that of [3-125I]T1 [Sorimachi, 79a]. However, since small amounts of unidentified TH sulfates 
were detected, it cannot be excluded that the free 125I - was released from sulfated [3-125I]T1. 
 
1.2.1 Dio1  
Dio1 is the only isozyme that exhibits both phenolic and tyrosyl ring deiodination 
activity. With iodothyronine substrates, Km values in the higher nanomolar to 
lower micromolar range and high vmax values (pmol/mg/min) were measured. In 
terms of vmax/Km ratios, rT3 is the preferred substrate of Dio1 [Köhrle, 02]. The 
deiodination reactions catalyzed by Dio1 follow ping pong kinetics with two sub-
strates [Kuiper, 05]. In the first half reaction, the iodothyronine substrate transfers 
an I+ to the selenolate anion (E-Se-) of the Sec within the active center thus form-
ing a putative selenenyl iodide intermediate (E-Se-I). In the second half reaction, 
this intermediate is reduced by an intracellular cosubstrate, which concomitantly 
regenerates the Sec residue of the enzyme. The monodeiodinated product and I - 
are released. In-vitro, the E-Se-I intermediate is efficiently reduced by dithiols, 
such as dithiothreitol (DTT) and dithioerythritol (DTE) [Köhrle, 02]. However, the 
putative physiologic cosubstrate regenerating Dio1 has not been identified yet. 
Moreover, the hypothesis that a productive deiodination reaction catalyzed by 
Dio1 might lead to suicide inactivation of Dio1 without regeneration of the active 
enzyme in-vivo, has not been rejected, so far [Köhrle, 02]. Another hallmark char-
acteristic of Dio1, which allowed for its early distinction from Dio2, was the inhibi-
tion of its catalytic activity by 6-n-propyl-2-thiouracil (PTU) [Oppenheimer, 72; 
Hesch, 75]. PTU inhibition of Dio1 is uncompetitive with the iodothyronine sub-
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strate, and there is strong evidence that PTU binds to the E-Se-I intermediate 
thus forming a selenenyl sulfide (E-Se-S-PTU), which is considered as a dead-
end complex [Visser, 88; du Mont, 01]. 
In humans, Dio1 mRNA and enzymatic activity were detected in the thyroid gland 
and in classical T3 target tissues, such as pituitary, liver, kidney and heart [Köhrle, 
02; Bianco, 02]. Dio1 mRNA was also detected in circulating mononuclear cells 
[Nishikawa, 98]. In contrast to rats, Dio1 enzymatic activity was notably absent 
from the human central nervous system [Campos-Barros, 96]. So far, no coherent 
data have been reported on the subcellular localization of the mature Dio1 pro-
tein. In liver, Dio1 was located to the cytosolic surface of the endoplasmatic re-
ticulum [Auf Dem Brinke, 79; Fekkes, 79; Fekkes, 80]. By contrast, in epithelial 
kidney cells, Dio1 was detected at the basolateral plasma membrane [Leonard, 
78; Leonard, 91; Leonard, 01]. 
Supplying a significant fraction of plasma T3 synthesized from T4 has long been 
considered as the pivotal biological function of Dio1 [Bianco, 02]. Plasma T3 is 
thought to be secreted from the thyroid gland but also to originate from peripheral 
5’-deiodination of T4, which could be catalyzed either by Dio1 or Dio2. However, a 
role of Dio1 was challenged by the unchanged serum T3 levels of mice carrying a 
targeted disruption of the Dio1 gene or mice genetically deficient in hepatic se-
lenoprotein translation due to albumin-driven knock-out of the tRNASer(Sec) (Trsp) 
gene [Schneider, 06; Streckfuss, 05]. So far, the biological function of Dio1 has 
not been demonstrated unequivocally. Considering that the vmax/Km ratios for the 
Dio1 catalyzed 5’-deiodination of rT3 and 3’,5’-T2 are much higher than that for T4, 
its catalytic action with respect to these substrates might reflect its major physio-
logical function [Köhrle, 84; Bianco, 02].  
 
1.2.2 Dio2 
Dio2 catalyzes only deiodinations of the phenolic ring. Its catalytic activity is 
clearly distinguishable from the phenolic ring deiodination activity of Dio1 since 
Introduction 
________________________________________________________________________________________________________________________ 
 13
Dio2 exhibits Km values in the lower nanomolar range and lower vmax values than 
Dio1. In terms of vmax/Km ratios, T4 represents the preferred substrate of Dio2 
[Köhrle, 02]. Its catalytic activity is insensitive to PTU. Deiodination reactions 
catalyzed by Dio2 follow sequential kinetics suggesting that both the iodothyron-
ine substrate and the cosubstrate must interact with the enzyme before the reac-
tion takes place [Visser, 82; Köhrle, 02]. The deiodination of an iodothyronine by 
Dio2 requires an endogenous reducing cosubstrate. Its identity remains elusive, 
but DTT works efficiently in-vitro [Köhrle, 02]. 
The Dio2 expression pattern is species-specific indicating that the enzyme might 
have species-specific biological functions [Bianco, 02]. Dio2 mRNA and/or enzy-
matic activity are expressed in the human thyroid gland, heart, kidney, pancreas, 
skeletal muscle, brain, spinal cord, keratinocytes and placenta [Salvatore, 96b; 
Murakami, 01; Salvatore, 96a; Bartha, 00; Croteau, 96; Campos-Barros, 96; Ka-
plan, 88]. By contrast, in rats, Dio2 enzymatic activity was not detected in the 
adult thyroid gland and heart [Bates, 99; Croteau, 96] but present in the neonatal 
thyroid gland as well as pituitary, brain, brown adipose tissue, pineal gland, thy-
mus, gonads and pregnant uterus [Bates, 99; Silva, 77; Cheron, 79; Visser, 82; 
Leonard, 88; Silva, 83; Kamiya, 99; Molinero, 95; Galton, 01]. Thus, Dio2 repre-
sents the only phenolic ring Dio activity in the adult human brain, whereas both 
Dio1 and Dio2 activity were detected in rat brain. In cell lines, both endogenous 
and transiently expressed FLAG-tagged Dio2 localized to the endoplasmatic re-
ticulum with the catalytic center facing the cytosol [Baqui, 00; Curcio, 01].  
Since the 5’-deiodination of T4 to T3 is the preferred reaction catalyzed by Dio2, 
this isozyme is assumed to generate biologically active T3 from local T4 sources 
for intracellular demands independently from circulating T3 [Köhrle, 05]. In serum 
of euthyroid mice carrying a targeted disruption of the Dio2 gene, T4 and TSH 
concentrations were elevated, but T3 concentrations were normal suggesting that 
the pituitary thyrotropes were not responding normally to the serum T4 concentra-
tion. These findings suggested that Dio2 is critically required for the feedback in-
hibition of TSH synthesis by plasma T4 [Schneider, 01]. 
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1.2.3 Dio3 
Dio3 catalyzes deiodinations of the tyrosyl ring, exclusively [Köhrle, 02]. Depend-
ing on the experimental enzyme source used, widely ranging apparent Km and 
vmax values were reported for the tyrosyl ring deiodination of T4 and T3 by Dio3. 
Maximum enzymatic activity required high concentrations of DTT, but the en-
dogenous cofactor(s) has (have) not been identified [Kaplan, 80]. Dio3 enzymatic 
activity was observed to be insensitive towards PTU [Croteau, 95].  
In adulthood, Dio3 activity is expressed in brain of humans and rats as well as in 
skin, eye and gonads of rats [Campos-Barros, 96; Kaplan, 80; McCann, 84; 
Huang, 85; Bates, 99; Huang, 05]. However, much higher Dio3 expression has 
been demonstrated in fetal tissues, such as brain, liver and intestine [Chan, 02; 
Kester, 04; Richard, 98; Galton, 91; Bates, 99] as well as at sites of the maternal-
fetal interface, such as uterus, placenta and umbilical arteries and veins [Huang, 
03; Galton, 99; Koopdonk-Kool, 96; Roti, 82; Bates, 99; Hernandez, 06]. Devel-
opmental profiles of Dio3 expression have been investigated for many tissues in 
various species [Köhrle, 02; references 162 - 171]. Dio3 activity was located to 
the microsomal subcellular fraction of several tissues [Höffken, 78b; Schoenmak-
ers, 95], and demonstrated as a phospholipid requiring enzyme [Santini, 92]. 
However, the definite subcellular location and topology have not been reported, 
so far [Bianco, 02].  
Dio3 contributes to thyroid hormone homeostasis but in contrast to Dio2 as a thy-
roid hormone inactivating enzyme, which is supported by the hypothyroidism in 
patients with Dio3 overexpressing hepatic hemangiomas [Huang, 00]. A function 
of Dio3 in protecting tissues from an excess of T4 and T3 actions has been widely 
accepted [Hernandez, 06]. This was proven true for embryogenesis, where ex-
cess or premature exposure of the embryo to maternal thyroid hormone levels 
can be detrimental, e.g. by the growth retardation, neonatal mortality and abnor-
mal thyroid status of the Dio3 knock-out mouse [Hernandez, 06] or by the block-
ade of metamorphosis in Xenopus laevis tadpoles overexpressing Dio3 [Huang, 
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99]. However, such a function of Dio3 remains speculative for adult organisms 
[Hernandez, 06]. 
 
1.3 Thyronamines 
The history of thyronamine (TAM) research seems peculiar. From 1951 to 1984, 
several papers were published every now and then, which were mostly lacking 
any topical consistency. In 2004, after a twenty year gap, TAMs aroused renewed 
interest due to a publication by Thomas S. Scanlan and co-workers [Scanlan, 04]. 
Ever since, the field of TAM research has become very vivid again.  
 
1.3.1 Structure of TAMs 
TAMs are a novel class of endogenous signaling compounds. In terms of struc-
ture, they differ from THs only concerning the absence of the carboxylate group 
of the β-alanine side chain. Following the same rules for nomenclature as THs, 
TAMs are designated TxAM, with x indicating the number of iodine atoms per 
molecule (Figure 5). Accordingly, there are nine TAMs differing either by the num-
ber or by the positions of the iodine atoms.  
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TAM R3 R5 R3’ R5’ 
T4AM I I I I 
rT3AM I H I I 
T3AM I I I H 
3’,5’-T2AM H H I I 
3,3’-T2AM I H I H 
3,5-T2AM I I H H 
3’-T1AM H I H H 
3-T1AM I H H H 
T0AM H H H H 
Figure 5: Structure of thyronines (THs) (A). Structure and nomenclature of thyronamines (TAMs) 
(B). R: variable residue, I: iodine, H: hydrogen. 
 
1.3.2 In-vivo detection of TAMs 
So far, only two representatives of TAMs, namely 3-T1AM and T0AM, have been 
detected in-vivo using an LC-MS/MS technique [Scanlan, 04]. Both compounds 
were measured in blood, heart, liver and brain of C57BL/6 adult male mice as 
well as in brain of several other species, such as rats and guinea pigs [Scanlan, 
04]. 3-T1AM was also detected in blood and brain of Djungarian hamsters 
[Braulke, 08].  
The presence of other TAMs in-vivo has not been proven yet. In the LC-MS/MS 
studies by [Scanlan, 04] the samples were simultaneously monitored for T0AM, 
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T1AM and T2AM, but neither T2AM isomer was detected in any of the tissues. 
Likewise, T3AM has not been detected, so far [Meyer, 83]. In early experiments 
applying butanolic extraction and subsequent paper chromatographic separation, 
131I labeled T4AM was found in plasma and in the thyroid glands but not in the 
thyroid derived Tg fractions of rats which had been treated with 131I [HILLMANN, 
58]. Furthermore, 131I labeled T4AM but no T3AM was detected in the plasma of 
two patients who suffered from metastasizing thyroid tumors and were treated 
with high dosages of 131I. Based on these experiments, T4AM was postulated to 
be present in-vivo at a serum concentration equalling 1 to 2 % of the serum T4 
concentration [HILLMANN, 58; HILLMANN, 61]. However, T4AM biosynthesized 
from endogenous precursors has not yet been detected yet.  
Hitherto, few publications have reported on endogenous TAM concentrations in 
tissues. 3-T1AM was estimated to be present in rat brain at subpicomole per gram 
quantities [Scanlan, 04]. This concentration is lower compared to 1 to 6 pmol/g T4 
which have been reported for rat brain using a radioimmunoassay technique 
[Pinna, 02]. For rat heart, an endogenous 3-T1AM concentration of 68 pmol/g wet 
weight was calculated [Chiellini, 07]. Interestingly, this concentration corresponds 
to the cardiac content of classical modulators of heart function, such as adrena-
line, dopamine and adenosine [Chiellini, 07]. Moreover, it exceeds the endoge-
nous intracardial T3 and T4 concentrations by factor 20 and 2, respectively 
[Chiellini, 07]. Even if it was not stated whether the hearts had been perfused, 
these findings indicate that TAMs can override TH concentrations locally in the 
heart. In the serum of Djungarian hamsters either adapted to long photoperiods 
(LP) or short photoperiods (SP), endogenous 3-T1AM was detected at a concen-
tration of roughly 5 nM [Braulke, 08]. 
 
1.3.3 Physiological effects of TAMs 
The physiological roles of TAMs remain elusive. In early studies, T4AM and T3AM 
were only 10 % as potent as T4 in terms of goiter prevention and stimulation of 
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oxygen consumption in rats [TOMITA, 56; THIBAULT, 51]. However, T3AM was 36 
times as potent as T4 at inducing tadpole metamorphosis [TOMITA, 56]. In more 
recent studies, intraperitoneal injection of 3-T1AM or T0AM into C57BL/6 wild type 
mice or Djungarian hamsters caused various prompt effects, such as hypother-
mia, metabolic repression, hyperglycemia, reduction of the respiratory quotient, 
negative chronotropy and negative inotropy [Scanlan, 04; Braulke, 08]. In most of 
these studies, a dose of 50 mg 3-T1AM or T0AM/kg body weight was injected into 
animals. In Djungarian hamsters, this dosage lead to an approximately tenfold 
increase in 3-T1AM blood concentration [Braulke, 08]. To this end, it is not known 
whether such changes in TAM blood and tissue concentrations have to be con-
sidered as physiological or pharmacological. Therefore, the effects of TAMs de-
scribed so far, will conditionally be classified and described as pharmacological 
effects, herein.  
 
1.3.4 Pharmacological effects of TAMs 
Upon intraperitoneal injection into C57BL/6 wild-type mice, 3-T1AM and T0AM 
reduced the body temperature within 30 min by roughly 8 °C at a half maximal 
effective concentration (EC50) of 59 and 178 µmol/kg body weight, respectively 
[Scanlan, 04]. The mice became inactive, but reflexes were retained indicating 
that they were not anesthetized. Furthermore, their skin cooled off, but they did 
not display any compensatory reactions, such as shivering, huddling or piloerec-
tion. The effect was completely reversible after 6 to 8 hours and so far, no side 
effects were reported even after repeated treatments over a period of 2 months 
[Scanlan, 04]. Although less pronounced, this hypothermic effect was also ob-
served after intraperitoneal injection of 3-T1AM into Djungarian hamsters 
[Braulke, 08]. 
In wild type C57BL/6 mice and in Djungarian hamsters, the hypothermia caused 
by 3-T1AM injection was temporarily preceded by a reduction in metabolic rate 
[Braulke, 08]. Since the extent of hypothermia and the amount of metabolic re-
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duction were highly correlated, the hypothermic effect was interpreted as a result 
of the reduced metabolic rate [Braulke, 08]. 
In addition to hypothermia and metabolic repression, wild type mice intraperito-
neally injected with 3-T1AM displayed an increase in blood glucose level [Regard, 
07]. This hyperglycemic effect was detectable within minutes after treatment, 
reaching a maximum of 250 % above basal 2 h after 3-T1AM injection and was 
completely reversed 8 h post-injection. It was accompanied by a decrease in 
plasma insulin levels and increase in plasma glucagon levels. Insulin applied 
exogenously 2 h after 3-T1AM injection normalized the blood glucose levels indi-
cating that the peripheral tissues had remained sensitive to insulin during the 3-
T1AM treatment [Regard, 07].  
Also within minutes after intraperitoneal 3-T1AM injection, the respiratory quotient 
(RQ) decreased from 0.9 to 0.7 both in wild type C57BL/6 mice and in Djungarian 
hamsters [Braulke, 08]. This was indicative of a rapid change in metabolic fuel 
utilization from predominantly carbohydrates (RQ ~ 0.9) before treatment to pri-
marily lipids after treatment (RQ ~ 0.7) [Braulke, 08]. Minimal RQ values were 
obtained 3 to 4.5 h post-treatment. The reduced RQ was maintained for more 
than 24 h, i.e. even after the recovery of metabolic rate and return to normother-
mia. This indicated that the treated animals required several hours to readjust 
their metabolic machinery to normal catabolism [Braulke, 08]. 
The hypothermic and metabolic effects of 3-T1AM intraperitoneally injected into 
wild type C57BL/6 mice were accompanied by rapid and reversible bradycardia 
[Scanlan, 04]. This effect was direct since it was reproducible by perfusing an ex-
vivo adult rat denervated working heart preparation with 3-T1AM. At concentra-
tions too low to elicit bradycardia, 3-T1AM decreased the cardiac output within 
minutes at an EC50 of 29 µM [Scanlan, 04].  
Conflicting data have been reported for the cardiac effects of T0AM. In the per-
fused, denerved rat heart, T0AM decreased the cardiac output within minutes at 
an EC50 of 83 µM while an effect on the heart rate was not reported [Scanlan, 04]. 
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By contrast, using an isolated guinea pig atria model, T0AM (2.9 nM to 9.5 µM) 
displayed positive inotropic effects and did not modify the heart rate [Boissier, 73]. 
In anesthetized rats, T0AM (3 to 30 mg/kg body weight) decreased the heart rate 
significantly [Boissier, 73]. Upon intravenous injection into anesthetized dogs, 
T0AM increased the cardiac output [Boissier, 73; Cote, 74]. However, T0AM in-
duced concomitant negative chronotropy in one study [Boissier, 73] but positive 
chronotropy in the other study [Cote, 74].  
 
1.3.5 Receptors for TAMs  
To this end, the physiological receptor(s) of TAMs has (have) not been identified 
unambiguously. While some receptors have been excluded as candidates, scat-
tered experimental evidence has been gathered for other receptors to mediate 
TAM signaling.  
The structural similarities of TAMs with THs and biogenic amines suggested that 
TAMs might signal via nuclear thyroid hormone receptors or plasma membrane-
bound receptors of biogenic amines. But considering the rapid onset of TAMs ef-
fects, the latter pathway appeared more likely. However, T0AM and 3-T1AM were 
reported neither to bind to nor to activate nuclear thyroid hormone receptors us-
ing nuclear receptor binding experiments and reporter gene assays, respectively 
[Scanlan, 04]. Furthermore, neither T0AM nor 3-T1AM activated the heterolo-
gously expressed Gαs-protein coupled dopamine D1 receptor and β2 adrenergic 
receptor [Scanlan, 04]. Thus, despite structural similarities, TAMs, THs and cer-
tain biogenic amines appear to signal via different receptors.  
The first receptor suggested to mediate TAM effects, was the membrane bound 
G-protein coupled trace amine associated receptor 1 (TAAR-1) [Scanlan, 04]. 
This suggestion was based on the finding that 3-T1AM, 3,3’-T2AM, 3,5-T2AM, 
T3AM and T0AM coupled the heterologously expressed rat TAAR-1 to cyclic 
adenosine monophosphate (cAMP) biosynthesis at EC50 values ranging from 14 
to 131 nM with respect to the indicated order [Scanlan, 04]. Given the structural 
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similarity between TAMs and biogenic amines as well as the expression of TAAR-
1 transcript in TAM target tissues, such as heart [Chiellini, 07] and pancreas 
[Regard, 07], TAAR-1 has been considered as an excellent candidate receptor for 
T0AM and 3-T1AM [Doyle, 07]. However, the concept of TAM signalling via a 
GαsPCR, such as TAAR-1, was challenged by experiments demonstrating that the 
negative chronotropic, negative inotropic and hyperglycemic effects of 3-T1AM 
were more consistent with an inhibition of cAMP accumulation through Gαi activa-
tion [Chiellini, 07; Regard, 07]. Yet, TAAR-1 has not been withdrawn as a candi-
date TAM receptor [Doyle, 07]. 
A second receptor proposed to mediate the effects of 3-T1AMs, was the α2A 
adrenergic receptor (Adra2a), which is an established GαiPCR inter alia ex-
pressed in pancreatic β-cells [Regard, 07; Bylund, 88]. In-vitro studies demon-
strated a higher affinity of 3-T1AM for Adra2a compared to epinephrine [Regard, 
07]. Coadministration of the Adra2a antagonist yohimbine with 3-T1AM inhibited 
the hyperglycemic effects of 3-T1AM. Moreover, 3-T1AM failed to induce hyper-
glycemia in Adra2a-null mice [Regard, 07].  
 
1.3.6 Signal transduction pathways activated by TAMs 
To assess the signaling pathways activated by TAMs in the heart, ex-vivo adult rat 
working heart preparations, which had been pretreated with various inhibitors of 
signaling cascades, were perfused with T0AM and 3-T1AM [Chiellini, 07]. Re-
markably, Bordetella pertussis toxin (PTX), an inhibitor of Gαi signaling did not 
interfere with the negative chronotropic effects of 3-T1AM thus excluding a role of 
Gαi proteins in mediating the effects of 3-T1AM on the heart. Instead, tyrosine 
phosphorylations and dephosphorylations were detected in the cytosolic and mi-
crosomal fraction of rat ventricles perfused with 3-T1AM suggesting that 3-T1AM 
might signal via tyrosine phosphorylation and dephosphorylation pathways 
[Chiellini, 07]. 
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1.3.7 Therapeutic applications of TAMs 
In adult C57BL/6 mice injected intraperitoneally with 3-T1AM or T0AM either 
1 or 2 h after or 2 days prior to the experimental induction of stroke, the infarct 
volumes were reduced compared to vehicle treated control mice [Doyle, 07]. The 
effect was abolished when the TAM treated mice were placed on a heat pad. This 
indicated that the neuroprotective effect of TAMs required the induction of hypo-
thermia [Doyle, 07]. 
 
1.3.8 Metabolism of TAMs 
So far, only one study has investigated potential metabolizing reactions of TAMs 
[Pietsch, 07]. T0AM and 3-T1AM, which are present in-vivo, but also T3AM were 
found to be readily sulfated by distinct human liver sulfotransferase (SULT) iso-
forms. Moreover, 3-T1AM was sulfated by homogenates of human brain and car-
diac tissue, i.e. target tissues of TAM action. These SULT actions might serve to 
attenuate and thus regulate TAM action [Pietsch, 07]. 
 
1.3.9 Biosynthesis of TAMs 
The pharmacological effects reported for TAMs identified an interesting discrep-
ancy. On the one hand, TAMs and THs are highly similar in structure (Figure 5), 
but on the other hand, the short-term hypothermic, negative chronotropic and 
negative inotropic effects of TAMs are opposite in direction to the actions of the 
classical thyroid hormone T3. Thus, TAMs were suggested to be derivatives of 
thyroid hormones that might serve to fine-tune or even antagonize thyroid hor-
mone effects [Liggett, 04].  
If TAMs were derivatives of THs, decarboxylation of the β-alanine side chain 
would be required for their biosynthesis. However, so far, no iodothyronine decar-
boxylating enzyme has been identified [Wu, 05]. If the putative decarboxylating 
enzyme was converting only THs with higher iodine content, such as T4, T3s or 
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T2s, Dio isozymes would be directly required to complete the biosynthesis of 3-
T1AM and T0AM by removing one to four iodine atoms. However, any role of Dio 
isozymes in TAM biosynthesis presupposes their ability to accept TAMs as sub-
strates. 
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1.4 Aims of the study 
In the present study, the ability of the Dio isozymes to accept TAMs as substrates 
was investigated.  
The various TAMs analyzed here differed only regarding the number or the posi-
tion of the iodine atoms. Therefore, an important first objective of this study was 
to establish a liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
method to allow for the unequivocal, simultaneous identification and quantification 
of all TAMs in the same sample. So far, no reference method for TAM quantifica-
tion has been available. Thus, a further objective of this study was to include the 
complete panel of THs as established Dio substrates into the LC-MS/MS protocol. 
This would allow for validating the performance of the LC-MS/MS method in 
quantifying Dio catalyzed reactions by comparing the kinetic constants of TH de-
iodination reactions obtained by LC-MS/MS to that obtained by independent 
methods, such as 125I - release assays or HPLC based radiochemical assays. 
The LC-MS/MS based analysis of TAMs and THs from Dio reaction mixtures re-
quired their prior extraction by a method compatible with LC-MS/MS measure-
ments. Thus, another aim of this study was to develop an appropriate extraction 
method allowing for the simultaneous isolation of all TAMs and THs from Dio re-
action mixtures. Further experiments aimed at validating the detection of ex-
tracted TAMs and THs by LC-MS/MS according to internationally accepted rec-
ommendations.  
The central objective of this study was to analyze the substrate specificities of the 
Dio isozymes towards iodothyronamines by independent methods, namely LC-
MS/MS based Dio assays and 125I - release assays. Since these analyses re-
quired isozyme specific Dio preparations, preliminary experiments were per-
formed to characterize the Dio expression pattern in cell line and tissue sources. 
Further LC-MS/MS based Dio assays aimed at characterizing the kinetic proper-
ties of selected TAM deiodination reactions and comparing those to the corre-
sponding THs.  
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2 Materials and Methods 
2.1 Chemicals and reagents 
The chemicals and reagents used in this study were obtained at the highest purity 
available and are listed in Table 1.  
Table 1: List of chemicals and reagents used in this study. 
Chemical Supplier 
[5’-125I]rT3, 250 µCi Perkin-Elmer, Jügesheim, Germany 
3,3’-T2 formula., Berlin, Germany 
3,3’-T2AM OHSU, Portland, Oregon, USA a 
3,5,3’-T3 formula., Berlin, Germany 
3,5,3’-T3AM formula., Berlin, Germany 
3,5-T2 formula., Berlin, Germany 
3,5-T2AM OHSU, Portland, Oregon, USA a 
3’,5’-T2 formula., Berlin, Germany 
3’,5’-T2AM OHSU, Portland, Oregon, USA a 
3’-T1 formula., Berlin, Germany 
3’-T1AM OHSU, Portland, Oregon, USA a 
3-T1 formula., Berlin, Germany 
3-T1AM OHSU, Portland, Oregon, USA a 
3-T1AM-d4 OHSU, Portland, Oregon, USA a 
acetic acid (glacial), 100 %, anhydrous Merck, Darmstadt, Germany 
acetone J.T. Baker, Deventer, The Netherlands 
acetonitrile Merck, Darmstadt, Germany 
AG 50W-X2 resin Bio-Rad, Munich, Germany 
agarose for electrophoresis Serva, Heidelberg, Germany 
albumin bovine fraction V, pH 7.0 Serva, Heidelberg, Germany 
ammonium hydroxide solution, 1 M Fluka, Steinheim, Germany 
Bio-Rad IgG protein standard Bio-Rad, Munich, Germany 
Bio-Rad protein assay dye reagent Bio-Rad, Munich, Germany 
bromophenol blue  Roth, Karlsruhe, Germany 
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cyclohexane Sigma-Aldrich, Steinheim, Germany 
dATP solution, 100 mM Fermentas, St. Leon-Rot, Germany 
dCTP solution, 100 mM Fermentas, St. Leon-Rot, Germany 
ddH2O 
• Millipore (Darmstadt, Germany) for LC-
MS/MS analyses  
• EASY pure UV compact ultrapure water 
system (Barnstedt, Germay) for all other 
experiments 
DEPC Roth, Karlsruhe, Germany 
dGTP solution, 100 mM Fermentas, St. Leon-Rot, Germany 
dipotassium monohydrogen phosphate Roth, Karlsruhe, Germany 
disodium hydrogen phosphate Merck, Darmstadt, Germany 
DMSO Sigma-Aldrich, Steinheim, Germany 
DTT Sigma-Aldrich, Steinheim, Germany 
dTTP solution, 100 mM Fermentas, St. Leon-Rot, Germany 
EDTA Sigma-Aldrich, Steinheim, Germany 
ethanol J.T.Baker, Deventer, The Netherlands 
ethidium bromide solution, 10 mg/ml Sigma-Aldrich, Steinheim, Germany 
ethyl acetate Sigma-Aldrich, Steinheim, Germany 
formaldehyde solution, 37 % J.T.Baker, Deventer, The Netherlands 
formamide AppliChem, Darmstadt, Germany 
forskolin Sigma-Aldrich, Steinheim, Germany 
glycerol, 99 % Sigma-Aldrich, Steinheim, Germany 
HCl, 37 % Merck, Darmstadt, Germany 
HEPES Merck, Darmstadt, Germany 
K2HPO4 Merck, Darmstadt, Germany 
KCl Merck, Darmstadt, Germany 
KH2PO4 Merck, Darmstadt, Germany 
methanol Roth, Karlsruhe, Germany 
MG-132 Biomol, Plymouth, PA, USA 
MOPS Roth, Karlsruhe, Germany 
Na2EDTA•H2O Roth, Karlsruhe, Germany 
Na2HPO4•2H2O Merck, Darmstadt, Germany 
NaCl Sigma-Aldrich, Steinheim, Germany 
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NaOH Merck, Darmstadt, Germany 
PMA Sigma-Aldrich, Steinheim, Germany 
PTU MP Biomedicals, Eschwege, Germany 
rT3 formula., Berlin, Germany 
rT3AM OHSU, Portland, Oregon, USA a 
SephadexTM LH-20 Amersham Biosciences, Piscataway, USA 
sodium acetate Roth, Karlsruhe, Germany 
sodium selenite Sigma-Aldrich, Steinheim, Germany 
sucrose Roth, Karlsruhe, Germany 
T0 formula., Berlin, Germany 
T0AM OHSU, Portland, Oregon, USA a 
T4 formula., Berlin, Germany 
T4AM formula., Berlin, Germany 
TCA Merck, Darmstadt, Germany 
tris Roth, Karlsruhe, Germany 
a TAMs were generously provided by Dr. Thomas Scanlan, Department of Physiology & Pharma-
cology, Oregon Health & Science University, Portland, OR, 97239-3098, USA. 
 
2.2 LC-MS/MS analysis 
2.2.1 Equipment and consumables for LC-MS/MS analysis 
TAM and TH analytes were separated using an Agilent 1100 integrated HPLC 
system consisting of a controller unit, two pumps including a degasser and an 
autosampler (Agilent, Waldbronn, Germany). Both the chromatographic column 
and the autosampler were operated at room temperature. Analytes were detected 
using an API365 triple quadrupole tandem mass spectrometer (Applied Biosys-
tems, Darmstadt, Germany) equipped with a TurboIonSpray interface. Nitrogen 
served as nebulizer, curtain and collision gas. The detection was performed using 
positive electrospray ionization (ESI+) in selected reaction monitoring (SRM) 
mode. Data processing was performed using Bio Analyst Version 1.3.1 software 
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(Applied Biosystems, Darmstadt, Germany). Other equipment and consumables 
used for the LC-MS/MS experiments are listed in Table 2. 
Table 2: List of equipment and consumables used for LC-MS/MS analyses. 
Product Supplier 
Analytical Guard Cartridge System 
(4.0 mm x 2.0 mm) Phenomenex, Aschaffenburg, Germany 
crimp caps with septum (Ø = 11 mm) Wicom, Heppenheim, Germany 
filters for HPLC eluent  
(pore size 0.45 µM) Millipore, Bedford, USA 
glass micro inserts (200 µl) Wicom, Heppenheim, Germany 
glass vials (2 ml, Ø = 11 mm) Wicom, Heppenheim, Germany 
Hamilton syringe device, H81320, 1001 TLL, 1 ml Hamilton, Darmstadt, Germany 
PEEK tubing (Ø = 0.13 mm) Agilent, Waldbronn, Germany 
scales “MC1 Analytic AC 210P” Sartorius, Göttingen, Germany 
syringe pump, Harvard Apparatus, #55-1111 Harvard Apparatus, Saint-Laurent, Canada 
Synergi Polar-RP 80 Å column 
(150 mm x 2.0 mm) Phenomenex, Aschaffenburg, Germany 
ultrasonic bath, Sonorex Super RK 510H Bandelin electronic GmbH, Berlin, Germany 
 
2.2.2 Preparation of TAM and TH stock solutions 
Two independently weighted and diluted 10 mM stock solutions were prepared for 
each TAM and TH analyte. Solvents were used as follows: 
• The diiodothyronines and all TAMs except for T4AM were dissolved in DMSO. 
• T0, monoiodothyronines, triiodothyronines and T4AM were dissolved in DMSO 
containing 100 µM HCl. 
•  DMSO containing 100 µM NH4+ was used to dissolve T4. 
The solutions were stable at - 80 °C in darkness for at least 2 years (see sections 
2.4.7 and 3.2.9).  
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2.2.3 Recording of mass spectra 
The device-specific mass spectrometric parameters used to record the parent ion 
mass spectra and product ion tandem mass spectra are shown in Table 3. 
Table 3: Device-specific mass spectrometric working parameters used to record the parent ion 
mass spectra and product ion tandem mass spectra. 
Parameter Value 
NEB (valve position) 11  
CUR (valve position) 10  
CAD (valve position, for tandem mass spectra only) 5  
TurboIon Spray (IS) voltage  5000 V 
interface temperature 0 °C 
 
The two 10 mM stock solutions that had independently been prepared for each 
analyte (section 2.2.2) were diluted in ddH2O:acetonitrile:acetic acid (50:50:1) to 
obtain two individual 10 µM working solutions of each analyte. These working 
solutions were directly injected into the mass spectrometer at a flow rate of 
10 µl/min using a Hamilton syringe device. To avoid background contaminations 
pure solvent was infused between the injections of different analyte working solu-
tions. Both the parent ion mass spectrum and the product ion tandem mass spec-
trum of each 10 µM working solution were recorded 5 times on 5 different days 
within a period of 3 months. 
 
2.2.4 Recording of chromatograms 
The device-specific mass spectrometric parameters used to record the chroma-
tograms are presented in Table 4.  
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Table 4:  Device-specific mass spectrometric working parameters used to record the chroma-
tograms. 
Parameter Value 
flow rate of mobile phase 300 µl/min 
NEB (valve postition) 11  
CUR (valve position) 10  
CAD (valve position) 5  
TurboIon Spray (IS) voltage 5000 V 
TurboIon Spray heater gas 8 l/min 
interface temperature 300 °C 
sample volume 10 µl 
needle level 6 mm 
sprayer position + 6 mm  
dwell time 90 ms 
Q1 peak width 0.7 amu 
Q3 peak width 0.7 amu 
 
Prior to each sample series the mobile phases were prepared freshly, filtered and 
degassed for 10 min using an ultrasonic bath. Furthermore, the column was 
equilibrated three times by performing three complete measurements injecting 
10 µl mobile phase. 
 
2.3 Extraction of TAMs and THs from Dio reactions 
Dio reactions to be subjected to LC-MS/MS analysis were prepared as described 
in section 2.8.7. Enzymatic reactions were stopped by adding 0.1 volumes 
100 % acetic acid. Subsequently, 20 nM 3-T1AM-d4 were added to each vial to 
serve as internal standard (IS). Acidified reaction mixtures were incubated at 
37 °C for 60 min. Proteins were precipitated by adding 3 volumes ice-cold ace-
tone and incubating at - 20 °C for 15 min. After centrifugation at 14,000 x g and 
4 °C for 5 min, supernatants were transferred into new Eppendorf tubes, acidified 
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with 0.002 volumes 30 % HCl, washed twice with 1 volume cyclohexane and then 
subjected to three subsequent extractions with 1.5 volumes ethyl acetate. Or-
ganic layers were combined and evaporated to dryness at 45 °C using a concen-
trator (eppendorf concentrator 5301, Eppendorf, Hamburg, Germany). Residues 
were redissolved in 30 µl ddH2O:methanol:acetic acid (90:10:1) and stored at       
- 20 °C until analysis of deiodination products by LC-MS/MS. Injection volumes 
were 10 µl with analytes dissolved in the mobile phase used for LC-MS/MS 
analysis.  
 
2.4 Validation of the LC-MS/MS method with extracted analytes 
2.4.1 Selectivity, matrix effects, process efficiencies and recoveries 
The following sets of samples were prepared to assess the selectivity of the LC-
MS/MS method for TAM and TH analytes extracted from Dio reactions. Moreover, 
potential interfering effects of Dio reaction matrices with TAM and TH detection by 
LC-MS/MS as well as process efficiencies and recovery rates were determined. 
• Samples of set 1 were Dio reactions used for LC-MS/MS analysis as de-
scribed in Table 11 with the exception that no substrate but appropriate 
amounts of DMSO were added. Such blank samples were prepared of all 
types of Dio reactions used in this study, namely reactions containing lysates 
of HepG2, MSTO-211H, ECC-1, HEK293 cells or mouse liver membrane frac-
tions either with or without 1 mM PTU. The respective Dio preparations had 
been heat-inactivated before. Dio reactions were subjected to liquid-liquid ex-
traction as described in section 2.3.  
• Samples of set 2 were obtained by adding 20 nM IS alone or together with 
10 nM, 500 nM or 7.5 µM of each TAM and TH analyte to set 1 samples after 
liquid-liquid extraction. 
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• Samples of set 3 were prepared by adding 20 nM IS alone or together with 
10 nM, 500 nM or 7.5 µM of each TAM and TH analyte to set 1 samples prior 
to liquid-liquid extraction. 
• Both 3,3’-T2AM and 3’,5’-T2AM as well as 3,3’-T2 and 3’,5’-T2 were separated 
sufficiently to allow for an unequivocal qualitative identification of each ana-
lyte, but baseline peak separation was not achieved by the chromatographic 
method developed herein (section 3.1.2). Therefore, separate set 2 and set 3 
samples were prepared containing only 3’,5’-T2AM and 3’,5’-T2. 
For set 2 and set 3 samples, each analyte concentration was investigated with all 
types of Dio reactions. Each sample was prepared in triplicate. Samples were 
measured by LC-MS/MS and the mean values of the mass spectrometric re-
sponse of the triplicate samples were determined. For set 2 and set 3 samples 
containing the IS alone, the absolute AUC of the IS was defined as the mass 
spectrometric response. By contrast, for samples containing the IS as well as 
TAM and TH analytes, the AUC ratio of analyte versus IS was considered as the 
mass spectrometric response as illustrated by the following formula:  
 
The selectivity of the LC-MS/MS method for TAM and TH analytes extracted from 
Dio reactions was investigated by comparing the mass spectrometer response of 
set 1 samples and set 2 samples within the analyte specific time windows.  
Matrix effects were estimated by comparing the mass spectrometric response of 
set 1 samples to pure solvent (ddH2O:acetonitrile:acetic acid, 50:50:1) and that of 
set 2 samples to solvent containing 20 nM IS alone or 20 nM IS together with the 
respective concentration of analytes. The following formula was used to report 
matrix effects in percent:  
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Hence, values below 100 % indicated analyte ion suppression whereas values 
above 100 % indicated analyte ion enhancement. The matrix effects for each 
analyte concentration were compared between the different deiodination reaction 
matrices using Kruskal-Wallis test. 
Process efficiencies (a combination of matrix effects and recovery rates) were 
estimated by comparing the mass spectrometric response of set 3 samples to 
solvent containing 20 nM IS alone or 20 nM IS together with the respective con-
centration of analytes. The following formula was used to report process efficien-
cies in percent:  
 
The process efficiencies of each analyte concentration were compared between 
the different deiodination reaction matrices using Kruskal-Wallis test. 
Recoveries were determined by comparing the mass spectrometric response of 
set 2 and set 3 samples. Values were calculated in percent using the following 
formula: 
 
The recoveries of each analyte concentration were compared between the differ-
ent deiodination reaction matrices using Kruskal-Wallis test. 
For recoveries, this series of experiments was repeated twice within 1 week. 
Thus, for each analyte and for each matrix, three grand means were obtained, 
which were again compared using Kruskal-Wallis test. These means served as 
reference values since they were compared to the recoveries determined in each 
routine series of samples described herein. Any routine series of samples was 
accepted when the analyte specific recoveries were within the 15 % coefficient of 
variation (CV) interval of the three analyte specific grand means.  
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2.4.2 Linearity and validation of 3-T1AM-d4 as an internal standard 
The following series of experiments was performed to determine the linear ranges 
of the LC-MS/MS method with extracted TAM and TH analytes. Furthermore, 3-
T1AM-d4 should be validated as IS for all analytes. For this purpose, Dio reac-
tions were prepared as described for use in LC-MS/MS analysis in Table 11 using 
heat-inactivated cell line lysates or mouse liver membrane fractions. DMSO or 
TAM and TH analytes were added yielding the following samples: 
• Samples of set 1 contained all TAMs and THs except for 3’,5’-T2AM and 3’,5’-
T2 at final concentrations of 250 pM, 1 nM, 5 nM, 25 nM, 100 nM, 250 nM, 
 500 nM, 1 µM, 2.5 µM, 5 µM and 7.5 µM.  
• Samples of set 2 contained 3’,5’-T2AM and 3’,5’-T2 at the same final concen-
trations. The reasons for excluding 3’,5’-T2AM and 3’,5’-T2 from these samples 
are described in section 3.1.2. 
• Samples of set 3 contained an appropriate amount of DMSO to serve as blank 
control. 
The IS was added to each sample at a constant concentration of 20 nM. All three 
sets of samples were prepared for all Dio reaction matrices. Samples of set 1 and 
set 2 were prepared in six replicates except for the samples containing 250 pM 
and 7.5 µM of analytes, which were prepared in ten replicates. Set 3 samples 
were also prepared in ten replicates. Samples were subjected to liquid-liquid ex-
traction (section 2.3) and measured by LC-MS/MS. At each concentration outliers 
were identified using Grubbs test and eliminated if found to be significant 
(p < 0.05). To check for homogeneity of variance over the calibration range, the 
variances of the samples containing TAM and TH analytes at final concentrations 
of 250 pM and 7.5 µM were compared using F-test. For all analytes and all Dio 
reaction matrices, homogeneity of variances was achieved using a weighted 
(1/analyte concentration) least squares model, which was therefore used to cal-
culate the calibration curves. The slopes and y-intercepts of the analyte specific 
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regression lines were compared between the different Dio reaction matrices using 
Kruskal-Wallis test.  
This series of experiments was repeated twice within 1 week. Thus, for each ana-
lyte and for each Dio reaction matrix, three calibration curves were obtained. 
These curves served as reference curves since they were compared to the cali-
bration curves determined in each routine series of samples described herein. 
Any routine calibration curve was accepted if its slope and y-intercept were within 
the 15 % coefficient of variation interval of the three reference curves.  
 
2.4.3 Limit of detection and limit of quantification with extracted analytes 
Set 1 and set 2 samples were prepared as described for calibration curve ex-
periments except that the following final analyte concentrations were achieved in 
the Dio reaction matrices: 100 pM, 250 pM, 500 pM, 750 pM, 1 nM, 2.5 nM, 
5.0 nM 7.5 nM, 10.0 nM and 12.5 nM. Each sample was measured by LC-
MS/MS. From the set 3 samples which had been generated for calibration curve 
experiments (section 2.4.2), the signal-to-noise ratios were calculated within the 
time windows in which the analytes were expected. The lowest analyte concen-
tration yielding an AUC ratio of at least 3 times the signal-to-noise ratio was de-
fined as the limit of detection (LOD). The lowest analyte concentration yielding an 
AUC ratio of 10 times the signal-to-noise ratio was defined as the limit of quantifi-
cation (LOQ). This sample series was repeated twice.  
 
2.4.4 Intra-assay precision and bias 
To validate the analyte specific intra-assay precisions and bias of the LC-MS/MS 
method for extract TAM and TH analytes, set 1 and set 2 samples were prepared 
as described for calibration curve experiments except that the analytes were 
added at final concentrations of 10 nM, 500 nM and 7.5 µM. Each sample was 
measured 10 times consecutively in the same run. Analyte concentrations were 
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calculated using the routine calibration curves. For each analyte, the intra-assay 
precision of the retention time was calculated as standard deviation while the in-
tra-assay precision of the analyte AUC concentration was determined as the coef-
ficient of variation. The intra-assay bias of the analyte concentrations were calcu-
lated as the percent deviations of the observed mean values from the respective 
reference values according to the following formula: 
 
x observed analyte concentration 
µ reference analyte concentration 
 
The analyte specific values for intra-assay precision and bias were compared 
between the different analyte concentrations and the different deiodination reac-
tion matrices using Kruskal-Wallis test.  
 
2.4.5 Inter-assay precision and bias 
Thirty aliquots of each of the aforementioned samples that had been generated to 
determine the intra-assay precision and bias, were stored in darkness at - 80 °C. 
Three aliquots of each sample were measured on 10 different days over a time 
period of 2 months. The concentrations of the analytes were calculated using the 
routine calibration curves. The triplicate values conducted for each analyte reten-
tion time and each analyte concentration obtained from every series of experi-
ments were used to calculate a daily mean. For each analyte, the inter-assay 
precision of the retention time was calculated as the standard deviation of the 
daily means subtracted by the analyte specific intra-assay precision. By contrast, 
the inter-assay precision of the analyte concentration was determined as the co-
efficient of variation of the daily means subtracted by the respective intra-assay 
precision. The inter-assay bias was calculated as the percent deviation of the 
grand means from each daily series of experiments from the respective nominal 
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value. The analyte specific values for inter-assay precision and bias were com-
pared between the different analyte concentrations and the different deiodination 
reaction matrices using Kruskal-Wallis test.  
 
2.4.6 Analyte stability in extracted Dio assays 
The following experiments were performed in order to control the stability of each 
individual TAM and TH analyte under auto-sampler and storing conditions, which 
included monitoring for non-enzymatic deiodinations. For that purpose, Dio reac-
tions were prepared as described for use in LC-MS/MS analysis in Table 11 using 
heat-inactivated cell line lysates or mouse liver membrane fractions. Each TAM 
and TH analyte was added individually at final concentrations of 10 nM, 500 nM 
and 7.5 µM while the IS was added at a constant final concentration of 20 nM to 
all samples. Six replicates of each sample were prepared in every type of Dio 
reaction matrix. Samples were subjected to liquid-liquid extraction and the resi-
dues were aliquoted. To monitor auto-sampler stability, the aliquots of freshly pre-
pared residues of three replicate samples were measured at the beginning, in the 
middle and at the end of a 2 day LC-MS/MS run. To assess storage stability, the 
aliquots of residues of three replicate samples were measured directly on the day 
of sample preparation and compared to aliquots which had been stored at - 20 °C 
for 1, 2 or 3 days, which was the longest storing period used in this study. The 
coefficient of variation of the analyte AUC ratio was calculated for every analyte 
concentration and Dio reaction matrix. The values obtained for each analyte con-
centration level and each deiodination reaction matrix were compared using 
Kruskal-Wallis test.  
 
2.4.7 Long-term stability of TAM and TH stock solutions 
From the 10 mM TAM and TH stock solutions prepared as described in section 
2.2.2 the following two samples were prepared using DMSO as solvent: 
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• Sample 1 contained all TAM and TH analytes except for 3’,5’-T2AM and 3’,5’-
T2 at a final concentration of 100 µM. The reasons for excluding 3’,5’-T2AM 
and 3’,5’-T2 from these samples are described in section 3.1.2. 
• Sample 2 contained 3’,5’-T2AM and 3’,5’-T2 at a final concentration of 100 µM. 
The IS was added to every sample at a final constant concentration of 20 µM. 
Twenty aliquots of both samples were stored in darkness at - 80 °C, - 20 °C and 
4 °C, respectively. At the beginning of each routine run, after equilibration of the 
column, 1 aliquot of sample 1 and 2 from each storing condition was diluted 
1:1000 in solvent (ddH2O:acetonitrile:acetic acid, 50:50:1) and subjected to LC-
MS/MS measurement. To compare the analyte AUC ratios, the coefficients of 
variations between the storing temperatures were calculated. These experiments 
were performed over a period of 2 years.  
 
2.5 Animal organs 
Livers from two male, adult, euthyroid C57BL/6 wild type mice at 24 weeks of age 
were kindly provided by Dr. Ulrich Schweizer (Institute of Experimental Endocri-
nology, Charité - Universitätsmedizin, Berlin, Germany). 
 
2.6 Cell culture 
2.6.1 Cell lines, cell culture media and consumables 
Tables 5 and 6 list the human cell lines, cell culture media and consumables used 
in this study.  
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Table 5: List of human cell lines serving as isozyme specific sources of Dios. 
Designation Organism Tissue Origin: ATCC® number a 
ECC-1 human endometrium carcinoma CRL-2923 
HEK293 human human embryonic kidney CRL-1573 
HepG2 human hepatocarcinoma HB-8065 
MSTO-211H human mesothelioma CRL-2081 
a identification number provided by the American Type Culture Collection (ATCC) 
 
Table 6: List of cell culture media and consumables used in this study. 
Product Supplier 
cell culture flasks (25, 75, 150 cm2) Biochrom, Berlin, Germany 
cell scraper, 30 cm Biochrom, Berlin, Germany 
DMEM medium Biochrom, Berlin, Germany 
DMEM-F12 medium Invitrogen, Karlsruhe, Germany 
falcon tubes (15, 50 ml) Biochrom, Berlin, Germany 
FCS Biochrom, Berlin, Germany 
RPMI-1640 medium Invitrogen, Karlsruhe, Germany 
serological pipettes (1, 2, 5, 10, 25 ml) Biochrom, Berlin, Germany 
6-well plates Biochrom, Berlin, Germany 
trypsin/EDTA solution in PBS w/o Ca2+, Mg2+ Biochrom, Berlin, Germany 
 
2.6.2 Routine propagation of cell lines 
HepG2 cells and ECC-1 cells were propagated in DMEM-F12 medium. HEK293 
cells were cultured in DMEM medium while MSTO-211H cells were grown in 
RPMI-1640 medium. All cell culture media were supplemented with 10 % (v/v) 
FCS and 100 nM sodium selenite to allow for optimal expression of Dio seleno-
proteins. Addition of antibiotics to the cell culture medium was omitted since some 
antibiotics, such as aminoglycosides, have been shown to induce stop-codon 
read-through and concomitant amino acid substitution at the selenocysteine (Sec) 
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codon in mammalian cells, which in turn led to a decrease in selenoenzyme activ-
ity, as Sec is essential for normal catalytic center function in selenoenzymes, such 
as Dio isozymes [Handy, 06]. Cells were propagated in an incubator (Hera cell 
incubator, Heraeus, Hanau, Germany) at 37 °C, 95 % humidity and at 5 % CO2. 
Cells were passaged at a confluence of 80 to 90 % under sterile conditions 
(Lamin Air® HB2448, Heraeus Instruments, Hanau, Germany). After rinsing twice 
with 1 x PBS, cells were detached by incubation in trypsin/EDTA solution for 
3 min at standard growing conditions. Trypsin was inhibited by adding fresh me-
dium containing 10 % (v/v) FCS. Cells were centrifuged for 5 min at 1000 x g and 
20 °C. After removing the supernatant, cells were resuspended in fresh medium 
and seeded at a minimum confluence of 20 %. 
 
2.6.3 Stimulation of specific Dio2 and Dio3 enzymatic activity 
Confluent MSTO-211H cells were serum-starved over night and then incubated in 
the presence of 10 µM forskolin and 700 nM MG-132 for 6 h in order to stimulate 
the endogenous Dio2 enzymatic activity [Curcio, 01]. Likewise, confluent and se-
rum-starved ECC-1 cells were treated with 100 nM PMA for 6 h in order to in-
crease the endogenous Dio3 enzymatic activity [Kester, 06].  
 
2.7 Gene expression analysis 
2.7.1 Working solutions for RNA analysis 
Table 7 lists the working solutions prepared for gene expression analysis. Unless 
otherwise stated, all working solutions were stored at room temperature. 
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Table 7: Composition of working solutions prepared for analysis of gene expression. 
Designation Composition 
1 x MOPS buffer diluted from 10 x MOPS buffer using ddH2O 
10 x MOPS buffer 4.0 M MOPS at pH 7.0, 1.0 M sodium acetate, 0.1 M EDTA in ddH2O, pH 7.0, autoclaved, stored in darkness 
1 x TAE buffer 40 mM tris-acetate, 1 mM EDTA in ddH2O, pH 8.3 
5 x RNA loading buffer 
4 mM EDTA, 720 µl 37 % (v/v) formaldehyde solution, 
2 ml 100 %(v/v) glycerol, 3084 µl formamide, 4 ml 10 x MOPS, 
16 µl saturated aqueous bromophenol blue solution, ad 10 ml 
DEPC water, stored at 4 °C 
6 x DNA loading buffer 0.25 % (v/v) saturated, aqueous bromphenol blue solution, 30 % (v/v) glycerol in ddH2O, stored at 4 °C 
DEPC water 1 ‰ DEPC was added to ddH2O, incubated at room tempera-ture for 24 h, sterilized by autoclaving and stored at - 20 °C. 
dNTP-Mix (100 mM) equal volumes of 100 mM solutions of dATP, dCTP, dGTP, dTTP, stored at - 20 °C 
molecular size marker  
1 µl Gene RulerTM 1 kb DNA ladder plus (Fermentas, St. Leon-
Rot, Germany), 1 µl 6 x loading dye solution (Fermentas, St. 
Leon-Rot, Germany), 4 µl ddH2O 
 
2.7.2 RNA isolation from human cell lines and mouse liver 
RNA was isolated from 5•105 cells and from pulverized mouse livers using the 
RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacture’s in-
structions.  
 
2.7.3 Determination of RNA concentration and purity 
To determine the concentrations and purities of RNA samples, 1 µl of each sam-
ple was applied directly to the NanoDrop® ND-1000 Spectrophotometer (peqlab, 
Erlangen, Germany). The UV/Vis spectra were recorded from 220 nm to 750 nm 
using DEPC water as blank control. Samples were measured in duplicates. The 
RNA concentrations were calculated applying the optical density at 260 nm and a 
molar absorption coefficient of 40 ng/µl. The ratios of OD260 to OD280 served to 
estimate RNA purities and were at least 2.0.  
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2.7.4 Control of RNA quality by gel electrophoresis and densitometry 
RNA quality was monitored by horizontal denaturating agarose gel electrophore-
sis. Agarose was dissolved by boiling in DEPC water. Prior to solidification of the 
gel, 10 % (v/v) formaldehyde solution (37 %), 10 % (v/v) 10 x MOPS buffer and 
5 µl ethidium bromide solution/100 ml gel were added. For sample preparation, 
2 µg total RNA and 2 µl 5 x RNA loading buffer were adjusted to a final volume of 
10 µl by adding DEPC water. Samples were heat denaturated at 65 °C for 5 min 
and subsequently cooled down on ice for 2 min. 9 µl of each sample were loaded 
onto the gel. Electrophoresis was performed in a horizontal Blue Marine 200 elec-
trophoresis unit (Serva, Heidelberg, Germany) for 2 h applying 4 V/cm gel and 
using 1 x MOPS buffer as running buffer. 
After electrophoresis, gels were scanned using the Vilber Lourmat gel documen-
tation system (LTF Labortechnik, Wasserburg, Germany). Densitometric analyses 
were performed using the BioCapt software. Optically well-defined bands of 
28 S rRNA and 18 S rRNA whose background corrected densitometric intensities 
on the scanned gel displayed a ratio at least 1.9 were considered indicative of 
intact total RNA.  
 
2.7.5 cDNA synthesis by RT- PCR 
cDNA was synthesized from 5 µg total RNA using the RevertAidTM first strand 
cDNA synthesis kit (Fermentas, St. Leon-Rot, Germany) according to the manu-
facture’s instructions. Incubations were performed in a thermal cycler (Primus, 
MWG Biotech, Ebersburg, Germany). 
 
2.7.6 Semiquantitative PCR 
PCR reactions were performed using the Taq DNA polymerase kit (Qiagen, Hil-
den, Germany) according to the manufacture’s instructions. Gene specific primer 
pairs were designed on the basis of cDNA sequences deposited in the GenBank 
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database. The primer pairs used in each reaction, their nucleotide sequences as 
well as the respective PCR product sizes are listed in Table 8.  
Table 8: List of gene-specific primer pairs used for PCR analyses including the respective nucleo-
tide sequences and PCR product sizes. 
Target 
gene 
Notation of 
primers 
GenBank 
Accession  
Nucleotide sequences of primers 
(5’ to 3’) 
Product 
size (bp) 
hDio1 hDio1 fwd NM000792 GTGCATGTGGTCGTGGGTAAA 604 
 hDio1 rev  CCCTCCTGGATTATGTAGAGCCTC  
hDio2 hDio2 fwd NM000793 TTCCTGCTGGTCTACATT 796 
 hDio2 rev  GGGAATTTTCCAACTGGG  
hDio3 hDio3 fwd NM001362 ATCATCTACATCGAGGAA 942 
 hDio3 rev  GAGATAGTTCGTCATCAG  
hGAPDH hGAPDH fwd NM002046 CCACCCATGGCAAATTCCATGGCA 592 
 hGAPDH rev  TCTAGACGGCAGCTCAGGTCCACC  
mDio1 mDio1 fwd NM007860 TCCAGTACTTCTGGTTTGTCCT 488 
 mDio1 rev  CAGCTTTACCCTTGTAGCAGAT  
mDio2 mDio2 fwd NM010050 ACTTCTCTACCACCACCTTCCT 384 
 mDio2 rev  CGAGGCATAATTGTTACCTGAT  
mDio3 mDio3 fwd NM172119  ACAGATTCACCCTATGTCATCC 378 
 mDio3 rev  CAACCTTTGACTTTCTTTGGAG  
mGAPDH mGAPDH fwd NM008084 TGGCAAAGTGGAGATTGTTGCC 155 
 mGAPDH rev  AAGATGGTGATGGGCTTCCCG  
 
The composition of the PCR samples was optimized in preliminary experiments 
to achieve sensitive amplification of single PCR products. According to the opti-
mized protocol, each PCR sample contained 1 µl undiluted cDNA as template, 
5 µl 10 x PCR buffer, 1 mM MgCl2, 250 mM dNTP mix, 100 nM respective fwd 
primer, 100 nM respective rev primer, 1.25 U Taq polymerase and was adjusted 
to a final volume of 50 µl by adding 40.25 µl DEPC water. The specificity of each 
PCR was confirmed in every experiment by incubating one sample in the ab-
sence of template cDNA.  
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The PCR samples were incubated in a thermal cycler (Primus, MWG Biotech, 
Ebersburg, Germany). In preliminary experiments, annealing temperatures be-
tween 58 °C and 65 °C were tested for each gene in order to optimize the sensi-
tivity, specificity and efficiency of the reactions. In subsequent optimization ex-
periments, the log-linear range of each PCR was determined by starting several 
identical reactions and removing the tubes one by one from the cycler after every 
second reaction cycle. For the hGAPDH and mGAPDH gene, a cycle number 
within the log-linear range was chosen. By contrast, for the Dio genes, a cycle 
number beyond the log-linear range was chosen since it was more important to 
exclude the expression of individual Dio transcripts in a cell line or tissue than to 
semiquantify the concentrations of the detectable Dio mRNAs. The optimized cy-
cler conditions are presented in Table 9. 
Table 9: Optimized thermal cycler conditions for PCR analyses.  
Step Reaction  Temperature (°C) Incubation time 
1 denaturation 95 3 min 
2 annealing 
optimized: 
hDio1: 64, hDio2: 58, hDio3: 58, hGAPDH: 61 
mDio1, mDio2, mDio3, mGAPDH: 58 
1 min 
3 elongation 72 1 min 
4 denaturation 95 30 s 
5 annealing optimized, see above 40 s 
6 elongation 72 1 min 
7 loop to step 4 optimized cycle numbers:  h/mDio1, h/mDio2, h/mDio3: 40, h/mGAPDH: 21 
8 final elongation 72 5 min 
 
2.7.7 Gel electrophoresis of PCR products 
The sizes of the PCR products were estimated by horizontal agarose gel electro-
phoresis. Agarose was dissolved by boiling in 1 x TAE buffer. Appropriate agarose 
concentrations were chosen to allow for sufficient separation of dsDNA in the size 
range of the respective PCR product, namely 2.0 % (w/v) for 100 to 500 bp and 
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1.5 % (w/v) for 500 to 1,000 bp. Prior to the solidification of the gel, 5 µl ethidium 
bromide solution/100 ml gel were added. For sample preparation, 10 µl PCR 
product and 3 µl 6 x DNA loading buffer were adjusted to a final volume of 18 µl 
by adding 5 µl ddH2O. 15 µl of each sample were loaded onto the gel. To esti-
mate the sizes of the PCR products, 5 µl molecular size marker were also elec-
trophorized on each gel. Electrophoresis was performed in a horizontal Blue Ma-
rine 200 electrophoresis unit (Serva, Heidelberg, Germany) for 45 min applying 
6 V/cm gel and using 1 x TAE buffer as running buffer. After electrophoresis, gels 
were scanned using the Vilber Lourmat gel documentation system (LTF La-
bortechnik, Wasserburg, Germany). 
 
2.8 Deiodinase assays 
Two types of Dio assays were used in this study. The classical assay, which was 
based on the release of radioiodide from a tracer, such as [5’-125I]rT3, was devel-
oped by Leonard and Rosenberg in 1980 and will be referred to as “125I - release 
assay”. It allowed for quantifying specific Dio1 and Dio2 activites. The novel as-
say, which relied on the measurement of deiodinated TAM or TH substrate and 
product by LC-MS/MS, was developed in this study and will be referred to as “LC-
MS/MS based Dio assay”. This method was suited to measure specific Dio1, 
Dio2 and Dio3 activities. 
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2.8.1 Working solutions for Dio assays 
The working solutions prepared for use in Dio assays are listed in Table 10. 
Table 10: Working solutions prepared for Dio assays. 
Working solution Composition 
1 mM DTT 1 mM DTT in ddH2O, stored at - 20 °C 
1 x PBS 
137 mM NaCl, 10 mM Na2HPO4•H2O, 2.6 mM KCl, 1.8 mM 
KH2PO4, ad 1000 ml ddH2O, pH 7.4, autoclaved, stored at 
4 °C 
10 % (v/v) acetic acid 10 % (v/v) acetic acid, stored at room temperature 
10 % (w/v) TCA 10 % (w/v) TCA in ddH2O, stored at 4 °C 
10 mM PTU 
PTU was mixed with 40 mM NaOH. 100 mM NaOH was 
added dropwise until PTU dissolved. pH was < 9.0. Stored at 
- 20 °C. 
100 mM HCl 100 mM HCl in ddH2O, stored at room temperature 
40 mM NaOH 40 mM NaOH in ddH2O, stored at room temperature 
AG 50W-X2 resin columns 
3 volumes AG 50W-X2 were stirred with 2 volumes 10 % 
acetic acid and filled into sarpette tips (2 ml PS, Sarstedt, 
Nümbrecht, Germany) equipped with filters (10 µm pore 
sized, MoBiTec, Göttingen, Germany). Stored at room tem-
perature. 
BioRad protein dye working solu-
tion 
Bio-Rad protein assay dye reagent was diluted 1:5 in ddH2O 
immediately before use. 
Dio homogenization buffer 
250 mM D(+) sucrose, 20 mM HEPES, 1 mM EDTA in 
ddH2O, pH 7.4 or pH 8.0, stored at 4 °C, 1 mM DTT was 
added prior to usage. 
eluent ethanol:1 M ammonium hydroxide solution (49:1), stored at room temperature 
potassium-phosphate-EDTA-
buffer 
Buffer A (1 M K2HPO4, 10 mM Na2EDTA•2H2O in ddH2O) was 
titrated with buffer B (1 M KH2PO4, 10 mM Na2EDTA•H2O in 
ddH2O) to adjust pH 6.8 or pH 8.0. Stored at 4 °C. 
protein standard 
Bio-Rad IgG protein standard was reconstituted according to 
the manufacture’s instruction, aliquoted and stored at 
- 20 °C. 
Sephadex LH-20 20 % (w/v) Sephadex LH-20 in 100 mM HCl, stored at room temperature 
stopping solution 10 % albumin bovine fraction V, 10 mM PTU in ddH2O, stored at - 20 °C 
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2.8.2 Optimization of sample preparation and reaction conditions for Dio 
assays 
The Dio isozymes differ considerably in their kinetic parameters and substrate 
preferences [Köhrle, 02]. Therefore, sample preparation and reaction conditions 
were optimized for each isozyme in preliminary experiments. The optimized pro-
tocols are listed in Table 11.  
In the present study, two independent methods were used to analyze Dio cata-
lyzed reactions, Firstly, classical 125I - release assays were employed, which 
quantify the release of 125I - from radiolabeled TH substrates [Leonard, 80]. Sec-
ondly, the LC-MS/MS method and the liquid-liquid extraction protocol developed 
herein were used to study the Dio catalyzed conversions of non radioactively la-
beled TAM and TH substrates. In 125I – release assays and in LC-MS/MS based 
Dio assays, which were designed to measure specific Dio activities and kinetic 
parameters of Dio catalyzed reactions, the reaction conditions were optimized to 
ensure that the reaction rates were proportional to the concentrations of TAM or 
TH substrate, cofactor DTT and protein as well as to the incubation time (Fig-
ures 10, 12, 14, 16, 18, 24; Tables 18, 19). In LC-MS/MS experiments which 
aimed at screening the substrate specificity of the Dio isozymes towards TAM 
and TH substrates, a prolonged incubation time of 120 min was used (Figures 11, 
13, 15, 17, 19 - 22).  
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Table 11: Optimized protocols for sample preparations and incubation conditions for Dio assays.  
Source of Dio preparation HepG2 mouse liver MSTO-211H ECC-1 HEK293 
type of Dio assay 125I - a LC-MS/MS 125I - a LC-MS/MS 125I - a LC-MS/MS 125I - a LC-MS/MS 125I - a LC-MS/MS 
pH of homogenization buffer 7.4 7.4 7.4 7.4 7.4 7.4 8.0 8.0 7.4 or 8.0 b 7.4 or 8.0 b 
µg protein/reaction 50 300 20 40 150 2000 300 600 20-600 b 40-2000 b 
[substrate] (µM) 0.05-2.0 0.05-20.0 0.2-4.4 0.05-20.0 0.002-0.05 0.01-0.5 1.0 0.05-5.0 0.01-4.4 b 0.01-20 b 
pH of potassium-phosphate-
EDTA buffer 
6.8 6.8 6.8 6.8 6.8 6.8 8.0 8.0 6.8 or 8.0 b 6.8 or 8.0 b 
[cosubstrate (DTT)] (mM) 20 20 20 20 20 20 50 50 20 or 50 b 20 or 50 b 
incubation time (min) 30 30 c or 120 d 15 15 c or 120 d 30 30 c or 120 d 30 30 c or 120d 15-30 b 15-120 b 
a 125I - release assay 
b adapted to the conditions used in the respective series of samples 
c as used in quantitative LC-MS/MS based Dio assays which were designed to measure specific Dio activities and kinetic parameters of Dio catalyzed reactions 
d as used in qualitative LC-MS/MS based Dio assays which were designed to screen the substrate specificity of Dio isozymes towards TAM and TH substrates 
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2.8.3 Generation of cell line derived Dio preparations 
Dio1 containing preparations were generated from untreated HepG2 cells. By 
contrast, Dio2 and Dio3 containing preparations were obtained from MSTO-211H 
and ECC-1 cells, respectively which had been pretreated as described in section 
2.6.3 to enhance the endogenous Dio2 or Dio3 expression. Dio deficient control 
preparations were obtained from untreated HEK293 cells.  
Cell layers were washed twice with ice-cold 1 x PBS and harvested by scraping in 
Dio homogenization buffer containing 1 mM freshly added DTT. HepG2 cells and 
MSTO-211H cells were harvested in homogenization buffer at pH 7.4 whereas 
ECC-1 cells were scraped in homogenization buffer at pH 8.0 (Tables 10, 11). 
Cell lysates were frozen in liquid nitrogen, thawed on ice and disrupted by sonica-
tion (ultrasonic processor, Braun, Melsungen, Germany) applying ten pulses of 
0.6 s at 100 w. Protein concentrations were determined as described in section 
2.8.5. The protein concentration required for either 125I - release assays or LC-
MS/MS based Dio assays was adjusted using the respective Dio homogenization 
buffer (Table 11). The Dio preparations were aliquoted into 40 µl samples for use 
in 125I - release assays and 80 µl samples for use in LC-MS/MS based Dio as-
says. Samples were stored at - 20 °C until use.  
 
2.8.4 Preparation of mouse liver membrane fractions 
For preparation of Dio1 containing mouse liver membrane fractions, livers from 
adult male C57BL/6 mice were pulverized (micro-dismembrator U, Braun, Mel-
sungen, Germany). Tissue powder was homogenized in Dio homogenisation 
buffer at pH 7.4 containing 1 mM DTT using a 1 ml luer-lock syringe (BD Plasti-
pak Becton Dickinson, Heidelberg, Germany) equipped with a disposable insulin 
needle (0.45 x 12 mm, Braun, Melsungen, Germany) and sonication as described 
above. Homogenates were centrifuged at 10,000 x g and 4 °C for 10 min (Centri-
fuge 54 17 R, Eppendorf, Hamburg, Germany). Supernatants were discarded. 
Pellets were resuspended in Dio homogenisation buffer at pH 7.4 and subjected 
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to another course of sonication. Protein concentrations were measured as de-
scribed in section 2.8.5. Appropriate protein concentrations were adjusted using 
Dio homogenization buffer at a pH of 7.4. The mouse liver membrane fractions 
were aliquoted into 40 µl samples for use in 125I - release assays and 80 µl sam-
ples for use in LC-MS/MS based Dio assays. Samples were stored at - 20 °C until 
use.  
 
2.8.5 Determination of protein concentration of Dio preparations 
The protein concentration of Dio preparations, namely cell line lysates and mouse 
liver membrane fractions, was determined by a modified Bradford protein assay 
[Bradford, 76]. For sample preparation, an appropriate amount of cell line lysate 
or mouse liver membrane fractions (usually 1 to 5 µl) was adjusted to 100 µl us-
ing ddH2O. Each sample was assessed in triplicates. In standard curve samples 
1, 2, 4, 5, 6 and 8 µl of protein standard (the IgG concentrations varied between 
batches ranging from 1.34 µg/µl to 1.45 µg/µl) were also adjusted to 100 µl using 
ddH2O. The blank value contained 100 µl ddH2O. Samples were incubated with 
900 µl BioRad protein dye working solution for 5 min at room temperature and 
then transferred into 1.5 ml curettes (Sestet, Numbest, Germany). OD595 values 
were measured in an Eppendorf Bio Photometer (Eppendorf, Hamburg, Ger-
many). The OD595 values of the standard curve samples were plotted against 
their protein concentrations. Linear regression analysis typically yielded standard 
curves with coefficients of determination (r2) > 0.95 allowing for calculation of pro-
tein concentrations of Dio preparations. 
 
2.8.6 125I - release assays 
The 40 µl aliquots of Dio preparations (see sections 2.8.3 and 2.8.4) were thawed 
on ice. Each sample was assessed using six replicate aliquots. Three replicates 
were mixed with 10 µl ddH2O and 10 µl 10 mM PTU, respectively. A substrate 
buffer was prepared according to the master mix protocol listed in Table 12.  
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Table 12: Composition of the substrate buffer master mix used in 125I - release assays. 
Reagent  Volume/aliquot 
potassium-phosphate-EDTA-buffer, pH 7.4  10 µl 
40 mM NaOH  0.41 µl 
1 M DTT  2 µl  
unlabeled rT3 (for concentrations see Table 11)  0.1 µl 
ddH2O  37.49 µl  
 
Prior to each assay, [5’-125I]rT3 was prepurified from 125I - originating from autora-
diolytic decay. [5’-125I]rT3 was applied to a freshly prepared column consisting of 
600 µl hydrochloric acid-equilibrated Sephadex LH-20 and a 10 µm pore sized 
filter (MoBiTec, Göttingen, Germany). 125I - was eluted by washing the column 
with 3 ml 100 mM HCl. After equilibrating the column with 3 ml ddH2O, [5’-125I]rT3 
was eluted into a fresh borosilicate glass tube (16 x 100 mm, Hartenstein, Würz-
burg, Germany) by applying 1 ml ethanol:1 M ammonium hydroxide solution 
(49:1) to the column and subsequent centrifugation for 5 min at 1,000 x g and 
4 °C (Cryofuge 5000, Heraeus Sepatech, Hanau, Germany). The tube was 
placed into a 50 °C water bath and the eluent was evaporated under a stream of 
nitrogen. The dried [5’-125I]rT3 was dissolved directly in substrate buffer. To quan-
tify the radioactivity of [5’-125I]rT3 in the substrate mix, the volume of the substrate 
mix to be applied to a single sample was mixed with 2 ml 10 % (v/v) acetic acid. 
Three replicates were prepared and measured in a γ-counter (1277 Gammamas-
ter, LKB Wallac, Turku, Finland). The radioactivity of [5’-125I]rT3 in the substrate 
mix was adjusted to 1,000 ± 200 cpm/µl.  
Deiodination reactions were started by adding 50 µl substrate buffer to each tube 
and immediately placing the tubes one by one into a water bath at 37 °C. To cor-
rect for background 125I - release which was not catalyzed by Dios, three blank 
samples devoid of any Dio preparation were included at the beginning and at the 
end of the incubation of each series of samples. To monitor inter-assay variations, 
aliquots from an in-house Dio1 preparation originating from mouse liver were also 
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included. For all 125I - release assays carried out in this study, the specific Dio1 
activity measured in these samples were within a 15 % coefficient of variation 
(CV) interval. 
Deiodination reactions were stopped by adding 0.5 volumes stopping solution to 
bind iodothyronines and by placing the samples on ice. 40 µl Dio preparations 
were added to the six blank samples. Three volumes 10 % (w/v) TCA were added 
and mixed with samples to precipitate proteins. After centrifugation at 14,000 x g 
for 5 min at room temperature (Centrifuge 5415C, Eppendorf, Hamburg, Ger-
many) iodothyronines, including [5’-125I]rT3, were contained in the protein pellets 
whereas released I -, including 125I -, was contained in the supernatants. To defi-
nitely separate 125I - from [5’-125I]rT3, 480 µl of each supernatant were applied to 
an AG 50W-X2 resin column, which had been equilibrated with 5 ml 10 % acetic 
acid. Released I - was eluted into polystyrene tubes (5 ml, Sestet, Numbest, 
Germany) by applying 2 ml 10 % (v/v) acetic acid to each column. Released 125I - 
was quantified in the γ-counter.  
Specific Dio1 and Dio2 activities were calculated according to the following for-
mula: 
 
2 factor accounting for that each released 
125I - reflects only half of 
the 5’-deiodinations of 5’[125I]rT3 
cpmsample mean radioactivity of triplicate aliquots of each sample (cpm) 
cpmblank mean radioactivity of six blank samples (cpm) 
nrT3 amount of unlabeled rT3 per reaction (nmol) 
cpm100 % mean of radioactivity in substrate mix per sample (cpm) 
mprotein amount of protein per reaction (mg) 
t incubation time (min) 
480/550 factor accounting for analyzing 480 µl of the 550 µl supernatants  
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The 125I - released in samples containing PTU was attributed to Dio2 while the 
difference in 125I - release between aliquots with and without PTU was used to 
calculate Dio1 activity.  
 
2.8.7 Dio assays based on LC-MS/MS 
The 80 µl aliquots of Dio preparations (see sections 2.8.3 and 2.8.4) were thawed 
on ice. In line with 125I - release assays, each sample was assessed using six 
replicate aliquots. Three replicates were mixed with 20 µl ddH2O and 20 µl 10 mM 
PTU, respectively. A substrate buffer was prepared according to the master mix 
protocol listed in Table 13. 
Table 13: Composition of the substrate buffer master mix used in LC-MS/MS based Dio assays.  
Reagent  Volume/aliquot 
potassium-phosphate-EDTA-buffer 
(for pH see Table 11) 
 20 µl 
40 mM NaOH  0.82 µl 
1 M DTT  4 µl or 10 µl (see Table 11) 
TAM or TH standard solution  
(for concentrations see Table 11) 
 0.2 µl 
ddH2O  74.98 µl or 68.98 µl (see Table 11) 
 
Deiodination reactions were started by adding 100 µl substrate buffer to each 
tube and immediately placing the tubes one by one into a water bath at 37 °C. 
Dio reactions were stopped and processed as described in section 2.3.  
 
2.8.8 Routine quality control samples for Dio assays based on LC-MS/MS 
The following control samples were routinely added to each series of samples of 
LC-MS/MS based Dio assays. 
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• Positive control samples were Dio reactions containing aliquots of an in-house 
preparation of mouse liver membrane fractions and 1 µM rT3 as a well-defined 
substrate of Dio1 both in the absence and in the presence of 1 mM PTU.  
• Negative control samples were Dio reactions containing lysates of Dio activity 
deficient HEK293 cells and 1 µM rT3 both in the absence and in the presence 
of 1 mM PTU. 
• Blank samples were Dio reactions containing lysates of heat inactivated cell 
line lysates or mouse liver membrane fractions depending on the Dio prepara-
tion to be used in the main samples and appropriate amounts of DMSO. Blank 
samples were prepared both in the absence and in the presence of 1 mM 
PTU.  
• Calibration curve samples were prepared as described for blank samples, but 
instead of DMSO, six appropriate concentrations of the Dio substrate to be in-
vestigated and of the putative deiodination products were added. Blank sam-
ples were prepared both in the absence and in the presence of 1 mM PTU. 
Calibration curves were calculated for each analyte as described in sections 
2.4.2 and 3.2.5. Thus, specific calibration curves were obtained for each ana-
lyte, which also took the analyte specific recovery rates into account. 
• Nevertheless, the recoveries of each analyte were monitored in each experi-
ment. For that purpose, calibration curve samples devoid of any substrate 
were prepared. After the liquid-liquid extraction procedure, analytes were 
added to the reconstituted residue at the appropriate final concentrations. Re-
coveries were determined as described in section 2.4.1 with the calibration 
curve samples serving as set 3 samples and the post-addition samples de-
scribed here serving as set 2 samples.  
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2.8.9 Calculation of apparent Km and vmax from Dio assays 
In 125I - release assays and LC-MS/MS based Dio assays which were designed to 
determine apparent Km and vmax values of Dio catalyzed reactions, the following 
substrates were used at the indicated concentrations:  
• 50 nM - 2.0 µM rT3 for Dio1 from HepG2 lysates 
• 200 nM - 4.4 µM rT3 for Dio1 from mouse liver membrane fractions 
• 10 nM - 50 nM rT3 for Dio2  
• 10 nM - 100 nM T3 for Dio3 
• 10 nM - 5 µM rT3AM, T3AM, 3-T1AM and 3-T1 for the respective Dio isozyme 
as indicated in Table 19 
The specific Dio activities were expressed as mol 125I - released/mg protein/min 
and mol deiodinated product/mg protein/min for 125I - release assays and LC-
MS/MS based Dio assays, respectively. The apparent Km and vmax values were 
determined by fitting the enzyme kinetic data to the Michaelis-Menten equation by 
means of nonlinear regression using GraphPad Prism Software version 4.00 
(GraphPad, San Diego, California, USA). The values reported for apparent Km 
and vmax are from three separate experiments performed in triplicate and are pre-
sented as mean ± SD. The values obtained for each Dio preparation by either 
method were compared using Wilcoxon test. 
 
2.9 Functional validation of newly identified TAM substrates 
125I - release assays were used to investigate the effect of TAMs on the 5’-
deiodination of rT3 by Dio1. Mouse liver membrane fractions were incubated for 
15 min with 0.2 - 4.4 µM rT3 and 0.1 - 10.0 µM TAM at each rT3 concentration 
used.  
The values reported for apparent Km and vmax were determined as described in 
section 2.8.9 and are presented as mean ± SD from three separate experiments 
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performed in triplicate. Linear regression lines from Eadie-Hofstee plots are used 
to display the effects of TAMs on the Km (represented by slope) and vmax (repre-
sented by y-intercept) of the 5’-deiodination of rT3 by Dio1.  
Ki values were determined by Dixon plots and linear regression analysis (Fig. 4, 
right panel). The values reported for Ki are from three separate experiments per-
formed in triplicate and are presented as mean ± SD. The effect of TAMs on the 
apparent Km and vmax of the conversion of rT3 by Dio1 from mouse liver mem-
brane fractions was analyzed statistically using Friedman test followed by Dunn’s 
post test. p < 0.05 was considered significant. 
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3 Results 
3.1 Detection of TAMs and THs by LC-MS/MS 
3.1.1 Optimization of compound-specific mass spectrometric parameters 
TAMs and THs were detected using positive electrospray ionization (ESI+) tan-
dem mass spectrometry applying selected reaction monitoring (SRM). The mass 
spectrum of each analyte was recorded to optimize the compound-specific mass 
spectrometric working parameters for the detection of the parent ion filtered by 
the first quadrupole. Likewise, the product ion tandem mass spectrum was re-
corded to optimize the parameters for the detection of the most intensive product 
ion filtered by the third quadrupole. Analytes which represented constitutional 
isomers, such as 3-T1AM and 3’-T1AM, were detected using the same mass 
spectrometric parameters. The optimized parameters are listed in Table 14. 
Table 14: List of the optimized compound-specific mass spectrometric working parameters. 
compound (m/z)a Q1b (m/z) Q3c DPd FPe EPf CEPg CEh CXPi 
T0AM 230.3 213.3 3.0 144.0 5.0 94.9 15.6 5.0 
monoiodothyronamines 356.2 339.2 10.0 138.0 6.0 85.0 15.0 8.0 
3-T1AM-d4 360.2 343.2 10.7 169.0 6.0 84.6 15.0 8.1 
diiodothyronamines 482.1 465.1 12.0 177.0 7.6 74.9 16.0 9.0 
triiodothyronamines 608.0 591.0 19.0 196.0 7.7 64.9 20.1 12.0 
T4AM 733.9 716.9 32.0 235.0 9.4 54.9 25.0 15.0 
T0 274.3 228.3 9.0 122.8 5.6 92.3 24.1 5.0 
monoiodothyronines 400.2 354.2 15.0 179.0 6.0 82.6 23.8 9.9 
diiodothyronines 526.1 480.1 18.3 186.0 7.5 72.3 25.5 11.3 
triiodothyronines 652.0 606.0 26.0 199.0 8.2 63.0 26.7 12.7 
T4 777.9 731.8 33.3 242.0 9.0 49.8 32.0 15.0 
a (m/z): mass to charge ratio 
b (m/z) Q1: m/z of parent ion in first quadrupole 
c (m/z) Q3: m/z of most intensive product ion in third quadrupole 
d DP: declustering potential (V) 
e FP: focusing potential (V) 
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f EP: entrance potential (V) 
g CEP: collision cell entrance potential (V) 
h CE: collision energy (V) 
i CXP: collision cell exit potential (V) 
 
Representative spectra including the interpretation of the reported (m/z) values 
are presented in the supplementary Figure S28. All TAMs showed the transition 
(M+H)+ ? (M+H-NH3)+ (Figure S28). Thus, this transition was used for the detec-
tion of each TAM. By contrast, the transition (M+H)+ ? (M+H-HCOOH)+ was 
used for detection of all THs. All spectra were reproducible as assessed by re-
peated recording over a time period of 3 months (data not shown). 
 
3.1.2 Chromatographic separation of TAMs and THs 
As described in section 3.1.1, analytes which represented constitutional isomers, 
such as 3-T1AM and 3’-T1AM, were detected using the same mass spectrometric 
parameters. This was in line with studies reporting that the fragmentation of the 
parent ions of 3-T1 and 3’-T1 as well as 3,5-T2, 3,3’-T2 and 3’,5’-T2 in the second 
quadrupole yielded identical product ions, even if the percent contribution of each 
product ion was unique to each constitutional isomer [Zhang, 06b; Zhang, 06a]. 
Thus, the distinction of constitutional isomers required their chromatographic 
separation prior to the detection by MS/MS. Complete chromatographic separa-
tion and symmetrical peak shapes of almost all TAMs and THs were achieved 
using a Synergi Polar-RP 80 Å column (150 mm x 2 mm) and a gradient elution 
program at a flow rate of 300 µl/min. The Synergi Polar-RP stationary phase was 
an ether-linked phenyl phase with hydrophilic endcapping. Thus, analyte retention 
was due to aromatic and reversed phase selectivity. The analytical column was 
equipped with an Analytical Guard Cartridge System (4.0 mm x 2.0 mm), which 
served to retain contaminants possibly contained in the mobile phase or in sam-
ples. The parameters of the gradient elution program are shown in Figure 6.  
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Figure 6: Parameters of the gradient elution program used for the chromatographic separation of 
TAMs and THs. Eluent A: ddH2O:acetonitrile:acetic acid (95:5:0.6), eluent B: ddH2O:acetonitrile: 
acetic acid (5:95:0.6). 
 
Both 3,3’-T2AM and 3’,5’-T2AM as well as 3,3’-T2 and 3’,5’-T2 were separated suf-
ficiently to allow for an unequivocal qualitative identification of each analyte, but 
baseline peak separation was not achieved by the chromatographic method de-
veloped herein. Since neither 3,3’-T2AM and 3’,5’-T2AM nor 3,3’-T2 and 3’,5’-T2 
were produced simultaneously by any of the Dio catalyzed reactions investigated 
in this study, the LC-MS/MS method was appropriate to analyze all these reac-
tions both qualitatively and quantitatively. Representative chromatograms of TAM 
and TH standard solutions including the analyte retention times obtained by the 
LC-MS/MS method are shown in Figure 7. 
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Figure 7: Representative chromatograms and retention times of TAM and TH standard solutions. 
30 pmol of T0AM, monoiodothyronamines (including 3-T1AM-d4, internal standard, IS), diiodothy-
ronamines, monoiodothyronines and diiodothyronines were injected. Due to the lower intensity of 
detection of T0, triiodothyronamines, T4AM, triiodothyronines and T4 in this method, 150 pmol of 
these compounds had to be injected to obtain peaks that were high enough to present them to-
gether with the aforementioned analytes in the same chromatogram. 3’,5’-T2AM and 3’,5’-T2 were 
not injected since their retention times (15.7 min and 13.7 min, respectively) were almost identical 
to that of 3,3’-T2AM and 3,3’-T2, respectively. 30 pmol 3-T1AM-d4 (IS) were injected, but the re-
spective peak is not visible since its retention time was identical to that of 3-T1AM. Chromatogram 
of TAM standard solutions (A), identification of TAMs and analyte specific retention times (B), 
chromatogram of TH standard solutions (C), identification of THs and analyte specific retention 
times (D), chromatogram of TAM and TH standard solutions (E). IS: internal standard. 
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3.2 Method validation 
The LC-MS/MS based analysis of TAMs and THs from biological matrices, such 
as Dio reactions, required prior extraction of the analytes by a method compatible 
to LC-MS/MS measurements. A method based on liquid-liquid extraction was de-
veloped as described in section 2.3. The detection of extracted analytes by LC-
MS/MS was validated according to internationally accepted recommendations 
[Shah, 00; Peters, 07]. 
 
3.2.1 Selectivity  
The LC-MS/MS method was found to be selective for all TAM and TH analytes 
since no interfering peaks were observed in the extracts of blank Dio reactions 
matrices (Figure 8).  
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Figure 8: Proof of selectivity of the LC-MS/MS detection of TAM and TH analytes extracted from 
Dio reactions. Chromatograms of extracts of blank Dio reaction matrices (left panel). Exemplary 
chromatograms of extracts from Dio reactions which contained heat inactivated HepG2 lysates, 
were devoid of PTU and were spiked with 500 nM individual TAM analytes prior to extraction 
(right panel). IS: internal standard. 
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3.2.2 Matrix effects 
Potential interfering effects of Dio reaction matrices with TAMs and THs were cal-
culated systematically for all Dio reaction matrices and all analytes. Since no 
relevant matrix effects were observed for any matrix and any analyte (Kruskal-
Wallis test), also no differences were detectable between the different Dio reac-
tion matrices (data not shown). Accordingly, the values obtained for Dio reaction 
matrices which contained HepG2 lysates and were devoid of PTU are shown ex-
emplarily in supplementary Table S20. 
 
3.2.3 Process efficiencies 
Since the matrix effects were negligible (section 3.2.2) and the recoveries were 
independent from analyte concentrations and Dio reaction matrices (section 
3.2.4), the values for process efficiencies were also comparable between the dif-
ferent analyte concentrations and matrices. Accordingly, the values obtained for 
Dio reaction matrices which contained HepG2 lysates and were devoid of PTU 
are shown exemplarily in supplementary Table S21. 
 
3.2.4 Recoveries 
To further validate the performance of the extraction method for TAMs and THs, 
the recoveries of all analytes were determined. As assessed by Kruskal-Wallis 
test (data not shown), the recoveries obtained for one analyte did not differ sig-
nificantly between the various analyte concentrations and the Dio reaction matri-
ces used. Therefore, the recovery data obtained for Dio reactions which con-
tained HepG2 lysates and 500 nM of each analyte but were devoid of PTU are 
presented exemplarily in Figure 9. 
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Figure 9: Recoveries of TAM and TH analytes extracted from Dio reaction matrices which con-
tained HepG2 lysates and 500 nM of each analyte but were devoid of PTU. 
 
3.2.5 Linearity 
Analyte specific calibration curves were recorded as described in section 2.4.2 in 
order to determine the linear ranges of the LC-MS/MS method for TAM and TH 
standard solutions and to validate 3-T1AM-d4 as an internal standard (IS) for all 
analytes. 
For all analytes and all Dio reaction matrices, homogeneity of variances was 
achieved using a weighted (1/analyte concentration) least squares model, which 
was therefore used to calculate the calibration curves. The slopes and  
y-intercepts of the analyte specific regression lines did not differ between the Dio 
reaction matrices as determined by Kruskal-Wallis test (data not shown). The co-
efficients of determination (r2) were ≥ 0.997 and are listed in Table 15. Thus, the 
LC-MS/MS method was linear over a wide range of analyte amounts and 3-
T1AM-d4 was verified as an appropriate IS for all TAM and TH analytes. 
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Table 15: List of analyte specific coefficients of determination (r2) obtained from calibration curves.  
Analyte r2 Analyte r2 
T0AM 0.9974 T0 0.991 
3-T1AM 0.9980 3-T1 0.991 
3’-T1AM 0.9984 3’-T1 0.995 
3-T1AM-d4 0.9971 3,5-T2 0.989 
3,5-T2AM 0.9972 3,3’-T2 0.981 
3,3’-T2AM 0.9972 3’,5’-T2 0.985 
3’,5’-T2AM 0.9974 T3 0.976 
T3AM 0.984 rT3 0.997 
rT3AM 0.9970 T4 0.985 
T4AM 0.9978   
 
Since 3-T1AM-d4 was validated as a suitable IS for all analytes, the AUCs of TAM 
and TH analytes will be expressed as follows in all experiments described herein: 
 
 
3.2.6 Limit of detection and limit of quantification 
For each analyte, identical LOD and LOQ values were obtained with each Dio 
reaction matrix. Both parameters were roughly one order of magnitude higher for 
TAM and TH analytes containing three or four iodine atoms compared to those 
containing zero to two iodine atoms per molecule with T0 being an exception as 
demonstrated in Table 16. 
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Table 16: List of LOD and LOQ values of TAM and TH analytes extracted from Dio reaction matri-
ces.  
Analyte LD LOQ Analyte LD LOQ 
T0AM 100 pM 250 pM T0 1 nM 2.5 nM 
3-T1AM 100 pM 250 pM 3-T1 250 pM 500 pM 
3-T1AM-d4 100 pM 250 pM 3’-T1 250 pM 500 pM 
3’-T1AM 100 pM 250 pM 3,5-T2 250 pM 500 pM 
3,5-T2AM 250 pM 500 pM 3,3’-T2 250 pM 500 pM 
3,3’-T2AM 100 pM 250 pM 3’,5’-T2 250 pM 500 pM 
3’,5’-T2AM 100 pM 250 pM T3 2.5 nM 5 nM 
T3AM 1 nM 2.5 nM rT3 2.5 nM 5 nM 
rT3AM 1 nM 2.5 nM T4 2.5 nM 5 nM 
T4AM 1 nM 2.5 nM    
 
3.2.7 Precision and bias  
Several stability parameters were determined to verify that the LC-MS/MS 
method worked reproducibly both on a within-day as well as day-to-day basis as 
described in (sections 2.4.4 and 2.4.5). Both intra- and inter-assay precision and 
bias did not differ significantly between the different concentrations of each ana-
lyte and the Dio reaction matrices as determined by Kruskal-Wallis test (data not 
shown). Accordingly, the analyte specific data obtained for PTU-free Dio reactions 
containing HepG2 lysates and 500 nM of each analyte are presented in Table 17. 
Intra- and inter-assay precision of retention times were < 2.14 sec 
and < 2.18 sec, respectively. Intra- and inter-assay precision of analyte concen-
trations ranged between 5.0 to 8.3 % and 5.6 to 11.0 %, respectively. Thus, the 
precision data were within the required limits of 15 % coefficient of variation, at all 
analyte concentrations studied [Shah, 00; Peters, 07]. Intra- and inter-assay bias 
of analyte concentrations ranged between 3.3 to 10.3 % and 6.1 to 12.4 %. Thus, 
bias data were also within the acceptance range of ± 15 % of the nominal values 
at all concentrations [Shah, 00; Peters, 07]. 
Results 
________________________________________________________________________________________________________________________ 
 67
Table 17: List of precision of analyte retention times as well as precision and bias of analyte con-
centrations as obtained for both intra- and inter-assay conditions. 
Analyte Intra-assay variation Inter-assay variation 
 Precision
of rt (s) a 
Precision of
[analyte] (%) 
Bias of  
[analyte] (%) 
Precision
of rt (s) a 
Precision of 
[analyte] (%) 
Bias of 
[analyte] (%) 
T0AM 2.14 8.3 5.2 2.18 11.0 6.1 
3-T1AM 1.64 5.9 3.9 1.36 6.6 6.9 
3’-T1AM 0.99 4.2 4.6 1.64 4.5 7.2 
3,5-T2AM 1.50 5.1 3.3 1.49 9.3 8.1 
3,3’-T2AM 1.34 5.0 3.2 1.73 5.8 8.5 
3’,5’-T2AM 1.46 5.3 3.9 1.46 5.4 6.4 
T3AM 1.57 5.0 7.8 1.42 5.6 13.7 
rT3AM 1.36 4.6 5.9 2.09 4.9 7.2 
T4AM 1.33 7.1 10.3 1.60 9.1 11.9 
T0 2.01 7.3 8.8 2.12 10.8 10.2 
3-T1 1.38 5.1 6.4 1.27 5.4 7.4 
3’-T1 1.79 5.2 7.0 1.64 5.7 4.6 
3,5-T2 1.25 5.5 2.4 1.35 6.4 6.3 
3,3’-T2 1.55 5.5 3.8 1.36 6.3 6.9 
3’,5’-T2 1.32 4.5 5.1 1.24 5.1 8.9 
T3 1.36 6.3 8.1 1.74 10.5 12.7 
rT3 1.46 5.9 9.4 1.78 10.0 6.3 
T4 1.83 5.2 3.9 1.28 10.7 12.4 
a The precision of the retention time is presented as standard deviation. 
b By contrast, the precision of the analyte concentration is presented as coefficient of variation. 
rt = retention time 
 
3.2.8 Analyte stability in extracted Dio assays 
The stability of TAM and TH analytes in extracted Dio assays was assessed as 
described in section 2.4.6 and did not differ between the analyte concentration 
levels and the Dio reaction matrices (Kruskal-Wallis test). Since the analyte spe-
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cific coefficients of variation never exceeded the inter-assay precisions of analyte 
concentration (data not shown), the analytes were considered as stable under the 
autosampler and storage conditions used in this study. Thus, non-enzymatic de-
iodinations under autosampler and storage conditions were excluded. 
 
3.2.9 Long-term stability of TAM and TH stock solutions 
The long-term stability of TAM and TH stock solutions, which were prepared as 
described in section 2.2.2, was monitored over a period of 2 years as depicted in 
section 2.4.7. Since the analyte specific coefficients of variation never exceeded 
the intra-assay precisions of analyte concentration (data not shown), the TAM and 
TH stock solutions were considered as stable.  
 
3.3 Isozyme specificity of Dio preparations  
The following human cell lines and tissues were selected as well-established 
sources for endogenous high specific activities of the respective Dio isozyme:  
• HepG2 for Dio1  
• mouse liver for Dio1 
• MSTO-211H for Dio2 
• ECC-1 for Dio3 
Still, to verify the exclusive expression of the respective Dio isozyme in each 
preparation, the following experiments were performed: 
• Dio transcripts were analyzed using semiquantitative RT-PCR. 
• Apparent Km and vmax of Dio1 and Dio2 activities were measured using 125I –
release assays employing rT3 as substrate. Additionally, apparent Km and vmax 
of Dio1 and Dio2 activities were measured using the novel liquid-liquid extrac-
tion and LC-MS/MS detection protocol also employing rT3 as substrate. The 
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values obtained by both methods were compared using Wilcoxon test thus 
validating the performance of the novel LC-MS/MS method in Dio assays.  
• Apparent Km and vmax of Dio3 activities were measured using LC-MS/MS 
based Dio assays and employing T3 as substrate. The specific activities ob-
tained for Dio3 in ECC-1 lysates were compared to the values obtained by a 
radiochemical, HPLC-based assay [Kester, 06]. 
• The substrate specificity of the Dio preparations towards all iodothyronines, 
namely T4, rT3, T3, 3’,5’-T2, 3,3’-T2, 3,5-T2, 3’-T1 and 3-T1, was analyzed using 
LC-MS/MS based Dio assays. 
 
3.3.1 HepG2 lysates as a source for Dio1 
In HepG2 lysates, Dio1 transcript and enzymatic activity were detected (Fig-
ure 10). The apparent Km and vmax values of the specific Dio1 activity with rT3 as 
obtained by 125I - release assay and by LC-MS/MS assay were typical of Dio1 
[Köhrle, 02] and did not differ significantly (Wilcoxon test; Figure 10B, C). Al-
though Dio2 transcript was detected, no corresponding PTU-insensitive specific 
Dio2 activity was measured. Such discrepancies between specific activity and 
cognate transcript are not unusual for selenoproteins, such as Dio isozymes, 
since successful selenoprotein translation is very complex, error-prone and less 
efficient than that of typical proteins [Gereben, 02; Dumitrescu, 05]. Dio3 expres-
sion was neither detected at the transcript nor at the activity level (Figure 10), 
which was in line with published data [Kester, 06]. 
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Figure 10: Expression of Dio transcripts in HepG2 cells as determined by RT-PCR (A) and quanti-
fication of specific Dio enzymatic activities in HepG2 lysates as determined by 125I - release as-
says (B) or LC-MS/MS based Dio assays (C). nd: not detected, na: not applicable. 
 
Incubation of HepG2 lysates with iodothyronine substrates revealed that T4 was 
weakly 5’-deiodinated to T3 (Figure 11A), which is consistent with previous find-
ings [Chopra, 76; Visser, 78; Kaplan, 78]. Furthermore, a small 3,3’-T2 peak was 
observed. Theoretically, 3,3’-T2 might have been formed by further 5-deiodination 
of T3 or by 5-deiodination of T4 to rT3 and subsequent rapid 5’-deiodination of rT3. 
The latter interpretation is consistent with published data [Visser, 79; Moreno, 94] 
and supported by the finding that rT3 was almost completely 5’-deiodinated to 
3,3’-T2 by Dio1 preparations from HepG2 cells whereas T3 was not deiodinated at 
all (Figure 11B, C). Apart from rT3, 3’,5’-T2 was also 5’-deiodinated to 3’-T1 (Fig-
ure 11D). The deiodinations of T4, rT3 and 3’,5’-T2 were completely inhibited by 
the Dio1 specific inhibitor PTU, which is in line with published Dio1 inhibitions 
characteristics [Köhrle, 02]. Both 3-T1 and 3’-T1 were no substrates of Dio1 from 
HepG2 lysates, which is consistent with previously reported data [Chopra, 81; 
Otten, 84; Sorimachi, 80a].  
However, some TH deiodination reactions which have been described for Dio1, 
namely the 3’-deiodination of 3,3’-T2 as well as the 5-deiodinations of T3 and 3,5-
T2 [Kuiper, 05; Chopra, 82], were not catalyzed by Dio1 from HepG2 lysates. 
Therefore, HepG2 lysates were used as an isozyme specific source of Dio1 in 
Results 
________________________________________________________________________________________________________________________ 
 71
further experiments, but an additional Dio1 preparation, namely mouse liver 
membrane fractions, was added to the analyses.  
 
 
Figure 11: Chromatograms of LC-MS/MS based Dio assays using HepG2 lysates as Dio1 specific 
preparations and 500 nM of the indicated iodothyronine as substrate. IS: internal standard. 
 
The analyte AUC ratio in PTU containing HepG2 incubations never differed from 
that measured in negative control samples, which contained either heat inacti-
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vated HepG2 lysates or Dio deficient HEK293 lysates (see section 2.8.8, data not 
shown). This was also observed for TAM substrates and for mouse liver mem-
brane fractions. Likewise, the TAM and TH analyte AUC ratios in heat inactivated 
MSTO-211H and ECC-1 lysates were never different from that measured in 
HEK293 lysates. Accordingly, with the reaction conditions used herein, the TAM 
and TH substrates were only subject to deiodination reactions but not to alternate 
non-deiodinative pathways reported for THs, such as sulfation, glucuronidation, 
ether-link cleavage or side chain modifications, such as decarboxylation and oxi-
dative deamination [Wu, 05].  
Furthermore, with each deiodination reaction analyzed herein, the amount of 
product(s) formed was always, without any exception, identical to the amount of 
substrate converted (data not shown). 
 
3.3.2 Mouse liver membrane fractions as a source for Dio1 
Liver membrane fractions from male C57BL/6 mice were used as a second 
source of Dio1 enzyme activity in this study since Dio1 from HepG2 cells did not 
catalyze all TH deiodination reactions which have been reported for Dio1 (section 
3.3.1). In mouse liver membrane fractions, Dio1 transcript and specific activity 
were detected (Figure 12A, B), which was consistent with previous data 
[Schneider, 06]. Again, 125I - release assays and LC-MS/MS assays employing 
rT3 as substrate yielded apparent Km values in the higher nanomolar range and 
high apparent vmax values (Figure 12B, C), which were typical of Dio1 activity 
[Schoenmakers, 92] and did not differ significantly between the two assays used 
(Wilcoxon test). Dio2 expression was neither detected at the transcript nor at the 
enzymatic activity level (Figure 12), which was in line with Dio2 expression re-
ported for rodent liver [Schneider, 06; Bates, 99]. By contrast, a Dio3 transcript 
was detected in mouse liver, while no corresponding specific Dio3 activity was 
measured (Figure 12). These findings were consistent with the detection of a 
Dio3 transcript in the liver of 6 to 12 week old female C57BL/6 mice but inconsis-
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tent with the measurement of cognate specific Dio3 activity [Boelen, 05]. How-
ever, the specific activity reported in the cited study was very low 
(0.5 fmol/mg protein/min at a substrate concentration of 1 nM T3). Besides, it was 
in disagreement with several studies on rat Dio3 expression, which have reported 
that specific Dio3 activity was highest in the fetus, decreased rapidly after birth 
and was absent in the adult [Bates, 99; Galton, 91; Huang, 88].  
 
Figure 12: Expression of Dio transcripts in mouse liver as determined by RT-PCR (A) and quanti-
fication of specific Dio enzymatic activities in mouse liver membrane fractions as determined by 
125I - release assays (B) or LC-MS/MS based Dio assays (C). nd: not detected, na: not applicable. 
 
As observed with Dio1 from HepG2 lysates, mouse liver membrane fractions also 
deiodinated T4 yielding T3 and 3,3’-T2 (Figure 13A). Likewise, rT3 and 3’,5’-T2 
were 5’-deiodinated (Figure 13B, D). In addition to Dio1 from HepG2 lysates, a 
weak 3’-deiodination of 3,3’-T2 was observed as well as faint 5-deiodinations of 
both T3 and 3,5-T2 (Figure 13C, E, F). All reactions were inhibited by PTU. The 
monoiodothyronines were the only THs not to be accepted as substrates of Dio1 
in these studies. Accordingly, no substrate disappearance was monitored in these 
reactions (Figure 13G, H). 
In summary, mouse liver membrane fractions catalyzed all TH deiodination reac-
tions which have been described for Dio1, so far (compare Figure 4 to Figure 13). 
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Therefore, they were employed as an additional Dio1 specific preparation in fur-
ther experiments.  
 
Figure 13: Chromatograms of LC-MS/MS based Dio assays using mouse liver membrane frac-
tions as Dio1 specific preparations and 500 nM of the indicated iodothyronine as substrate. IS: 
internal standard. 
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3.3.3 MSTO-211H lysates as a source for Dio2 
MSTO-211H cells expressed the Dio2 transcript exclusively (Figure 14A). Fur-
thermore, the typical nanomolar Km reported for Dio2 [Köhrle, 02] and the high 
vmax previously reported for MSTO-211H cells were measured using 125I – release 
assays and LC-MS/MS based Dio assays with rT3 as substrate [Curcio, 01] (Fig-
ure 15B, C).  
 
Figure 14: Expression of Dio transcripts in MSTO-211H cells as determined by RT-PCR (A) and 
quantification of specific Dio enzymatic activities in MSTO-211H lysates as determined by 125I - 
release assays (B) or LC-MS/MS based Dio assays (C). nd: not detected, na: not applicable. 
 
T4, rT3 and 3’,5’-T2 were 5’-deiodinated by MSTO-211H lysates in a PTU-
insensitive fashion (Figure 15A, B, D), which is in line with known inhibition char-
acteristics of Dio2 [Köhrle, 02] (section 1.2.2). T3, 3,3’-T2 and 3’-T1, which have 
either not been reported or been excluded as Dio2 substrates, so far, were also 
not deiodinated in these experiments (Figure 15C, E, G). Since Dio2 catalyzes 
phenolic ring deiodinations exclusively, iodothyronines containing only tyrosyl ring 
iodine atoms, namely 3,5-T2 and 3-T1, served as negative control substrates. In-
deed, neither substrate disappearance nor product formation were observed in 
incubations with these two compounds (Figure 15F, H). Taken together, the sub-
strate specificity of MSTO-211H lysates in these assays mirrored that reported for 
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Dio2. Therefore, MSTO-211H lysates represented an isozyme specific prepara-
tion of Dio2. 
 
Figure 15: Chromatograms of LC-MS/MS based Dio assays using MSTO-211H lysates as Dio2 
specific preparations and 500 nM of the indicated iodothyronine as substrate. IS: internal stan-
dard. 
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3.3.4 ECC-1 lysates as a source for Dio3 
In ECC-1 lysates, both Dio3 transcript and enzymatic activity were detected (Fig-
ure 16A, C). The specific Dio3 activities measured in LC-MS/MS based Dio as-
says were in line with those obtained by a radiochemical, HPLC-based assay 
[Kester, 06]. Just like in HepG2 cells, no Dio2 enzymatic activity was measured in 
ECC-1 cells despite the detection of a Dio2 transcript. Since Dio1 mRNA and 
minimal Dio1 enzymatic activity were found in ECC-1 lysates (specific Dio1 activ-
ity of 23 ± 3 fmol 125I - released/mg protein/min at a final rT3 concentration of 
1.0 µM), they were used as a specific source for Dio3 only in the presence of 
1 mM PTU as an efficient inhibitor of Dio1.  
 
Figure 16: Expression of Dio transcripts in ECC-1 cells as determined by RT-PCR (A) and quanti-
fication of specific Dio enzymatic activities in ECC-1 lysates as determined by 125I - release as-
says (B) or LC-MS/MS based Dio assays (C). nd: not detected, na: not applicable. 
 
The isozyme specificity of such ECC-1 lysates containing 1 mM PTU was verified 
by assessing their substrate specificity towards the complete panel of iodothyron-
ines. Tyrosyl ring deiodinations of all iodothyronines containing tyrosyl ring iodine 
atoms, namely T4, rT3, T3, 3,3’-T2, 3,5-T2 and 3-T1, were observed (Figure 17A, B, 
C, E, F, H). Since these reactions were not inhibited by PTU, they were unambi-
guously catalyzed by Dio3. Apart from 3-T1, which has not been reported as a 
Dio3 substrate yet, all of the observed tyrosyl ring deiodinations have already 
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been reported as Dio3 catalyzed reactions [Köhrle, 02; Sorimachi, 79a; Sorima-
chi, 79b; Sorimachi, 77]. Iodothyronines containing only phenolic ring iodine at-
oms, namely 3’,5’-T2 and 3’-T1, served as negative control substrates since Dio3 
catalyzes tyrosyl ring deiodinations exclusively. Indeed, neither substrate disap-
pearance nor product formation was observed in incubations with these two com-
pounds (Figure 17D, G). Taken together, the reactions catalyzed by Dio3 from 
ECC-1 lysates were in line with the substrate specificity reported for Dio3 towards 
THs. Based on these experiments, ECC-1 lysates containing 1 mM PTU were 
considered as an isozyme specific preparation of Dio3. 
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Figure 17: Chromatograms of LC-MS/MS based Dio assays using ECC-1 lysates as Dio3 specific 
preparations and 500 nM of the indicated iodothyronine as substrate. Since minimal Dio1 enzy-
matic activity was found in ECC-1 lysates, they were used as a specific source for Dio3 only in the 
presence of 1 mM PTU as an efficient inhibitor of Dio1. IS: internal standard. 
 
3.3.5 HEK293 lysates as negative controls 
HEK293 lysates served as negative control preparations since no Dio activities 
were measured despite a strong signal for Dio2 mRNA and a faint band for Dio3 
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transcript (Figure 18). Moreover, none of the iodothyronine substrates was con-
verted by HEK293 lysates (data not shown).  
 
Figure 18: Expression of Dio transcripts in HEK293 cells as determined by RT-PCR (A) and quan-
tification of specific Dio enzymatic activities in HEK293 lysates as determined by 125I - release 
assays (B) or LC-MS/MS based Dio assays (C). nd: not detected, na: not applicable. 
 
3.4 Identification of TAM deiodination reactions 
3.4.1 TAM substrates of Dio1 containing HepG2 lysates  
To test the ability of Dio1 from HepG2 cells to accept TAMs as substrates, HepG2 
lysates were incubated as described in Table 11 using various concentrations of 
TAMs as substrates. Both rT3AM and 3’,5’-T2AM were readily 5’-deiodinated to 
3,3’-T2AM and 3’-T1AM, respectively at all substrate concentrations tested (Figure 
19B, D). As both reactions were sensitive to PTU inhibition, they were unambigu-
ously catalyzed by Dio1. No conversions of rT3AM and 3’,5’-T2AM were observed 
in negative control experiments performed with HEK293 lysates or heat-
inactivated HepG2 lysates (data not shown). All other iodothyronamines were not 
deiodinated by HepG2 cell lysates under these conditions and at the substrate 
concentrations tested (Figure 19A, C, E -H). The finding that T4AM was no sub-
strate of Dio1 was in line with a previous study [Köhrle, 84].  
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Figure 19: Chromatograms of LC-MS/MS based Dio assays using HepG2 lysates as Dio1 specific 
preparations and 500 nM of the indicated iodothyronamine as substrate. IS: internal standard. 
 
3.4.2 TAM substrates of Dio1 containing mouse liver membrane fractions 
In line with HepG2 experiments, rT3AM and 3’,5’-T2AM were 5’-deiodinated in a 
PTU-sensitive way (Figure 20A, B). In contrast to the HepG2 assays, 3,3’-T2AM 
was 3’-deiodinated yielding 3-T1AM (Figure 20C). In addition, weak 5-
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deiodinations at the tyrosyl rings of T3AM and 3,5-T2AM gave rise to 3,3’-T2AM 
and 3-T1AM, respectively (Figure 20D, E). 
 
 
Figure 20: Chromatograms of LC-MS/MS based Dio assays using mouse liver membrane frac-
tions as Dio1 specific preparations and 500 nM of the indicated iodothyronamine as substrate. IS: 
internal standard. 
 
3.4.3 TAM substrates of Dio2 containing MSTO-211H lysates 
Of all iodothyronamines, only rT3AM and 3’,5’-T2AM were 5’-deiodinated by Dio2 
from MSTO-211H lysates yielding 3,3’-T2AM and 3’-T1AM, respectively (Fig-
ure 21). In contrast to HepG2 lysates, these 5’-deiodination reactions were not 
sensitive to PTU, which is in agreement with the known inhibition characteristics 
of Dio2. 
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Figure 21: Chromatograms of LC-MS/MS based Dio assays using MSTO-211H lysates as Dio2 
specific preparations and 500 nM of the indicated iodothyronamine as substrate. IS: internal stan-
dard. 
 
3.4.4 TAM substrates of Dio3 containing ECC-1 lysates 
To inhibit the weak Dio1 enzymatic activity that had been found in ECC-1 cells, 
1 mM PTU was used throughout the incubations. Tyrosyl ring deiodinations of all 
TAMs (Figure 22) except those without tyrosyl ring iodine, namely 3’,5’-T2AM and 
3’-T1AM, were observed (data not shown). As these reactions occurred in the 
presence of PTU, they were clearly catalyzed by Dio3.  
 
Results 
________________________________________________________________________________________________________________________ 
 84
 
Figure 22: Chromatograms of LC-MS/MS based Dio assays using ECC-1 lysates as Dio3 specific 
preparations and 500 nM of the indicated iodothyronamine as substrate. Since minimal Dio1 en-
zymatic activity was found in ECC-1 lysates they were used as a specific source for Dio3 only in 
the presence of 1 mM PTU as an efficient inhibitor of Dio1. IS: internal standard. 
 
3.4.5 Summary of Dio substrate specificities towards TAMs 
The newly identified TAM deiodination reactions catalyzed by each Dio isozyme 
are summarized in Figure 23.  
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Figure 23: Summary of the newly identified TAM deiodination reactions catalyzed by each Dio 
isozyme. Arrows: pointing to lower left: phenolic ring deiodinations, pointing to lower right: tyrosyl 
ring deiodinations, light green: phenolic ring deiodinations catalyzed by the respective Dio 
isozyme, dark green: tyrosyl ring deiodinations catalyzed by the respective Dio isozyme, black: 
deiodination reactions which were theoretically possible but found not to be catalyzed by the re-
spective Dio isozyme. 
 
3.5 Functional validation of newly identified TAM substrates 
To substantiate the newly identified TAM deiodination reactions, it was investi-
gated which TAMs would interfere with an established TH deiodination reaction. 
Those TAMs which had been identified as Dio substrates in the LC-MS/MS ex-
periments were expected to compete with a classical TH substrate in a Dio cata-
lyzed reaction. By contrast, those TAMs which were excluded as Dio substrates 
in the LC-MS/MS experiments were not expected to do so.  
Mouse liver membrane fractions, which represent a rich source of Dio1 as dem-
onstrated in Figure 12, were subjected to 125I - release assays using rT3 as sub-
strate and increasing concentrations of the various TAMs as inhibitors. Mouse 
liver membrane fractions were chosen as an exemplary Dio source in these as-
says since both phenolic and tyrosyl ring TAM substrates had been identified for 
this enzyme preparation in LC-MS/MS experiments (Figure 13). rT3 was chosen 
since it represents the preferred substrate of murine Dio1. In line with previous 
reports, rT3 was 5’-deiodinated by Dio1 from mouse liver membrane fractions fol-
lowing Michaelis-Menten kinetics with an apparent Km of 0.43 ± 0.023 µM and 
apparent vmax of 142.7 ± 2.7 pmol 125I - released/mg/min (Figure 12).  
rT3AM, 3’,5’-T2AM and 3,3’-T2AM, which had been identified as phenolic ring 
substrates of Dio1 from mouse liver membrane fractions in LC-MS/MS experi-
ments, inhibited the 5’-deiodination of rT3. Both 3’,5’-T2AM and 3,3’-T2AM lead to 
a significant increase in apparent Km as determined by Friedman test followed by 
Dunn’s post test (Figure 24A, B; Table 18). Moreover, 3’,5’-T2AM and 3,3’-T2AM 
caused slight decreases in apparent vmax, which reached statistical significance. 
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Therefore, 3’,5’-T2AM and 3,3’-T2AM acted as mixed inhibitors, with competitive 
and noncompetitive elements. Dixon plots revealed Ki values of 2.6 ± 0.4 µM and 
4.8 ± 0.1 µM for 3’,5’-T2AM and 3,3’-T2AM, respectively (Figure 24A, B; Table 18). 
By contrast, rT3AM decreased the apparent vmax of rT3 conversion without signifi-
cantly changing the apparent Km indicating that rT3AM behaved as a noncompeti-
tive inhibitor (Figure 24C; Table 18). From the change in apparent vmax for rT3, a 
Ki value of 1.3 ± 0.2 µM was calculated for rT3AM.  
T3AM and 3,5-T2AM, which had been identified as weak tyrosyl ring substrates of 
Dio1 (Figure 13C, F), also acted as noncompetitive inhibitors (Figure 24D, E; Ta-
ble 18). As expected from the LC-MS/MS studies, T3AM and 3,5-T2AM exhibited 
high Ki values of 34.0 ± 2.6 µM and 85.0 ± 7.7 µM, respectively. 
TAMs which were not converted by Dio1 from mouse liver membrane fractions in 
the LC-MS/MS experiments, namely T4AM, 3’-T1AM and 3-T1AM, failed to show 
any effect on the 5’-deiodination of rT3 by Dio1 up to a concentration of 10 µM 
(Table 18).  
Taken together, the results of the competition assays were consistent with the 
data obtained from the LC-MS/MS experiments. 
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Figure 24: TAM substrates of Dio1 inhibit the 5’-deiodination of rT3 by Dio1 in 125I - release as-
says. The effect of TAMs on the apparent Km and vmax of the 5’-deiodination of rT3 by Dio1 was 
analyzed using Friedman test followed by Dunn’s post test and p < 0.05 was considered signifi-
cant. 3’,5’-T2AM and 3,3’-T2AM acted as mixed inhibitors (A, B) whereas rT3AM, T3AM and 3,5-
T2AM caused noncompetitive inhibition (C - E). The mean ± SD values reported for apparent Km, 
apparent vmax and Ki values are from three separate experiments performed in triplicate. 
 
Table 18: Effects of iodothyronamines on the 5’-deiodination of rT3 by Dio1 from mouse liver 
membrane fractions. 
 Apparent Km (µM rT3) 
Apparent vmax 
(pmol a/mg/min) 
Ki 
(µM) 
Mode of 
inhibition 
vehicle 0.43 ± 0.02 142.7 ± 2.7 na na 
3’,5’-T2AM (5 µM) 1.19 ± 0.1* 136.4 ± 4.8* 2.6 ± 0.4 mixed 
3,3’-T2AM (5 µM) 0.86 ± 0.04* 136.9 ± 2.9* 4.8 ± 1.1 mixed 
rT3AM (5 µM) 0.42 ±0.01 31.3 ± 2.3* 1.3 ± 0.2 noncompetitive 
T3AM (5 µM) 0.43 ± 0.03 124.5 ± 4.7* 34.0 ± 2.6 noncompetitive 
3,5-T2AM (5 µM) 0.42 ± 0.02 134.9 ± 2.1* 85.0 ± 7.7 noncompetitive 
T4AM (5 µM) 0.43 ± 0.03 144.2 ± 4.1 na na 
3’-T1AM (5 µM) 0.42 ± 0.04 141.9 ± 1.4 na na 
3-T1AM (5 µM) 0.43 ± 0.03 142.1 ± 5.2 na na 
The apparent Km, apparent vmax and Ki values are from three separate experiments performed in 
triplicate and are presented as mean ± SD. * designates statistical difference with p < 0.05 as 
determined by using Friedman test followed by Dunn’s post test. na: not applicable. a I - released. 
Shading: light grey: TAMs which have been identified as phenolic ring substrates of Dio1 in LC-
MS/MS assays, grey: TAMs which have been identified as tyrosyl ring substrates of Dio1 in LC-
MS/MS assays, dark grey: TAMs which have been excluded as Dio1 substrates in LC-MS/MS 
assays. 
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3.6 Kinetic constants of selected TAM deiodination reactions  
To characterize the kinetic properties of TAM deiodination reactions, the apparent 
Km and vmax of selected TAM deiodination reactions were measured and com-
pared to that of the corresponding TH.  
At first, the deiodination of rT3AM by all Dio preparations used herein was com-
pared to that of rT3. rT3AM was chosen since it represented the only TAM which 
had been identified as a substrate of all Dio isozymes. Furthermore, it repre-
sented the TAM corresponding to the preferred TH substrate of human and mur-
ine Dio1, namely rT3. For each Dio preparation used, the apparent Km values for 
the deiodination of rT3AM were comparable to those observed with rT3 (Table 19). 
The 5’-deiodination of rT3AM by Dio1 from HepG2 lysates and mouse liver mem-
brane fractions as well as by Dio2 from MSTO-211H lysates was catalyzed at 
lower apparent vmax values compared to rT3 (Table 19). By contrast, the apparent 
vmax of the 5-deiodination of rT3AM by Dio3 from ECC-1 lysates was more than 
twofold higher compared to that observed for rT3 (Table 19). 
Secondly, the 5-deiodination of T3AM by Dio3 from ECC-1 lysates was compared 
to that of T3. T3AM was chosen since it represented the TAM corresponding to the 
preferred substrate of Dio3, namely T3. Both reactions were characterized by a 
similar apparent Km, however, T3AM was 5-deiodinated at a lower apparent vmax 
than T3. For Dio2, the preferred substrate T4 could not be compared to its corre-
sponding TAM since T4AM was excluded as a substrate of Dio2 from MSTO-211H 
lysates (see section 3.4.3). 
Finally, the apparent Km and vmax of the 3-deiodination of 3-T1AM to T0AM by Dio3 
from ECC-1 lysates was studied since this reaction might directly account for the 
biosynthesis of T0AM in-vivo. The reaction was catalyzed at an apparent Km of 
1.2 ± 0.3 µM and an apparent vmax of 2.4 ± 0.06 pmol T0AM/mg protein/min. By 
contrast, 3-iodothyronine (3-T1), which represents the corresponding iodothyron-
ine, was deiodinated at the tyrosyl ring at an apparent Km of 1.6 ± 0.09 µM and an 
apparent vmax of 0.089 ± 0.05 pmol T0/mg protein/min. Hence, 3-T1AM was 3-
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deiodinated at a higher vmax/Km ratio and thus represented a better substrate of 
Dio3 from ECC-1 lysates than 3-T1 (Table 19; compare Figure 17H to 22F). 
 
Table 19: Apparent Km and vmax of selected TAM and TH deiodination reactions as measured by 
LC-MS/MS. 
Dio 
isozyme 
Dio 
preparation substrate 
Km 
(µM substrate) 
vmax (pmol deiodination 
product/mg protein/min) 
Dio1 HepG2 
 
rT3AM 
rT3 
0.63 ± 0.05 
0.59 ± 0.03 
1.5 ± 0.08 
2.2 ± 0.06 
 mouse liver rT3AM 
rT3 
0.48 ± 0.04 
0.43 ± 0.02 
83.4 ± 1.9 
142.7 ± 2.7 
Dio2 MSTO-211H rT3AM 
rT3 
0.006 ± 0.002 
0.005 ± 0.001 
0.088 ± 0.012 
0.130 ± 0.026 
Dio3 ECC-1 rT3AM 
rT3 
0.29 ± 0.03 
0.29 ± 0.04 
0.42 ± 0.02 
0.18 ± 0.03 
  T3AM 
T3 
0.017 ± 0.004 
0.006 ± 0.002 
1.9 ± 0.2 
2.9 ± 0.2 
  3-T1AM 
3-T1 
1.2 ± 0.3 
1.6 ± 0.09 
2.4 ± 0.06 
0.089 ± 0.05 
The apparent Km and vmax values were determined by LC-MS/MS based Dios assays using an 
incubation time of 30 min and 10 nM - 5 µM of the respective TAM as substrate. The values rep-
resent the mean ± SD from three separate experiments performed in triplicate.  
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4 Discussion 
4.1 Analysis of TAM and TH deiodination reactions LC-MS/MS 
The central objective of this study was to analyze the ability of the Dio isozymes 
to accept TAMs as substrates. Such experiments required the development of a 
method for the detection and quantification of TAMs which had been subjected to 
Dio catalyzed reactions. However, non-radiolabeled TAMs were incompatible with 
all techniques which have so far been used to study Dio catalyzed reactions. De-
iodination reactions have mainly been analyzed employing 125I or 131I radiolabeled 
substrates in iodide release assays, high performance liquid chromatography 
(HPLC) methods, thin layer chromatography protocols or radioimmuno assays 
(RIAs) (for detailed review see Köhrle, 02). The generation of TAM specific anti-
bodies as a prerequisite to the analysis of TAMs by RIAs has been hampered by 
their small size and great similarity in structure. TAMs are a group of nine small 
molecules exhibiting molar masses between 230.3 and 733.9 g/mol [Scanlan, 
04]. Moreover, they differ from one another only regarding the number or the po-
sition of the iodine atoms (Figure 5). Several TAMs represent constitutional iso-
mers, such as T3AM and rT3AM or 3-T1AM and 3’-T1AM. Apart from being poorly 
accessible to antibody detection, the analysis of TAM deiodination reactions by 
any of the aforementioned radiochemical methods was hampered by the unavail-
ability of 125I or 131I radiolabeled TAMs. So far, no method has been developed to 
study deiodination reactions of non-radioactively labeled substrates. 
Mass spectrometric techniques allow for analyzing compounds without radioac-
tive labeling, such as endogenous compounds. Although LC-MS and LC-MS/MS 
methods for the detection of various unlabeled Dio substrates, such as T4 and T3, 
have been developed [Gu, 07; Soldin, 05; Soukhova, 04; Holm, 04; Thienpont, 
99; Tai, 04; Tai, 02; De Brabandere, 98], these techniques have not been used to 
study Dio catalyzed reactions but rather to investigate the concentrations of the 
respective THs in tissue or cell culture samples. Furthermore, although one LC-
MS/MS method has been published for the detection of 3-T1AM and T0AM from 
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serum and solid tissues [Scanlan, 04], no protocol was available allowing for the 
analysis of the complete TAM panel including the discrimination of TAM constitu-
tional isomers. However, in order to monitor potential sequential TAM deiodina-
tion reactions, it was necessary to include TAMs of all iodination grades. Fur-
thermore, in order to clearly distinguish between phenolic and tyrosyl ring 
deiodination of a TAM substrate, it was essential to determine the exact constitu-
tional isomerism of the product of the deiodination reaction. Therefore, an impor-
tant first objective of this study was to establish an LC-MS/MS method capable of 
the unequivocal, simultaneous identification all TAMs in the same sample.  
To evaluate the possible physiological relevance of putatively identified TAM de-
iodination reactions, the kinetic constants Km and vmax should be determined and 
compared to that of established Dio catalyzed reactions, e.g. TH deiodination re-
actions. Therefore, the LC-MS/MS method should not only allow for the identifica-
tion but also for the quantification of TAMs. However, so far, no reference method 
for TAM quantification has been available. Thus, a further objective of the present 
study was to include the complete panel of THs as established Dio substrates into 
the LC-MS/MS protocol. This would allow for validating the performance of the 
LC-MS/MS method in quantifying Dio catalyzed reactions by comparing the ki-
netic constants of TH deiodination reactions obtained by LC-MS/MS to that ob-
tained by independent methods, such as 125I - release assays or HPLC based 
radiochemical assays. 
In line with TH constitutional isomers, such as 3-T1 and 3’-T1 [Zhang, 06b] or 3,5-
T2, 3,3’-T2 and 3’,5’-T2 [Zhang, 06a], constitutional TAM isomers were indistin-
guishable in terms of MS/MS parameters. Fragmentation of the parent ion in the 
second quadrupole yielded identical product ions even if the percent contribution 
of each product ion was unique to each constitutional isomer. This was observed 
both in the positive (Figure S28) and in the negative electrospray ionization mode 
(data not shown). Therefore, the distinction of constitutional TAM and TH isomers 
required their chromatographic separation prior to the detection by MS/MS. The 
novel HPLC method developed herein allowed for the complete baseline separa-
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tion of all except one pair of constitutional TAM and TH isomers. This has not 
been achieved by any other chromatographic method, so far. Thus, the novel LC-
MS/MS method presented herein, allowed for the unequivocal detection and 
quantification of all TAMs and THs from the same sample. Accordingly, the posi-
tion of each iodine atom removed from a TAM or TH substrate in a Dio catalyzed 
reaction was backtracked unequivocally. 
The novel LC-MS/MS method had further advantages over the classical radio-
chemical assays. First of all, it allowed for analyzing deiodination reactions of 
substrates without radioactive labeling. Thus, it circumvented a general disadvan-
tage of all radiochemical assays, which is that they depend on the assumption 
that the isotopic substitution of an atom has no effects on the chemical properties 
of the substrate and that any effects on its kinetic properties are small enough to 
be neglected in the analysis [Cornish-Bowden, 04]. Being independent from ra-
dioactive labeling, a broader spectrum of candidate substrates could be investi-
gated by LC-MS/MS. Secondly, employing the novel LC-MS/MS method product 
formation and substrate disappearance were monitored simultaneously and were 
both quantifiable. Moreover, sequential monodeiodinations were monitored. By 
contrast, iodide release assays fully rely on the equimolar production of labeled 
iodide and deiodinated product. Thus, using such assays, it remains elusive if the 
removal of the labled iodine atom from the substrate was preceded by the re-
moval of an unlabeled iodine atom or by an alternate metabolization reaction of 
the substrate. Analyzing deiodination reactions of 125I or 131I radiolabeled sub-
strates by chromatographic techniques yields a more comprehensive picture of 
the reaction since both the labeled substrate and the labeled product(s) are de-
tected. However, once the 125I or 131I label has been cleaved off, the further fate of 
the deiodination product remains elusive. Finally, in contrast to RIAs, LC-MS/MS 
experiments are devoid of antibody cross reactions. Compared to radioactive as-
says, this LC-MS/MS method was of course less sensitive and more time-
consuming but yielded a more direct and complete picture of deiodination cas-
cades, which was considered indispensable for establishing new enzyme sub-
strates.  
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The LC-MS/MS based analysis of TAMs and THs from Dio reaction mixtures re-
quired their prior extraction by a method compatible with LC-MS/MS measure-
ments. Thus, a method based on liquid-liquid extraction allowing for the simulta-
neous isolation of all TAMs and THs from Dio reaction mixtures was developed 
herein (section 2.3). This method did not produce any interfering effects for the 
detection of all analytes with Dio reaction matrices (section 3.2.2). Furthermore, it 
yielded reproducible recovery rates, which were independent from the protein 
content, pH and amount of DTT of the Dio reaction matrix as well as from the ad-
dition of PTU (section 3.2.4). However, the recovery rates of TAM and TH ana-
lytes containing one or two iodine atoms were higher than that of the remaining 
analytes (Figure 9). Accordingly, the former analytes yielded lower LOD and LOQ 
values compared to the latter analytes (Table 16). Furthermore, in terms of LOD 
and LOQ values, the liquid-liquid extraction and LC-MS/MS detection protocol 
was more sensitive for TAM analytes when compared to the respective corre-
sponding TH analytes (compare for instance right panel of Figure 11 to right panel 
of Figure 19). This was not due to differences in recovery rates (Figure 9). How-
ever, the more sensitive detection of TAMs compared to THs had already been 
observed in chromatograms of standard solutions which had not been subjected 
to deiodination reactions and liquid-liquid extraction (Figure 7C). Therefore, it 
might be postulated that the conditions used for HPLC and analyte ionization 
were more effective in producing (M+H)+ ions of analytes with ethylamine side 
chains than (M+H)+ ions with β-alanine side chains. 
 
4.2 Isozyme specificity of Dio preparations 
In order to study the substrate specificity of each Dio isozyme towards TAMs, it 
was essential to generate isozyme specific Dio preparations. Since the LC-
MS/MS studies required high specific activities of each Dio isozyme, endoge-
nously expressed enzymes were preferred over transfected and recombinantly 
expressed ones. The cell lines used in this study were well-established isozyme 
specific sources for the respective Dio and had already been used as isozyme 
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specific Dio models by other research groups: HepG2 for Dio1 [Kester, 06; Ja-
kobs, 02], MSTO-211H for Dio2 [Curcio, 01] and ECC-1 for Dio3 [Kester, 06]. Fur-
thermore, membrane fractions from murine livers have frequently been described 
as a rich source of Dio1 [Schoenmakers, 92; Schneider, 01; Schneider, 06; 
Streckfuss, 05]. Nevertheless, several experiments of the present study aimed at 
verifying the exclusive expression of the respective Dio isozyme in each Dio 
preparation. However, characterizing the expression of Dio isozymes in cell lines 
and tissues is challenging in several respects.  
First of all, Dio isozymes are representatives of selenoproteins [Köhrle, 05]. The 
insertion of the rare amino acid selenocysteine (Sec) into the active center of Dio 
isozymes occurs cotranslationally at a UGA stop codon whose recoding requires 
the concerted interaction of the Sec-loaded tRNASer(Sec), the Sec insertion se-
quence (SECIS) and several mRNA and tRNA binding proteins [Köhrle, 05]. Suc-
cessful selenoprotein translation is very complex, error-prone and less efficient 
than that of typical proteins [Gereben, 02; Dumitrescu, 05; Berry, 91b]. Thus, the 
presence of a Dio transcript does not inevitably guarantee its translation into a 
functional protein [Köhrle, 05]. Therefore, when measuring the Dio transcripts in 
candidate cell lines and tissues by RT-PCR, cycle numbers within and beyond the 
log-linear range were used (section 2.7.6) since it was more important to exclude 
the expression of individual Dio mRNAs in a cell line or tissue than to 
(semi)quantify the concentrations of the detectable Dio mRNAs. Accordingly, the 
presence of any Dio1 and Dio3 transcript in MSTO-211H cells was unequivocally 
excluded thus validating the isozyme specificity of MSTO-211H cells for Dio2 
(Figure 14A). Likewise, the presence of Dio3, Dio2 and Dio1 transcripts in HepG2 
cells, mouse liver and HEK293 cells was ruled out, respectively (Figure 10A, 12A, 
18A). However, the Dio2 transcript, which was detected in all cell lines, only cor-
responded to Dio2 enzymatic activity in MSTO-211H cells but was not functional 
in the other cell lines. Similarly, the Dio3 transcript detected in mouse liver and 
HEK293 cells did not correlate to any Dio3 enzymatic activity (Figure 12, 18).  
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A second difficulty encountered when analyzing the expression of Dio isozymes is 
the unavailability of antibodies specific for Dio isozymes. Therefore, studies char-
acterizing Dio proteins usually employ non-immunological techniques, such as 
affinity labeling with alkylating substrates analogs, such as N-bromoacetyl-[125I]-
T3/T4, or 75Se incorporation. However, these methods do not allow for the dis-
crimination between Dio isozymes, either.  
Thus, the only way to comprehensively characterize the expression of Dio 
isozymes in cell lines or tissues is to analyze both the Dio transcripts and the 
cognate enzymatic activities. In this study, the enzymatic Dio activities were not 
merely measured using one established substrate of the respective isozyme. In-
stead, by taking advantage of the novel LC-MS/MS method, the substrate speci-
ficity of the Dio preparations towards all iodothyronines was analyzed and com-
pared to literature data. The ability of the LC-MS/MS method to backtrack the 
position of each iodine atom removed from the substrate combined with the us-
age of the Dio1 specific inhibitor PTU allowed for unequivocally assigning deiodi-
nation reactions to Dio isozyme identities (see sections 1.2.1 - 1.2.3). Phenolic 
and tyrosyl ring deiodination reactions which were insensitive to PTU were attrib-
uted to Dio2 and Dio3, respectively. By contrast, both phenolic and tyrosyl ring 
deiodination reactions which were sensitive to PTU were classified as Dio1 cata-
lyzed reactions.  
Both HepG2 lysates and mouse liver membrane fractions catalyzed a phenolic 
ring deiodination of T4 yielding T3 and a tyrosyl ring deiodination of T4 yielding rT3, 
which was almost completely 5’-deiodinated to 3,3’-T2 (Figure 11A, 13A). Fur-
thermore, both Dio1 preparations catalyzed deiodinations of rT3 and 3’,5’-T2 at 
their phenolic rings. As these reactions were completely inhibited by PTU, they 
were clearly catalyzed by Dio1. These substrate specificities and inhibition char-
acteristics were in line with published properties of Dio1 [Köhrle, 02; Kuiper, 05; 
Lumholtz, 78]. However, only mouse liver membrane fractions but not HepG2 
lysates catalyzed the phenolic ring deiodination of 3,3’-T2 and the tyrosyl ring de-
iodinations of T3 and 3,5-T2, all of which have frequently been described as Dio1 
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catalyzed reactions [Kuiper, 05; Wu, 05; Chopra, 82]. Therefore, both Dio1 prepa-
rations were used to study the ability of Dio1 to accept TAMs as substrates.  
MSTO-211H lysates catalyzed the phenolic ring deiodinations of all THs possess-
ing two iodine atoms in the phenolic ring, namely T4, rT3 and 3’,5’-T2. Since these 
reactions were not inhibited by 1 mM PTU, they were unambiguously catalyzed 
by Dio2. However, so far, only T4 and rT3 have been described as Dio2 substrates 
[Köhrle, 02] whereas no study has been published analyzing 3’,5’-T2 as a sub-
strate of Dio2 (Figure 4). Considering the absence of Dio1 and Dio3 transcripts in 
MSTO-211H cells, which validated this cell line as an exclusive source of Dio2, 
3’,5’-T2 was considered as a newly identified substrate of Dio2. The remaining 
THs possessing one iodine atom at their phenolic ring, namely T3, 3,3’-T2 and 3’-
T1, which have either previously been excluded as Dio2 substrates or not been 
reported as Dio2 substrates yet [Chopra, 81; Smallridge, 84] (Figure 4), were not 
converted by MSTO-211H lysates. Taken together, MSTO-211H lysates were 
considered as an isozyme specific source of Dio2 capable of deiodinating all 
known TH substrates of Dio2 and therefore appropriate to comprehensively ana-
lyze the substrate specificity of Dio2 towards TAMs as a new group of potential 
Dio substrates.  
ECC-1 lysates had previously been described as an isozyme specific source of 
Dio3 [Kester, 06]. However, when analyzing their substrate specificity towards 
THs both in the presence and in the absence of 1 mM PTU, two types of deiodi-
nation reactions were observed. Firstly, all THs possessing iodine atoms in their 
tyrosyl rings were 5- or 3-deiodinated in a PTU-insensitive fashion (Figure 22). 
Secondly, T4, rT3 and 3’,5’-T2 were weakly deiodinated at their phenolic rings, but 
those reactions were inhibited by PTU (data not shown). In line with these LC-
MS/MS experiments, analysis of ECC-1 lysates by 125I - release assays employing 
rT3 as substrate, disclosed a weak PTU sensitive enzymatic Dio1 activity (specific 
activity of 23 ± fmol/mg protein/min at a final rT3 concentration of 1 µM). Thus, the 
phenolic ring deiodination reactions of T4, rT3 and 3’,5’-T2 and were attributed to 
Dio1. Furthermore, in all following experiments, 1 mM PTU was added to each 
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reaction catalyzed by ECC-1 lysates to efficiently inhibit the Dio1 enzymatic activ-
ity. Of all tyrosyl ring TH substrates identified for Dio3 from ECC-1 cells in the 
present study, T4, rT3, T3, 3,3’-T2 and 3,5-T2 had been described before [Köhrle, 
02; Sorimachi, 79a; Sorimachi, 77]. By contrast, 3-T1, which has not been re-
ported as a substrate of Dio3, so far, was identified as a new but weak Dio3 sub-
strate in the present study. 
Taken together, the position of the iodine atoms removed from TH substrates was 
always, without any exception, in line with the published Dio catalytic properties. 
With Dio1 preparations both phenolic and tyrosyl ring deiodination reactions were 
observed whereas phenolic and tyrosyl ring deiodination reactions were observed 
exclusively with Dio2 and Dio3 preparations, respectively. Additionally, all TH 
substrates previously described were indeed converted by the respective Dio 
isozymes. These findings confirmed the isozyme specificity of the Dio prepara-
tions used in this study. 
 
4.3 Dio substrate specificity towards TAMs 
The LC-MS/MS screening experiments demonstrated that all Dio isozymes were 
capable of catalyzing TAM deiodination reactions. Each Dio isozyme exhibited a 
unique substrate specificity towards TAMs. Dio3 from ECC-1 lysates displayed 
the broadest substrate specificity since it accepted all TAMs with tyrosyl ring io-
dine atoms as substrates. By contrast, the substrate specificities of Dio1 and Dio2 
were more restricted. Dio2 from MSTO-211H lysates catalyzed only phenolic ring 
deiodinations of rT3AM and 3’,5’-T2AM. 
In the present study two different Dio1 preparations, namely HepG2 lysates and 
mouse liver membrane fractions were used. Interestingly, their substrate specifici-
ties did not overlap completely. While rT3AM and 3’,5’-T2AM were deiodinated at 
the phenolic rings by both preparations, 3,3’-T2AM, T3AM and 3,5-T2AM were ex-
clusively deiodinated by mouse liver membrane fractions (compare Figure 19 to 
Figure 20). These differences were in line with the discrepancies observed in the 
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studies analyzing the substrate specificities of HepG2 lysates and mouse liver 
membrane fractions towards THs. While T4, rT3 and 3’,5’-T2 were deiodinated at 
the phenolic rings by both preparations, T3, 3,3’-T2 and 3,5-T2 were exclusively 
converted by mouse liver membrane fractions (compare Figure 11 to Figure 13). 
These discrepancies persisted even when the pH of the homogenization buffer 
and the potassium phosphate buffer were progressively increased to 8.0 (refer to 
Table 11, data not shown). Therefore, these data might suggest that species-
specific factors modulate the Dio1 substrate specificity towards TAMs. This notion 
was supported by the finding that the weak Dio1 enzymatic activity detected in 
the human ECC-1 cell line catalyzed the phenolic ring deiodination of T4, rT3 and 
3’,5’-T2 but no PTU sensitive deiodinations of T3, and 3,3’-T2 and 3,5-T2 (data not 
shown). So far, no species-specific substrate specificities have been reported for 
Dio isozymes. However, species-specific substrate preferences have been re-
ported for Dio1, which in dogs prefers sulfated T3 and sulfated 3,3’-T2 over rT3 but 
in humans, rats and mice prefers rT3 over other (sulfated) THs [Laurberg, 82; 
Schoenmakers, 92; Toyoda, 95; Toyoda, 97]. 
The identified TAM substrates were functionally verified by inhibiting the Dio1 
catalyzed phenolic ring deiodination of rT3, which represents the preferred deiodi-
nation reaction catalyzed by murine Dio1 [Köhrle, 02]. This experimental strategy 
has frequently been used to verify or even identify Dio substrates [Chopra, 77; 
Kaplan, 78; Visser, 79; Sorimachi, 79b; Fekkes, 82; Chopra, 82; Köhrle, 86]. For 
instance, in one study the phenolic ring deiodination of rT3 by Dio1 from rat liver 
microsomes was competitively inhibited by THs which also serve as Dio1 sub-
strates, namely 3’,5’-T2, T4, T3 and 3,5-T2. By contrast, 3-T1 and T0, which do not 
represent Dio1 substrates, did not inhibit the reaction significantly [Fekkes, 82]. In 
the competition experiments performed herein, mouse liver membrane fractions 
were chosen as an exemplary Dio source for several reasons. First of all, mouse 
liver membrane fractions served as a rich and isozyme specific source of Dio1. 
Secondly, they represented a Dio1 preparation of high physiological and ex-vivo 
relevance. Finally, both phenolic and tyrosyl ring TAM deiodination reactions were 
identified for this enzyme preparation in the LC-MS/MS based Dio assays (Fig-
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ure 20). In the competition experiments, the phenolic ring substrates rT3AM, 3’,5’-
T2AM and 3,3’-T2AM were potent inhibitors exhibiting Ki values in the lower µM 
range, i.e. comparable to the Km value of the phenolic ring deiodination of rT3 of 
roughly 0.4 µM (Table 18). By contrast, the Ki values of the tyrosyl ring substrates 
T3AM and 3,5-T2AM were roughly one order of magnitude higher. These data 
were consistent with the LC-MS/MS experiments in which the phenolic and tyro-
syl ring substrates were converted readily and weakly, respectively. Furthermore, 
TAMs which had been excluded as substrates of Dio1 from mouse liver mem-
brane fractions in the LC-MS/MS studies, namely T4AM, 3’-T1AM and 3-T1AM, 
failed to show any effect in the competition assays thus verifying the former re-
sults.  
It is unclear why only some TAM substrates acted as mixed inhibitors with pre-
dominantly competitive elements (3’,5’-T2AM and 3,3’-T2AM) whereas other 
TAMs unexpectedly acted as noncompetitive inhibitors (rT3AM, T3AM and 3,5-
T2AM; see Table 18) thus suggesting a more complex mechanism of interference 
than mere competition of two substrates for the same active center. So far, impor-
tant data are lacking which might help to clarify this discrepancy. First of all, the 
number of active centers of the endogenous Dio1 holoenzyme remains elusive 
[Leonard, 05]. The finding that Dio1 catalyzes both phenolic and tyrosyl ring deio-
dination reactions, even with the same substrate, namely T4, has already led to 
the hypothesis that the Dio1 enzyme might possess more than one active center. 
Different modalities for substrate binding were suggested so that either the iodine 
atoms of the phenolic ring of those of the tyrosyl ring are in close proximity to the 
active center of the enzyme [Toyoda, 97]. Either two distinct binding sites for phe-
nolic and tyrosyl ring deiodination substrates or a single site to which substrates 
bind with a considerable degree of freedom or in different orientations were pro-
posed [Toyoda, 97]. Supporting a single active center, it was demonstrated that 
the Dio1 mRNA encodes a 27 kD polypeptide, transfection of the cognate cDNA 
yielded a catalytically active Dio1 [Berry, 91a], and the 27 kD polypeptide func-
tioned as an independent catalytic center [Curcio-Morelli, 03]. However, two 
27 kD polypeptides were reported to homodimerize [Leonard, 01], and catalytic 
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activity was preserved when only one subunit was catalytically competent 
[Leonard, 05]. The three-dimensional structure of Dio1, which might help to de-
termine the number of active centers of the enzyme, has not been resolved yet. 
In addition to uncertainties about the composition of the Dio1 holoenzyme, the 
molecular conformation of only one TAM, namely T3AM, has been reported 
[Cody, 84]. Therefore, comprehensive structure-function relationships for Dio1 
and TAM substrates, comparable to those of Dio1 and TH substrates, are not 
available. Speculations on inhibition mechanisms based on extrapolations from 
the available structures of THs seems daring, as the presence (in THs) or ab-
sence (in TAMs) of the dissociated carboxylate functional group in the tyrosyl ring 
side chain might contribute to different conformational orientations of the iodothy-
ron(am)ines with iodine atoms in 3- and 5-position, which limits the flexibility of 
the phenolic ring as illustrated by the skewed or anti-skewed structures reported 
for THs [Cody, 80; Cody, 81; Okabe, 82]. However, so far, it can be excluded that 
the modes of inhibition depend solely on the iodine substitution pattern of the 
TAM substrates on the position of the iodine removed.  
 
4.4 Substrate preferences and kinetic properties of deiodina-
tion reactions 
The capability of the LC-MS/MS detection method to monitor sequential deiodina-
tion reactions provided a tool to estimate the substrate preferences of the Dio 
isozymes. Incubation of HepG2 lysates and mouse liver membrane fractions with 
T4 revealed that T4 was weakly 5’-deiodinated to T3 (Figure 11A; Figure 13A), 
which is consistent with previous findings [Chopra, 76; Visser, 78; Kaplan, 78]. 
Furthermore, a small 3,3’-T2 peak was observed. Theoretically, 3,3’-T2 might have 
been formed by further 5-deiodination of T3 or by 5-deiodination of T4 to rT3 and 
subsequent rapid 5’-deiodination of rT3. The latter interpretation is consistent with 
published data [Visser, 78; Visser, 79] and supported by the finding that rT3 was 
almost completely 5’-deiodinated to 3,3’-T2 by Dio1 preparations whereas T3 was 
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only weakly 5-deiodinated by mouse liver membrane fractions or not deiodinated 
at all by HepG2 lysates (Figure 11B, C; Figure 13B, C). Thus, without determining 
the kinetic constants of T4, T3 and rT3 conversion by Dio1, it can be concluded at 
least qualitatively that human and murine Dio1 prefer rT3 over T4 and T3, which is 
in line with published substrate preferences [Köhrle, 02]. 
Interestingly, further sequential monodeiodination cascades were only observed 
in the cases of the tyrosyl ring deiodinations of T3 and T3AM by Dio3 containing 
ECC-1 lysates (Fig. 17C, Figure 22C). The sequential monodeiodination of T3 has 
already been reported using rat brain homogenates [Kaplan, 80] or intact cultured 
NCLP-6E monkey hepatocarcinoma cells as sources of Dio3 [Sorimachi, 77]. 
However, in all other experiments described herein, one-step deiodination reac-
tions were monitored even if the product proved to be readily convertible by the 
respective Dio isozyme when used as a direct substrate. Considering that the 
sensitivity of the LC-MS/MS method used herein was inversely proportional to the 
degree of iodination of TAM and TH analytes, except for the more sensitive detec-
tion of T1(AM)s compared to T0(AM), the predominant absence of sequential 
monodeiodination reactions indicates that Dio isozymes prefer TAMs and THs 
with higher iodine content over those with lower iodine content as substrates.  
In previous publications, further sequential deiodination cascades have been de-
scribed. For instance, in one study using intact NCLP-6E monkey hepatocarci-
noma cells, which express both Dio1 and Dio3 [Sorimachi, 79b; Baqui, 03], [3’,5’-
125I]T4 was sequentially deiodinated at the phenolic ring by Dio1 yielding rT3 and 
3’,5’-T2. Furthermore, the T3 formed from T4 was completely deiodinated at the 
tyrosyl ring by Dio3 yielding 3,3’-T2 and 3’-T1. Additionally, sulfated 3,3’-T2 and 
sulfated 3’-T1 were detected [Sorimachi, 79a]. However, since T4 was metabo-
lized by intact cultured cells, the cited study cannot be compared directly to this 
study which used Dio preparations, such as cell line homogenates and mouse 
liver membrane fractions. In intact cells but not in Dio preparations, the bioavail-
ability of THs (and presumably also TAMs) to the active center of a Dio isozyme is 
regulated by their transport into the cell, their retention time within the cell and 
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non-deiodinative pathways, which might precede the deiodination reaction 
[Sorimachi, 79a]. Accordingly, several TH substrates were extensively sulfated by 
intact NCLP-6E cells [Sorimachi, 77] whereas little or no conjugation was ob-
served with homogenates of this cell line [Sorimachi, 79b]. Likewise, rT3 was sul-
fated by intact cultured rat hepatoma R117-21B cells but not by homogenates 
thereof [Sorimachi, 80b]. In line with these findings, the TAM and TH substrates 
were only subject to deiodination reactions but not to non-deiodinative pathways 
with the cell line lysates and mouse liver membrane fractions used in this study 
(section 3.3.1). Additionally, deiodination reactions catalyzed by Dio preparations, 
such as cell line homogenates, cannot automatically be extrapolated to in-vivo 
reactions observed in cultured cells or animal models because of the greatly su-
praphysiological thiol concentrations used [Kaplan, 83].  
Despite the capability of the LC-MS/MS method to unravel relative substrate 
specificities among substrates and products of sequential monodeiodination cas-
cades, kinetic experiments were also included in the present study. The apparent 
Km and vmax of selected TAM deiodination reactions were measured and com-
pared to that of the respective TH in order to estimate their physiological potential 
to be substrates of Dio isozymes. Considering the use of mainly cell line derived 
Dio preparations and the few data available on TAM concentrations in-vivo, the 
data obtained here are of preliminary nature. However, all TAM deiodination reac-
tions analyzed quantitatively herein were catalyzed at apparent Km values which 
were in the same concentration range as those observed with the respective cor-
responding TH [Köhrle, 02] (Table 19). These findings support a putative in-vivo 
relevance of the respective TAM reactions analyzed. Furthermore, the tyrosyl ring 
deiodinations of rT3AM and 3-T1AM by Dio3 from ECC-1 lysates exhibited higher 
apparent vmax/Km ratios than their corresponding THs. Thus, with the Dio3 prepa-
ration and the reaction conditions used in this study, rT3AM and 3-T1AM repre-
sented better substrates of Dio3 than rT3 and 3-T1.  
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4.5 Structural requirements of Dio substrates 
The identification of TAMs as Dio substrates provided further new insights into the 
structural requirements for Dio substrates in general. Dio isozymes have long 
been known not only to convert THs but also various endogenous iodine contain-
ing TH metabolites [Wu, 05; Visser, 94; Köhrle, 84].  
 
Figure 25: Structure of endogenous T4 metabolites.  
 
For instance, the glucuronic acid ester of T4 (Figure 25D) was shown to be deio-
dinated at the phenolic ring by microsomes from euthyroid rat livers, which served 
as a source for Dio1, and by microsomes from hypothyroid rat brains, which were 
considered as a source for Dio2 [Hays, 92]. Furthermore, the acetic acid analogs 
to T4 and T3, namely tetraiodothyroacetic acid (tetrac) (Figure 25B) and triio-
doacetic acid (triac) proved to be better substrates for hepatic Dio1 than T4 and 
T3 [Wu, 05; Köhrle, 84; Köhrle, 86]. Likewise, sulfation of the phenolic hydroxyl 
group of T3 enhanced its tyrosyl ring deiodination by hepatic Dio1 [Visser, 94]. 
This facilitated deiodination upon sulfation was hypothesized to mechanistically 
be due to an improved interaction of the negatively charged sulfate group with 
protonated residues in the active center of the basic Dio1 protein [Visser, 94]. In 
comparison to THs, their glucuronidated and sulfated metabolites as well as their 
acetic acid analogs either carry additional negative charges or exhibit a nega-
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tively charged tyrosyl ring side chain (Figure 25). However, so far, it has not been 
possible to generally attribute the enhanced catalytic Dio activities towards the 
aforementioned metabolites to their additional net negative charges. Instead, 
upon sulfation, the tyrosyl ring deiodinations of T4, T3 and triac by Dio1 are accel-
erated while the phenolic deiodinations may either be inhibited (T4), unaffected 
(rT3) or stimulated (3,3’-T2, 3,3’- diiodothyroacetic acid) [Visser, 94].  
The structural requirements of Dio substrates have further been studied exten-
sively using large series of TH analogs [Köhrle, 84; Köhrle, 86]. However, apart 
from T4AM, no other TAM was included in these studies. In one series of L-T4 
analogs [Köhrle, 84], highest affinities in terms of lowest apparent Km values were 
obtained for substrates carrying a negatively charged but no positively charged 
functional group within the tyrosyl ring side chain (Figure 26E, F). Medium affini-
ties were observed with L-T4 and D-T4, which both exhibit a zwitterionic side 
chain (Figure 26A, B), while lowest affinities were obtained for analogs with a 
positively charged side chain, such as T4AM and L-T4-ethylester (Figure 26C, D).  
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Figure 26: Structure-activity relationships of L-T4 analogs for the phenolic ring deiodination cata-
lyzed by Dio1 from rat liver microsomes. Partly adopted from [Köhrle, 84]. tetrac: tetraiodothy-
roacetic acid, nd: not detectable.  
 
In the study cited above, the negative net charge of the tyrosyl ring side chain 
seemed to be dominant in determining the affinity of the T4 analogs to Dio1, since 
tetrac and N-acetyl-L-T4 exhibited similarly low Km values despite great differ-
ences in side chain constitution and spatial confirmation (Figure 26 E, F). By con-
trast, N-acetyl-L-T4 exhibited a much lower Km value for Dio1 than L-T4-ethylester 
(Figure 26D, F), a compound with a comparable bulky but positively charged side 
chain. [Köhrle, 84].  
However, the data obtained in the present study do not confirm a dominant role of 
the net negative charge of the tyrosyl ring side chain in determining the affinity of 
a substrate to Dio1. Instead, in most instances, the TAM deiodinating reactions 
identified in this study were identical to the deiodination reactions observed with 
the corresponding THs (compare Figure 4 to Figure 23). First of all, Dio3 from 
ECC-1 lysates catalyzed tyrosyl ring deiodinations of all TAMs and THs possess-
ing tyrosyl ring iodine atoms. Thus, at least with TAM and TH substrates, the sub-
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strate specificity of Dio3 appears to be independent from the degree of iodination 
and the presence of the carboxylate group of the tyrosyl ring side chain. Sec-
ondly, both rT3AM and rT3 were readily converted by each Dio isozyme. Further-
more, 3’,5’-T2AM and 3’,5’-T2 were substrates of Dio1 and Dio2. Finally, both 
T3AM, 3,3’-T2AM, 3,5-T2AM and their corresponding THs were deiodinated iden-
tically by Dio1 from mouse liver membrane fractions. Consequently, the specificity 
of the Dio isozymes towards the aforementioned substrates was independent 
from the tyrosyl ring carrying an ethylamine or a β-alanine side chain at the tyro-
syl ring. 
However, with T4 and T4AM the substrate specificity of the Dio isozymes towards 
TAMs and THs exhibited qualitative differences. While T4 was accepted as a sub-
strate of each Dio isozyme, T4AM was identified as an exclusive substrate of 
Dio3. Hence, towards T4 and T4AM, the substrate specificity of the respective Dio 
isozyme might depend on the structure of the tyrosyl ring side chain. However, it 
can be excluded that the different acceptabilities of T4 and T4AM as Dio sub-
strates are due to T4 and T4AM undergoing non-deiodinative metablization reac-
tions which precede the deiodinations since it was demonstrated in preliminary 
experiments that, with the conditions used herein, the TAM and TH substrates 
were only subject to deiodination reactions (section 3.3.1). 
The identification of TAMs as Dio substrates shows that Dio isozymes can con-
vert endogenous substrates with a positively charged tyrosyl ring side chain. As 
mentioned above (section 4.4), some TAMs represented better Dio substrates 
than the corresponding TH, which has to be attributed to the positively charged 
ethylamine side chain.  
 
4.6 The role of Dio isozymes in TAM biosynthesis 
The identification of TAMs as isozyme specific Dio substrates strongly supports a 
role of Dio isozymes in the yet unknown pathways of TAM biosynthesis. There 
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are two putative mechanisms of TAM production, none of which can be excluded 
yet.  
First of all, TAMs might be synthesized de-novo. This would require ether-bond 
coupling of two tyrosyl rings resembling the biosynthesis of T4 and T3 within the 
Tg molecule [Dunn, 01] Figure 1). Moreover, de-novo biosynthesis of 3-T1AM 
from T0AM would necessitate an iodination reaction of T0AM. So far, such reac-
tions have only been described within the thyroid gland involving TPO and DUOX 
[Ris-Stalpers, 06]. However, neither significant release of iodothyronines with 
lower iodination grade than T4 or T3 nor direct secretion of TAMs from the thyroid 
gland have been reported yet.  
Secondly, TAMs could be derived from THs by decarboxylation of the β-alanine 
side chain. The aromatic amino acid decarboxylase (AADC) has been proposed 
as a candidate enzyme for TH decarboxylation [Scanlan, 04] partly due to its rela-
tively broad substrate specificity including L-3,4-dihydroxyphenylalanine (L-dopa) 
and 5-hydroxytryptophane [Zhu, 95]. If there were decarboxylating activities for all 
THs, e.g. if 3-T1 could be decarboxylated to 3-T1AM and T0 could be decarboxy-
lated to T0AM, the role of Dio isozymes in TAM biosynthesis would be an indirect 
one, namely synthesizing sufficient amounts of 3-T1 and T0 from T4. But if the pu-
tative decarboxylating activities were restricted to iodine containing THs, i.e. 3-T1 
could be decarboxylated to 3-T1AM but T0 could not be decarboxylated to T0AM, 
a tyrosyl ring Dio activity would be required directly to produce T0AM from 3-T1AM 
(Figure 27).  
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Figure 27: Pathways suggested for TAM biosynthesis. Arrows: light green: phenolic ring deiodina-
tion reactions catalyzed by Dio1 or Dio2, dark green: tyrosyl ring deiodination reactions catalyzed 
by Dio1 or Dio3. Blue arrows: putative decarboxylation reactions which might represent the first 
step of TAM biosynthesis. Dashed lines: TAMs which have been excluded as precursors of the 
biosynthesis of 3-T1AM and T0AM.  
 
With the panel of newly identified TAM deiodinating reactions described here, se-
quential deiodination from T4AM to T0AM appears possible (Figure 27). Since a 
considerable number of deiodination reactions was excluded, this panel allows for 
confining the biosynthetic pathways of 3-T1AM and T0AM. It suggests a synthesis 
of endogenous T0AM from 3-T1AM via tyrosyl ring deiodination by Dio3 rather 
than from 3’-T1AM via phenolic ring deiodination. By contrast, endogenous 3-
T1AM is equally likely to be synthesized from 3,3’-T2AM via phenolic ring deiodi-
nation and from 3,5-T2AM via tyrosyl ring deiodination, provided that 3,5-T2AM or 
3,3’-T2AM occur in-vivo. So far, only 3-T1AM and T0AM have been detected 
endogenously [Scanlan, 04]. The detection of TAMs with higher iodine content in-
vivo might have been hampered by the fact that their mass spectrometric detec-
tion is technically more difficult. Alternatively or additionally, their levels in-vivo 
could be very low due to putative rapid deiodination to 3-T1AM and T0AM. If the 
biosynthesis of T0AM started with a decarboxylation of 3-T1 or 3,5-T2, it might be 
completed by Dio3 catalyzed reactions. However, if it started with a decarboxyla-
tion of 3,3’-T2, T3, rT3 or T4, both Dio1 and Dio3 would be required to complete 
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T0AM biosynthesis. In the case of rT3 or T4 being the precursor of TAM biosyn-
thesis, Dio2 activity might be involved to complete T0AM biosynthesis catalyzing 
the phenolic ring deiodination of rT3AM to 3,3’-T2AM. However, this reaction 
might equally well be catalyzed by Dio1. Based on the newly identified substrate 
specificities of Dio isozymes towards TAMs, 3’,5’-T2AM and 3’-T1AM are excluded 
as precursors of 3-T1AM and T0AM biosynthesis, respectively (Figure 27). 
Considering the limited knowledge on the physiologic function(s) of TAMs and 
their concentrations in-vivo and, it is speculative to predict the tissues which 
might be involved in TAM biosynthesis.  
 
4.7 Sulfated TAMs 
Due to the recent discovery of TAM sulfation by hepatic, cardiac and brain sul-
fotransferases (SULTs), the spectrum of Dio substrates could become even 
broader [Pietsch, 07]. T0AM and 3-T1AM, which are detectable in-vivo, were 
found to be readily sulfated by human liver SULT1A3. Moreover, 3-T1AM was sul-
fated by homogenates of human brain and cardiac tissue, i.e. target tissues of 
TAM action. The biological impact of TAM sulfation reactions remains to be estab-
lished. The introduction of a sulfate group into a phenolic ring modifies its elec-
tronic environment [Wu, 05]. With many other endogenous and xenobiotic sub-
strates, biological SULTs functions are inactivation and detoxification. Therefore, 
the sulfation of TAMs might serve to attenuate and thus regulate TAM actions 
[Pietsch, 07]. However, TAMs might also temporarily be inactivated by sulfation 
and be recovered from their sulfated form by the catalytic activity of sulfatases 
when TAM actions are required [Wu, 05]. In this respect, sulfated TAMs might 
serve as a reservoir for biologically active TAMs.  
It remains to be tested, if sulfated T0AM (T0AMS), 3-T1AMS and T3AMS are de-
tected in-vivo, whether they can also be deiodinated and, if so, whether TAM sul-
fation has any effect on the efficiency of their deiodination. According to literature 
data on TH sulfation, Dio1 would be the most likely candidate to catalyze deiodi-
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nations of sulfated TAMs as deiodinations of sulfated THs by Dio2 and Dio3 are 
very limited [Wu, 05].  
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5 Conclusions 
3-T1AM and T0AM have recently been identified as endogenous signaling mole-
cules exhibiting remarkable in-vivo effects, such as rapid and profound hypo-
thermia, hyperglycemia, reduction of the respiratory quotient, negative chrono-
tropy and negative inotropy [Scanlan, 04; Braulke, 08]. So far, basically all fields 
of TAM biology are still open to research. It is not known if further representatives 
of TAMs apart from 3-T1AM and T0AM are present in-vivo and, if so, at which tis-
sue concentrations and half lives. It remains elusive if the aforementioned in-vivo 
effects represent the physiological TAM actions or are merely pharmacological in 
nature. Moreover, the physiological receptor(s) of TAMs has (have) not been 
identified unequivocally. Further unsettled issues include the site, pathways and 
regulation of TAM biosynthesis, their transport in blood and across biological 
membranes as well as possible pathophysiological implications.  
Considering the structural similarity of TAMs and THs, it has frequently been sug-
gested that TAMs might be biosynthesized as metabolites of THs by decarboxyla-
tion of the β-alanine side chain. If the yet unidentified decarboxylating enzyme 
was converting only THs with higher iodine content, such as T4, T3s or T2s, Dio 
isozymes would be directly required to complete the biosynthesis of 3-T1AM and 
T0AM by removing one to four iodine atoms. However, any role of Dio isozymes 
in TAM biosynthesis presupposes their ability to accept TAMs as substrates. 
Given this possible new role of Dio isozymes in TAM biosynthesis, the present 
study aimed at analyzing the substrate specificities of the Dio isozymes towards 
TAMs. A particular strength of this study was its completeness since each Dio 
isozyme was analyzed with the complete panel of iodothyronamines. TAMs were 
subjected to in-vitro deiodination reactions catalyzed by isozyme specific Dio 
preparations, which had been validated extensively. To analyze the deiodination 
products, a novel liquid-liquid extraction protocol and an LC-MS/MS method were 
developed, which allowed for the unequivocal, simultaneous identification and 
quantification of all TAMs in the same sample. The extraction protocol did not 
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produce any interfering effects for the LC-MS/MS detection of the TAM analytes 
with the Dio reaction matrices. Furthermore, it yielded reproducible recovery 
rates, which were independent from the protein content and pH of the Dio reac-
tion matrices. With the HPLC method developed herein, complete baseline sepa-
ration of all except one pair of constitutional TAM isomers was achieved, which 
had not been accomplished by any other method, so far. Accordingly, the position 
of each iodine atom removed from a TAM or TH substrate in a Dio catalyzed re-
action was backtracked unequivocally. Since the complete panel of THs as estab-
lished Dio substrates was also included into the LC-MS/MS protocol, its perform-
ance in analyzing Dio catalyzed reactions was successfully compared to classical 
125I - release assays. The position of the iodine atoms removed from TH sub-
strates was always, without any exception, in line with the published Dio catalytic 
properties. Additionally, all TH substrates previously described were indeed con-
verted by the respective Dio isozymes supporting the functionality of the Dio 
preparations and their suitability to study new Dio substrates. 
The present study demonstrates that all Dio isozymes are capable of catalyzing 
TAM deiodination reactions with each Dio isozyme exhibiting a unique substrate 
specificity towards TAMs. The TAM deiodination reactions were analyzed using 
two independent analytical techniques. First of all, they were monitored directly 
by LC-MS/MS in the most comprehensive way ever reported for Dio catalyzed 
reactions. Both product formation, including the formation of sequential monode-
iodination products, and substrate disappearance were monitored simultaneously 
and were both quantifiable. Secondly, the identified TAM substrates were func-
tionally verified by inhibiting the Dio1 catalyzed phenolic ring deiodination of rT3. 
Kinetic experiments demonstrated that with the Dio preparations and the reaction 
conditions used in this study, some TAMs represented better Dio substrates than 
the corresponding THs. Another interesting aspect of these data was that TAMs 
represent the only endogenous Dio substrates reported, so far, which possess a 
positively charged side chain at the tyrosyl ring. 
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Taken together, it is concluded that the present study supports a role for Dio 
isozymes in TAM biosynthesis. Thus, it also strengthens the hypothesis that 
TAMs are biosynthesized as TH metabolites. Moreover, by excluding a consider-
able number of TAM deiodination reactions, the biosynthetic pathways of the re-
cently identified endogenous signaling molecules 3-T1AM and T0AM were con-
fined. Hence, Dio isozymes do not only control the bioavailability of T3 to classical 
nuclear thyroid hormone receptors but might also play an essential role in regulat-
ing the bioavailability of 3-T1AM and T0AM to their rapidly acting and putatively 
plasma membrane-bound receptors. Although their physiologic function remains 
elusive, 3-T1AM and T0AM have already revealed promising therapeutic potential 
since they represent the only endogenous compounds to induce hypothermia as 
a prophylactic or acute treatment of stroke and might thus be expected to cause 
fewer side effects than synthetic compounds [Doyle, 07]. Consequently, an im-
proved knowledge of the biosynthetic pathways of 3-T1AM and T0AM will contrib-
ute to a better understanding of their pharmacokinetic properties and thus help to 
reduce side effects. 
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Supplementary figures and tables 
Figure S28 
 
 
(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
230.3 (M+H)+ a  120.2 (M+H-1,4-dihydroxybenzene)+ 
213.3 (M+H-NH3)
+ a  111.1 (1,4-dihydroxybenzene)
+ 
 
 
 
(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
356.2 (M+H)+ a  195.3 (M+H-NH3-I-OH)+ 
339.2 (M+H-NH3)
+ a    
212.3 (M+H-NH3-I)+ a    
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(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
356.2 (M+H)+  195.3 (M+H-NH3-I-OH)+ 
339.2 (M+H-NH3)
+    
212.3 (M+H-NH3-I)+    
 
 
 
(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
360.2 (M+H)+  216.3 (M+H-NH3-I)+ 
343.2 (M+H-NH3)+ or   199.3 (M+H-NH3-I-OH)+ 
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(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
482.1 (M+H)+  a  372.0 (4) (M+H-1,4-dihydroxybenzene)+ 
465.1 (M+H-NH3)+  a  338.2  (M+H-NH3-I)+ 
   245.1 (3) (M+H- 
1,4-dihydroxybenzene-I)+ or  
(M+H-NH3-
monohydroxybenzene-I)+ 
   211.3 (2) (M+H-NH3-I-I)+ 
   183.2 (1) (M+H-C2H7N-I-I)+ 
 
 
(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
482.1 (M+H)+  a  372.0 (4) (M+H-1,4-dihydroxybenzene)+ 
465.1 (M+H-NH3)+  a  338.2  (M+H-NH3-I)+ 
   245.1 (3) (M+H- 
1,4-dihydroxybenzene-I)+ or  
(M+H-NH3-
monohydroxybenzene-I)+ 
   211.3 (2) (M+H-NH3-I-I)+ 
   183.2 (1) (M+H-C2H7N-I-I)+ 
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(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
482.1 (M+H)+  a  372.0 (4) (M+H-1,4-dihydroxybenzene)+ 
465.1 (M+H-NH3)+  a  338.2  (M+H-NH3-I)+ 
   245.1 (3) (M+H- 
1,4-dihydroxybenzene-I)+ or  
(M+H-NH3-
monohydroxybenzene-I)+ 
   211.3 (2) (M+H-NH3-I-I)+ 
   183.2 (1) (M+H-C2H7N-I-I)+ 
 
 
 
(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
608.0 (M+H)+  591.0 (M+H-NH3)+ 
   464.1 (M+H-NH3-I)+ 
   337.2 (M+H-NH3-I-I)+ 
   210.3 (M+H-NH3-I-I-I)+ 
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(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
608.0 (M+H)+  591.0 (M+H-NH3)+ 
   464.1 (M+H-NH3-I)+ 
   337.2 (M+H-NH3-I-I)+ 
   210.3 (M+H-NH3-I-I-I)+ 
 
 
 
(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
733.9 (M+H)+  716.9 (M+H-NH3)+ 
   590.0 (M+H-NH3-I)+ 
   463.1 (M+H-NH3-I-I)+ 
   336.2 (M+H-NH3-I-I-I)+ 
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(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
274.3 (M+H)+  211.3 (M+H-NH3-HCOOH)+ 
257.3 (M+H-NH3)+  182.2 
(3) (tyrosine)+ 
228.3 (M+H-HCOOH)+  164.3 (2) (M+H-1,4-dihydroxybenzene)+ 
   119.2 (tyrosine-NH3-HCOOH)+ 
   111.1 (1) (1,4-dihydroxybenzene)+ 
 
 
 
(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
400.2 (M+H)+ b  337.2 (5) (M+H-NH3-HCOOH)+ b 
383.2 (M+H-NH3)+ b  256.3 
(4) (M+H-NH3-I)+ b or 
(M+H-OH-I) b 
354.2 (M+H-HCOOH)+ b  244.2 (3) (M+H-HCOOH- 
1,4-dihydroxybenzene)+ 
256.3 (M+H-NH3-I)+ b or 
(M+H-OH-I) b 
 227.3  (M+H-HCOOH-I)+ 
   210.3 (2) (M+H-NH3-HCOOH-I)+ 
   199.2 (1) (M+H-CH4O2N-I)+ 
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(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
400.2 (M+H)+ b  337.2 (6) (M+H-NH3-HCOOH)+ b 
383.2 (M+H-NH3)+ b  256.3 
(5) (M+H-NH3-I)+ b or 
(M+H-OH-I) b 
354.2 (M+H-HCOOH)+ b  244.2 (4) (M+H-HCOOH- 
1,4-dihydroxybenzene)+ 
256.3 (M+H-NH3-I)+ b or 
(M+H-OH-I) b 
 227.3 (3) (M+H-HCOOH-I)+ 
   210.3 (2) (M+H-NH3-HCOOH-I)+ 
   199.2 (1) (M+H-CH4O2N-I)+ 
 
 
(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
526.1 (M+H)+ c  463.1 (5) (M+H-NH3-HCOOH)+ c 
509.1 (M+H-NH3)+ c  382.2 
(4) (M+H-NH3-I)+ c or 
(M+H-OH-I) c 
480.1 (M+H-HCOOH)+ c  353.2 (3) (M+H-NH3-I-I)+ 
   336.2 (2) (M+H-NH3-HCOOH-I) 
   310.2 (1) (M+H-NH3-β-alanine-I)+ 
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(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
526.1 (M+H)+ c  463.1 (5) (M+H-NH3-HCOOH)+ c 
509.1 (M+H-NH3)+ c  382.2 
(4) (M+H-NH3-I)+ c or 
(M+H-OH-I) c 
480.1 (M+H-HCOOH)+ c  353.2 (3) (M+H-NH3-I-I)+ 
   336.2 (2) (M+H-NH3-HCOOH-I) 
   310.2 (1) (M+H-NH3-β-alanine-I)+ 
 
 
 
(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
526.1 (M+H)+ c  463.1 (5) (M+H-NH3-HCOOH)+ c 
509.1 (M+H-NH3)+ c  382.2 
(4) (M+H-NH3-I)+ c or 
(M+H-OH-I) c 
   353.2 (3) (M+H-NH3-I-I)+ 
480.1 (M+H-HCOOH)+ c  336.2 (2) (M+H-NH3-HCOOH-I) 
   310.2 (1) (M+H-NH3-β-alanine-I)+ 
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(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
652.0 d, e (M+H)+  635.0 (M+H-NH3)+ 
   606.0 (M+H-HCOOH)+  d, e 
   508.1 (M+H-NH3-I)+ 
   479.1 (M+H-HCOOH-I)+ 
 
 
 
(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
652.0 (M+H)+  635.0 (M+H-NH3)+ 
   606.0 (M+H-HCOOH)+ 
   508.1 (M+H-NH3-I)+ 
   479.1 (M+H-HCOOH-I)+ 
Supplementary figures and tables 
________________________________________________________________________________________________________________________ 
 141
 
(m/z) (amu) Interpretation  (m/z) (amu) Interpretation 
777.9 f, g (M+H)+  731.9 f (M+H-HCOOH)+ 
   634.0 (M+H-NH3-I)+ 
   380.2 (M+H-NH3-I-I-I)+ 
Figure S28: Representative parent ion mass spectra (left panel) and product ion tandem mass 
spectra (right panel) of 10 µg/ml analyte working solutions. The parent ion mass spectra show 
the optimized detection of the parent ions (largest mass in each spectrum) in the first quadrupole. 
The product ion tandem mass spectra outline the optimized detection of the most intensive prod-
uct ion, namely (M+H-NH3)+ in the case of TAMs (A - J) and (M+H-HCOOH)+ in the case of THs 
(K - S). 
a [Scanlan, 04] 
b [Zhang, 06b] 
c [Zhang, 06a] 
d [Thienpont, 99] 
e [Tai, 04] 
f [De Brabandere, 98] 
g [Tai, 02] 
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Table S20: Exemplary matrix effects obtained for Dio reactions which contained HepG2 lysates 
and were devoid of PTU. 
Analyte Analyte concentration in the Dio reactions 
 10 nM 500 nM 7.5 µM 
T0AM 101 ± 4.8 104 ± 5.9 103 ± 4.2 
3-T1AM 96 ± 3.7 102 ± 2.7 96 ± 4.1 
3-T1AM-d4 99 ± 4.4 101 ± 4.1 96 ± 5.2 
3’-T1AM 103 ± 2.4 99 ± 2.1 98 ± 2.0 
3,5-T2AM 102 ± 4.9 103 ± 4.1 104 ± 4.8 
3,3’-T2AM 100 ± 1.7 101 ± 1.3 99 ± 2.4 
3’,5’-T2AM 101 ± 4.3 99 ± 2.9 98 ± 4.5 
T3AM 99 ± 4.9 104 ± 5.5 99 ± 5.4 
rT3AM 97 ± 3.6 100 ± 3.3 101 ± 2.8 
T4AM 100 ± 6.7 96 ± 4.9 98 ± 5.8 
T0 103 ± 7.0 97 ± 6.3 98 ± 6.6 
3-T1 98 ± 1.2 104 ± 2.5 96 ± 1.9 
3’-T1 107 ± 2.3 98 ± 1.6 103 ± 0.9 
3,5-T2 96 ± 4.8 96 ± 3.9 100 ± 5.1 
3,3’-T2 104 ± 5.0 101 ± 4.6 96 ± 4.8 
3’,5’-T2 99 ± 2.4 98 ± 3.1 104 ± 3.0 
T3 98 ± 4.7 99 ± 5.4 98 ± 4.2 
rT3 103 ± 3.1 104 ± 4.0 109 ± 2.7 
T4 103 ± 5.2 96 ± 4.1 99 ± 4.6 
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Table S21: Exemplary process efficiencies obtained for Dio reactions which contained HepG2 
lysates and were devoid of PTU. 
Analyte Analyte concentration in the Dio reactions 
 10 nM 500 nM 7.5 µM 
T0AM 59 ± 5.1 62.4 ± 5.0 57 ± 4.9 
3-T1AM 79 ± 4.2 85 ± 3.5 87 ± 3.9 
3-T1AM-d4 82 ± 5.2 91 ± 5.7 79 ± 4.9 
3’-T1AM 89 ± 3.8 86 ± 5.2 81 ± 5.6 
3,5-T2AM 82 ± 1.7 85 ± 3.6 87 ± 1.5 
3,3’-T2AM 81 ± 2.6 83 ± 1.8 79 ± 2.5 
3’,5’-T2AM 83 ± 4.0 80 ± 3.7 77 ± 4.1 
T3AM 60 ± 4.7 63 ± 4.6 61 ± 3.9 
rT3AM 60 ± 4.6 64 ± 3.2 65 ± 3.8 
T4AM 50 ± 7.0 49 ± 6.8 50 ± 6.1 
T0 48 ± 5.4 46 ± 5.1 48 ± 4.9 
3-T1 82 ± 4.1 85 ± 3.2 79 ± 4.7 
3’-T1 93 ± 1.6 89 ± 1.9 90 ± 2.8 
3,5-T2 80 ± 2.0 80 ± 3.3 84 ± 2.1 
3,3’-T2 90 ± 3.1 88 ± 3.6 96 ± 2.4 
3’,5’-T2 88 ± 3.9 88 ± 3.4 92 ± 4.4 
T3 69 ± 6.0 70 ± 5.7 68 ± 6.2 
rT3 74 ± 5.9 75 ± 5.6 78 ± 5.9 
T4 56 ± 3.6 56 ± 4.0 53 ± 5.1 
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